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Thesis summary
Previous Work
Although the amyloid precursor protein (APP) is known to have a central role in Alzheimer's
disease, its cellular function is poorly characterised.
To better  understand  the cellular  functions  of  APP,  an interactome of  APP’s  intracellular
domain  (AICD)  was  generated  using  a  proteo-lipososome  based  assay,  which  enabled
interactions to be identified within a membrane context.  In addition to proteins known to bind
AICD,  novel  interactors  were  identified,  including  the  mechanistic  target  of  rapamycin
complex 1 (mTORC1) and the phosphoinositide kinase PIKfyve complex.
Binding of AICD to the two complexes was confirmed by Western blotting of treated AICD-
proteoliposomes and pulldowns of purified protein by AICD.
Project Aims
This project aimed to investigate the biological relevance of the APP/mTOR and APP/PIKfyve
complex interactions.
Results
Investigation of the APP/mTOR interaction showed mTOR signalling increased in mammalian
cells overexpressing APP/AICD, while loss of function studies determined  C. elegans APP
(APL-1) is involved in mTOR ortholog function. The APP/PIKfyve interaction was investigated
with  APP family  knockdown,  and  TAT-AICD:  a  new molecular  tool  to  allow acute  AICD
overexposure  within  the  cell. Knockdown  decreased  PIKfyve  function,  while  TAT-AICD
exposure increased PIKfyve function in mammalian tissue culture.
mTOR and PIKfyve are important to degradative pathway progression, and results suggested
APP modulates the activity of these proteins.  
Protein  degradation  is  important  in  human  disease,  including  Alzheimer's  disease.
Experiments elaborating APP relevance in the lysosome demonstrated that APP degradation
is  dependent  on  sorting,  endosomal  acidification  and  the  inhibition  of  mTOR.  Further
experiments linked PIKfyve inhibition to these degradative processes, in particular, to lower
organelle acidification and altered late endosome morphology.
Summary
These results suggest an interdependence between APP, mTOR and PIKfyve, where APP
appears  to  impact  lysosomal  function,  while  also  being  dependent  upon  it  for  down-
regulation.
Key words: Alzheimer's disease, AICD, APP, cell penetrating peptide, mTOR. 
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1.1 Alzheimer’s Disease
Alzheimer’s  disease is  named after  Alois  Alzheimer,  who  first  described  the  clinical  and
pathological characteristics of the disease in one of his patients.  Alzheimer’s disease, a form
of dementia characterised by profound memory loss and confusion, is a neurodegenerative
disorder primarily related to ageing.
Over 100,000 people are diagnosed with Alzheimer's each year (127,095 between 2013-
2014)  (HSCIC 2015),  with  approximately  850,000 people  living with  dementia in  the UK
today (Alzheimer’s Society 2014).  By 2025, the number is expected to exceed 1 million and
by 2050 it is projected to include over 2 million people (Lewis  et al., 2014).  More women
than  men  develop  Alzheimer’s;  in  the  UK  around  62%  of  cases  are  female  while
approximately 38% are male (Lewis et al., 2014) with dementia being the leading cause of
death among women in the UK with 12.2% of deaths per year attributable to the disease
(ONS 2014).  Stemming from the progressive nature of the disease, the patient’s condition
deteriorates over time, with death occurring several years after diagnosis (Wolfson  et al.,
2001) and the patient requiring increasing care up until  then. Because the degradation is
primarily  of  higher  brain  function,  death  occurs  indirectly:  dehydration,  pneumonia  and
cachexia are the most commonly reported causes (Chandra et al., 1986).
1.1.1 Pathology
Gross pathological changes in Alzheimer’s disease include cerebral atrophy, particularly in
the cortex and hippocampus, as well as “plaques and tangles”; protein aggregates of amyloid
beta (Aβ) plaques and hyperphosphorylated tau (neurofibrillary tangles).
Alzheimer’s disease can exhibit pathological changes of varying severity (Braak and Braak
1991) and at different scales – from visible pathology to microscopic, histological changes.
The changes often seen upon visual inspection of the Alzheimer’s brain (via neuroimaging or
14
post-mortem) include generalised atrophy of the cerebral hemisphere, affecting white and
grey matter. As might be expected in a neurodegenerative disease, ventricle size can be
severely increased, although this is limited to the lateral and third ventricles (de la Monte
1989).  Marked atrophy also occurs in the amygdala, hippocampus, and medial temporal
lobes (Wenk 2003).  In spite of pathology altering the cerebrum, the cerebellum is relatively
spared from disease,  allowing faculties such as fine motor control  to remain, even when
cognitive function is lost (Karas et al., 2003).
The main microscopic signs of Alzheimer’s disease are protein aggregates characterised by
their morphology, staining profile and the specific protein involved in their formation. These
can be found alongside more general changes, such as neuron loss and variations in glial
cell number and size in affected regions of the brain (West  et al., 1994; Mackenzie  et al.,
1995).
Plaques consist of aggregated Aβ peptide, these plaques appear as argyrophilic extracellular
deposits, varying in size and found in two general forms: diffuse and neuritic. Diffuse plaques
are homogeneous masses that do not accumulate congo red stain, while neuritic plaques
contain a dense core of Aβ and cellular material that can be stained with congo red or silver
surrounded with  a  silver  stained “halo”.   Neuritic  plaques,  as their  name suggests,  also
contain abnormal neuritic and microglial processes.  Neurofibrillary tangles are lesions found
in the brain consisting of hyperphosphorylated tau protein creating intracellular paired helical
fragments (Stelzmann et al., 1995; Kidd 1963; Wischik et al., 1988).  Neurofibrillary tangles
are seen as silver stained fibrillar flecks formed in the cell body of neurons, they consist of
hyperphosphorylated forms of the microtubule associated protein tau.  Although the tangles
are  within  living  neurons,  upon  cell  death  the  tangle  remains  as  an  insoluble  'ghost'
(Reviewed in Perl 2010).
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1.1.1.1 The Amyloid Precursor Protein and Alzheimer’s Disease
The  plaques  found  in  Alzheimer’s  disease  come  about  through  processing  of  amyloid
precursor protein (APP) by secretases.  Beta secretase BACE1 (Reviewed in Vassar 2004)
and  the  gamma  secretase  complex  (Reviewed  in  Iwatsubo  2004)  cut  APP  to  release
aggregation prone Aβ peptides, while alpha secretase cleavage produces non-amyloidogenic
products (Reviewed in Allinson et al., 2003). In addition to extracellular peptide release, the
action of secretases also produce the larger soluble, secreted remnant of the extracellular
domain (sAPP) and the intracellular domain of APP (AICD) (Figure 1).
Figure 1.) The Secretase processing of APP.  APP is cleaved by secretases to produce secreted APP (sAPP)
and APP intracellular  domain  (AICD),  APP may be  cut  by either  alpha  or  beta  secretase.   If  cut  by alpha
secretase, the Aβ stretch of  APP is disrupted, leading to a non-amyloidogenic product along with the longer
sAPPα after gamma secretase release (left panel).  If cut by beta secretase, an aggregation prone product results
alongside sAPPβ and AICD.
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Research into APP continues to focus on the origins and effect of amyloid beta, however,
with  respect  to  determining  APP's  functional  roles  within  the  cell,  Aβ  is  unlikely  to  be
important and is not the most 'interesting' segment of the protein.  The Aβ stretch is not
conserved evolutionarily beyond a handful of mammals (Podlisny  et al., 1991), while APP
orthologues exist  in  Drosophila  melanogaster and  Caenorhabditis  elegans (Rosen  et  al.,
1989; Daigle and Li 1993).  Several biological roles have been attributed to APP, with the
intracellular and extracellular regions of APP designated domains relating to their structure
and function.
1.1.1.2 The Amyloid Cascade Hypothesis
The amyloid cascade hypothesis states that Aβ is the primary cause of Alzheimer’s disease:
the cleavage of APP leads to the release and aggregation of Aβ (specifically Aβ42), which
causes cell death leading to dementia (Hardy and Allsop 1991; Reviewed in Karran  et al.,
2011).   The hypothesis  that  Aβ is  the primary cause of  Alzheimer’s has a large body of
research supporting  it:  most  familial  Alzheimer’s  mutations  increase the amount  of  Aβ42
formed  (Tanzi  and  Bertram  2005)  and  Aβ  itself  appears  to  exert  a  neurotoxic  effect
(Goodman  and  Mattson  1994).    A  myriad  of  effectors  have  been  implicated  in  Aβ
neurotoxicity, be it interference with insulin signalling (Xie  et al., 2002), Wnt (Reviewed by
Caricasole  et  al., 2003),  alcohol  dehydrogenase  (Lustbader  et  al., 2004),  or  by  altering
microglial activation (Reviewed in Bamberger and Landreth 2001).
1.1.2 Genetics of Alzheimer’s Disease
The expression and processing of APP is central to the development of Alzheimer’s disease.
Overexpression of APP is known to lead to early onset Alzheimer’s disease, seen clinically in
Down’s  syndrome  patients  as  a  result  of  the  extra  copy  of  APP  from  the  trisomy  of
chromosome 21.  A range of APP mutations that alter its processing and cleavage have been
found in the majority of familial Alzheimer's disease cases.  In addition, other mutations that
alter APP processing have been found to predispose individuals to dementia.  Known APP
mutations include 'Indiana' (V717F), 'London' (V717I) and 'Swedish' (K670N/M671L) (Goate
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et al., 1991; Murrel et al., 1991; Mullan et al., 1992; Crews et al., 2010; Figure 2).  Mutations
in the gene encoding gamma secretase protein, which cleaves APP, also leads to familial
Alzheimer’s disease (Sherrington et al., 1995; Wasco et al., 1995).
Figure 2.)  Location of Alzheimer’s disease related mutations in APP (from Crews et al. 2010). Mutations
listed: Swe = Swedish, Lon = London, Ind = Indiana, Iowa, Arc = Arctic, Italian, Dutch, Flemish.
Other than changes in APP and APP processing genes, one of the most well known genetic
risk  factors  for  developing  Alzheimer’s  disease  is  the  apolipoprotein  E  (APOE)  4  allele
(Corder  et al.,  1993). APOE is a gene that codes a transporter of lipoproteins, cholesterol,
and fat soluble vitamins.  While the role of APOE4 in Alzheimer’s pathogenesis is unclear, it
has been implicated in a variety of processes relevant to the disease, from the regulation of
Aβ aggregation and deposition to lipid metabolism, synaptic plasticity, and neuroinflammation
(Reviewed in Liu et al., 2013).  More recently, APOE4 has also been found to be associated
with high intracellular calcium levels and apoptosis rates after mechanical injury (Jiang et al.,
2015).
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Table 1.) GWAS hits for Alzheimer's disease (from Lambert et al. 2013). Genome-wide association study hits
for Alzheimer's disease showing gene, gene product and biological role(s).
Gene Gene Product Role
ABCA7 ATP-binding cassette A, 
member 7
Cholesterol regulation (Kaminski et al., 2000).
BIN1 Bridging integrator 1 Membrane dynamics, muscle development (Nicot
et al., 2007; Sakamuro et al., 1996).
CLU Clusterin Complement, apoptosis, lipid transport, cell 
adhesion, autophagy (Koltai 2014; Sansanwal et 
al., 2015). Note that the PTK2B-CLU GWAS 
signal distinction is unclear.
CR1 Complement receptor 1 Complement regulation (Lida et al., 1982; Khera 
and Das 2009).
EPHA1 Ephrin type-A recptor 1 Neuronal migration (Torii et al., 2009)
MS4A6A-MS4A4EMembrane-spanning 4-
domain sub-family A
Immune cell activation (Stashenko et al., 1981; 
Ravetch and Kinet 1991; Proitsi et al., 2014).
PICALM Phosphatidylinositol 
binding clathrin assembly 
protein
Trafficking (Tebar et al., 1999).
CD33 Cluster of differentiation 
33
Myeloid lineage development (Paul et al., 2000; 
Hernández-Caselles et al., 2006)
HLA-DRB5-DRB1 MHC II DRβ5 and 1 Immunocompetence/histocompatibility (antigen 
presentation) (Holling et al., 2004).
SORL1 Sortilin-related receptor L 
(DLR class) 1
Trafficking (Andersen et al., 2005).
PTK2B Protein tyrosine kinase 2βMAPK signalling, calcium flux, hippocampal LTP 
(Lev et al., 1995). Note that the PTK2B-CLU 
GWAS signal distinction is unclear.
SLC24A4 Solute carrier family 24 
member 4
Sodium/potassium/calcium exchanger, may be 
involved in neural development, hair and skin 
pigmentation (Sulem et al., 2007).
ZCWPW1 Zinc finger, CW type with 
PWWP domain 1
Epigenetic regulation (He et al., 2010).
CELF1 CUGBP, Elav-like family 
member 1
Control of alternative splicing (Gallo et al., 2010).
NME8 NME/NM23 family 
member 8
Ciliary function (Duriez et al., 2007).
FERMT2 Fermitin family member 2 Actin assembly and cell shape modulation, 
angiogenesis (Pluskota et al., 2011).
CASS4 Cas scaffolding protein 
family member 4
Actin dynamics (Kirsch et al., 1999).
INPP5D Inositol polyphosphate-5-
phosphatase
Negative regulator of myeloid cell proliferaton. 
Interacts with CD2AP; involved in actin 
remodelling and membrane trafficking (March et 
al., 2000).
MEF2C Myocyte enhancer factor 
2
Involved in cardiac and vascular development, 
neuronal survival (Akhtar et al., 2012).
Genome-wide association studies (GWAS) are a powerful tool for studying genetic variations
and their association with disease.  GWAS for late onset Alzheimer’s disease has found a
host of genes significantly associated with the condition (Table 1).  GWAS is limited by the
ability to pick out a specific gene from a cluster of genes (resolution), indeed Lambert et al.
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note  that  the  region  of  interest  around  ZCWPW1  is  large,  containing  about  10  genes
including MADD which is  already implicated in  Alzheimer's disease (Del  Villar  and Millar
2004).  Another limitation of GWAS is the understanding of how these gene 'hits' may be
contributing to the disease.  In spite of the limitations, these studies are contributing to an
increasingly clear  picture of  the disease and how it  develops.  Indeed,  when observed in
terms of gene product, the Alzheimer's GWAS results show a pattern of genes related to
neuronal maintenance, immune function, cytoskeletal dynamics, membrane dynamics and
membrane trafficking.
1.1.3 Alzheimer's Therapy and the Focus of 
Research
The only  licensed  therapies  for  Alzheimer's  to  date  are  supportive  in  nature,  promoting
cholinergic transmission (cholinesterase inhibitors donepezil, galantamine and rivastigmine)
or mitigating excitotoxicity using the NMDA receptor antagonist memantine (Kaduszkiewicz
et al., 2005; Koch et al., 2008).  It could be argued that current research has been driven by
the need for an effective, disease modifying therapy for Alzheimer’s disease.
In the last 10 years there have been attempts to develop new treatments, but clinical trials
have consistently failed to show both efficacy and safety. Immunotherapy was one approach
in which amyloid plaques were targeted for removal by the patient’s own immune system.
Interestingly,  even  with  successful  removal  of  plaques,  disease  progression  continued
(Holmes  et al., 2008). Another class of drugs that  have so far failed were the secretase
inhibitors; in theory lowering APP processing should minimise plaque formation and therefore
slow disease progression,  but  these enzymes have multiple biological targets.    Gamma
secretase cleaves Notch, CD44, cadherins, ephrin-B2 and ErbB4 (De Strooper et al., 1999;
Ni et al., 2001; Lammich et al., 2002; Marambaud et al., 2003; Georgakopoulos et al., 2006);
BACE1 is required for proper muscle spindle formation and peripheral myelination (Willem et
al., 2006;  Cheret  et  al., 2013).   With  the  broad  significance  of  secretase  processing,
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iInhibition should be expected to have profound effects on an organism, indeed the safety
profile of secretase inhibitors in clinical trials has been poor (Svedružić et al., 2013).
The failure to find safe effective therapeutics for Alzheimer’s disease only highlights the need
for a better understanding of the proteins involved in the condition.  Despite being the protein
underpinning  Alzheimer’s  disease,  research  into  APP has  been  neglected  relative  to  its
product Aβ.
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1.2 The APP Gene Family
The APP family are all type I transmembrane proteins, with a large extracellular portion made
of multiple distinct domains, and a smaller intracellular tail.  The APP family appears to have
emerged  ~900  million  years  ago  in  Bilaterians,  coinciding  with  the  evolution  of  nervous
systems  and  synapses.   Known  early  examples  of  APP  are  found  in  the  nematode
(roundworm) Caenorhabditis elegans and the fruit fly Drosophila melanogaster (expressing a
single gene each, APL-1 and APPL, respectively) (Shariati and De Strooper 2013; Figure 3).
The early emergence and conserved nature of APP suggest an important role in cell biology
(Daigle and Li 1993), furthermore, APP family protein isoforms are expressed throughout the
organism,  not  just  neuronally,  demonstrating  that  a  wider  biological  role  has  developed
(Sisodia et al., 1993).
Figure 3.) The Evolutionary History of APP family proteins (from Shariati and De Strooper 2013).  The APP
family emerged ~900million  years  ago (mya)  with  APL-1  and APPL in  worms and flies,  but  has undergone
duplication and contraction in divergent species (orange and blue spots, respectively).
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Figure 4.) Domain structures for APP family members (from Müller and Zheng 2012). All members contain
conserved, shared features including an acidic domain (Ac), E2 (ectodomain 2) and E1 (ectodomain 1), as well as
an intracellular YENPTY motif.  APP is unique in containing the Aβ  stretch, while APLP1 and APP's evolutionary
ancestors lack a Kunitz-type protease inhibitor (KPI) domain. E1 contains a heparin binding domain (HBD) and
copper binding domain (CuBD).
In humans, the APP family consists of APP, and APP like proteins 1 and 2 (APLP1 and 2,
respectively).  These proteins share many structural  elements (Figure 4),  in particular,  an
almost identical intracellular domain.  In spite of the structural similarities, the APP family
proteins have a multitude of isoforms, which through their domain inclusion and/or tissue
specificity may dictate very different functions.
1.2.1.1 Differences of APP, APLP1 and APLP2
APLP1, unlike APP and APLP2 is restricted to neurons of the central and peripheral nervous
system (Slunt et al., 1994; Lorent et al., 1995), and consists of two almost identical isoforms
with 650 and 651 amino acids, respectively (Uniprot.org).  APLP1 is also set apart from the
other APP family members within the brain by its apparent restriction to post-mitotic cortical
plate neurons, while APLP2 can be found in the proliferating ventricular/sub-ventricular zones
and APP is expressed in both  (Lopez-Sanchez et al., 2005).  APLP1 may be even further
restricted to post-synaptic membranes (Kim et al., 1995; Lo et al., 1995; Thinakaran et al.,
1995; Lyckman  et al. 1998).  While structurally distinct  from full  length APP and APLP2,
APLP1 overlaps somewhat with shorter isoforms lacking a KPI domain (exon 7, present in
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APP751,  APP770,  APLP2763);  interestingly  these  KPI  negative  isoforms  are  also  neuronally
predominant (Kitaguchi et al., 1988; Ponte et al., 1988; Tanzi et al., 1988).   While the domain
structure of  APLP2 appears more similar  to  APP than APLP1,  particularly  in  light  of  the
shared KPI domain, APLP2 has been proposed to be the most evolutionarily divergent family
member (Shariati and De Strooper 2013).
1.2.2 Structure of APP Family Members
1.2.2.1 Extracellular Domains
The  extracellular  domains  of  APP family  proteins  share  conserved  regions,  divided  into
ectodomain 1 (E1) and ectodomain 2 (E2).  The E1 of APP family proteins can be further
subdivided into a heparin binding domain and a copper binding domain.
At the N-terminal extremity of APP family proteins is a heparin binding domain (HBD), a site
which  contains  many  basic  residues  on  its  surface  capable  of  binding  extracellular
proteoglycans (Small et al., 1994). The HBD also contains a hydrophobic pocket, proposed
as a site for dimerisation or protein binding, indeed this site has been suggested as being a
ligand binding site or otherwise functioning as a growth factor in vivo (Rossjohn et al., 1999).
Neighbouring the HBD is  the copper/metal  binding domain,  a stretch containing a single
alpha-helix and beta-sheet, capable of binding metal ions (Bush et al., 1993).  This binding
appears to be able to reduce copper (II) to copper (I) (Multhaup et al., 1996), the functional
significance of this is unclear but has been proposed as a regulator of copper homeostasis
(Barnham et al., 2003).
Alternative  splicing  of  APP and  APLP2  produces  a  Kunitz-type  protease  inhibitor  (KPI)
domain,  this  may  be  significant  because  serine  proteases  are  implicated  in  promoting
neuronal cell growth (Wang and Reiser 2003).  Interestingly, KPI domain isoforms appear to
be more common in  non-neuronal  cells  such as  astrocytes  and a variety of  blood cells
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(Rohan de Silva et al., 1997; Van Nostrand et al., 1991a; Bush et al., 1990; Gardella et al.,
1990; Van Nostrand et al., 1991b).  Many potential roles for KPI domains appear to be linked
to wound repair and regulating blood clotting through inhibition of serine proteases.
C-terminal to the acidic and KPI domain is the E2 domain; forming multiple alpha-helices,
this domain dimerises supporting a model where APP can self-associate. Similar to the E1
domain,  the  E2  domain  has  heparin  (Clarris  et  al., 1997)  and  metal  binding  capability
(Dahms et al., 2012).  Within the E2 domain of APP is the “RERMS” motif, which has been
found to be sufficient for the growth promoting actions of secreted APP (Rosen et al., 1989;
Ninomiya et al., 1993; Roche et al., 1994).
1.2.2.2 Cell Adhesion Model of APP Function
The  extracellular  domains  of  APP family  proteins  are  diverse,  but  are  beginning  to  be
understood in the context of cell adhesion.  Dimerisation of the extracellular domains has
been studied at some length previously in the context of proteolytic processing and cell-cell
adhesion (Scheuermann et al.,  2001; Soba et al., 2005; Munter et al., 2007), with potential
for a role in synaptic adhesion (Baumkötter et al., 2011).
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Figure 5.) Model of APP dimerisation (from Hoefgen et al., 2014). Heparin (blue line) induces dimerisation of
the E1 domains, if the APP molecules exist in the same cell (a) this leads to E2 binding, if the APP molecules exist
in different cells (b) this leads to cell-cell adhesion.
Understanding  of  the  nature  of  the  APP  family’s  extracellular  domain  has  allowed  the
formulation of a model for the function in cell adhesion. Extracellular matrix (ECM) induced
dimerisation  may  either  bind  APP/APLP  from  the  same  cell  or  two  separate  cells  for
anchorage  (Hoefgen  et  al., 2014;  Figure  5).   In  this  model,  the  maintenance  of  an
extracellular interaction would dictate the intracellular output of APP.
1.2.2.3 Intracellular Domain
The intracellular domain of APP family members is highly conserved (King and Turner 2004),
both between members (APP, APLP1, APLP2) and through lineage (APL-1, APPL).  Nuclear
magnetic  resonance  (NMR)  study  has  determined  that  AICD has  a  dynamic  secondary
structure (Ramelot  et al., 2000). AICD adopts flexible conformation capable of interacting
with a wide number of targets in much the same way as α-synuclein, the central protein in
Parkinson's disease (Uversky et al., 2003).  The intrinsic disorder in peptide sequences like
AICD is thought to support molecular recognition in an intracellular signalling context in a
multitude of  ways.   It  allows binding of  partners  transiently,  with  high specificity but  low
affinity;  the  protein  also  accomodates  its  own conformation  to  bind  diverse partners.   A
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protein with dynamic,  low complexity structure may also aid its own rapid destruction,  a
feature particularly useful for important regulatory proteins (Uversky et al., 2005).
Three sequence motiffs are known to be of importance to AICD.  The YTSI sequence is
important in the sorting of APP, obeying the YXXΦ consensus motif for clathrin mediated
endocytic sorting (Lai et al., 1998; Bonifacino et al., 2003).  The VTPEER motif is the second
prominant sequence, allowing the stabilisation of AICD with Fe65 family proteins through the
dimeric adaptor protein 14-3-3γ (Sumioka et al., 2005).  The third and perhaps most widely
studied feature of AICD is the GYENPTY sequence, containing an NPXY motif.  NPXY is
found in tyrosine receptor kinases among others (Chen  et al., 1990; Bonifacino and Traub
2003; Lemmon and Schessinger 2010), and is able to regulate endocytosis and trafficking
(Lai  et  al., 1995;  Perez  et  al.,  1999;  Ring  et  al.,  2007).  The GYENPTY motif  of  APP is
important for the function of known interactors that bear a phosphotyrosine binding domain
such  as  X11,  Fe65  family  proteins  (Borg  et  al., 1996)  and  JIP (Matsuda  et  al., 2001).
Interestingly, mutation of the GYENPTY sequence alters APP trafficking (Perez et al., 1999),
resulting in diminished Aβ production (Ring et al., 2007).
AICD  is  released  through  gamma  secretase  cleavage  much  like  Notch,  a  protein  that
promotes  proliferative  signalling  during  neurogenesis  via  intracellular  domain  nuclear
translocation. Indeed AICD has been shown to regulate gene expression by interacting with
Fe65 and Tip60 (Cao and Sudhof 2001).  The possibility of AICD being part of a G-coupled
receptor signaling-like pathway has been found, where AICD was found to interact with Gαo
(Nishimoto et al., 1993; Brouillet et al., 1999).  AICD Gαo interaction has since been proposed
as contributing to synaptogenesis (Ashley et al., 2005) or calcium homeostasis (Leissring et
al., 2002; Shaked et al., 2009).   
Interestingly, Alzheimer’s disease-like pathology can be brought about by overexpression of
AICD independent of APP (Ghosal  et al., 2009). Specifically, AICD overexpression in mice
produces  memory  deficits,  widespread  neuronal  death  in  the  hippocampus  and  dentate
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gyrus, and is associated with prolific tau hyperphosphorylation.
The  intracellular  domain  of  APP family  proteins  has  received  limited  attention  regarding
mechanistic  output  and  interactions,  therefore  studying  this  domain  may  yield  better
understanding of APP, its gene family, and perhaps Alzheimer’s disease itself.
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1.3 The Endosome
Cells are highly ordered and compartmentalised, but the internal structure needs to maintain
a balance between import  and export  of  components.  The cell  must  transport  cargos to
where they are needed and rapidly alter the composition of its membranes in response to
changing  needs.  The  cell  fulfils  the  needs  of  dynamic  compartmentalisation  through
intracellular trafficking: the budding, fission and fusion of membrane enclosed compartments
collectively known as the endosome (Figure 6).
Figure 6.)  Road map of  the secretory and endocytic  pathways (from Alberts  et  al., 2008).  From the
endoplasmic reticulum to the plasma membrane, membranes are important to transport and process cell products
and external materials.  A) Compartments and sites which contribute to intracellular trafficking are as follows: the
endoplasmic  reticulum,  the  Golgi  apparatus,  secretory  vesicles,  plasma  membrane  (cell  exterior),  early
endosome, late endosome and lysosome. B) Red arrows show secretory pathways, blue arrows denote retrieval
(recycling) pathways and green arrows indicate the endocytic pathway.
Many  cellular  products  and  specific  extracellular  materials  are  either  unable  to  diffuse
through the cytoplasm,  or  are required in  a limited range of  locations.   Some would be
harmful  if  allowed outside of  their  functional  locations.  The cell  produces and transports
products in a way that only exposes them to environments necessary to their movement and
function (Cung et al., 1989).
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1.3.1 Mechanisms of Intracellular Vesicular 
Trafficking
1.3.1.1 Endosomal Identity and Phosphoinositides
Phosphoinositides (PIPs) are a class of phospholipids that, although low abundance in cell
membranes, have an important role to play in regulating cellular homeostasis.  PIPs act as a
membrane anchored signal that can communicate the identity of a membrane, ensuring the
correct assembly of protein complexes and by extension the behaviour of that component of
the  cell.  There  are  a  number  of  PIPs,  enabling  differential  labelling,  they  differ  in  the
presence of phosphate (alone or in combination) on the third, fourth and fifth carbon of the
inositol ring.  When membrane identity changes occur, phosphate patterns on the inositol
head  can  be  rapidly  altered  through  the  action  of  kinases  and  phosphatases  (Table  2;
Reviewed in Di Paolo and Camilli 2006; Krauss and Haucke 2007).  PIPs also act as a pool
of secondary messengers: diacylglycerol and cytosol soluble inositol phosphates have their
own impact on cell behaviour (Reviewed in Hokin 1985).
Table 2.) Overview of phosphoinositides: location of enrichment and roles (from Paolo and Camilli 2006;
Kraub and Haucke 2007).  Relevant kinases and phosphatases are also listed.
PIP Enrichment Roles Forming Kinase Phosphatase
PI(3)P Early endosome Protein recruitment for 
trafficking
Vps34 Myotubularins
PI(3,5)P2 Late endosome Control of fission / 
fusion events, GLUT4 
translocation
PIKfyve Myotubularins, Fig4
PI(4)P Golgi Protein recruitment / 
destabilisation for 
trafficking
PI4KA
PI(4,5)P2 Plasma membrane Protein recruitment for 
trafficking, Na ion 
channel opening, actin
rearrangement, 
second messenger 
pool
PI4P5Ks Synaptojanin, 
OCRL
PI(3,4,5)P3 Plasma membrane Positive mTORC2 
signal (via PDK1)
PIK3CA (P110a) PTEN, 
synaptojanin, 
SHIP2
1.3.1.2 Vesicle Formation
Transport  between  endosomal  compartments  and  the  plasma membrane  requires  cargo
specific, distinct vesicles to be formed. The formation of vesicles come about through the
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recruitment of coat proteins around a membrane, deforming that membrane and 'cutting' it
from its source.  These coat proteins can be clathrin, COPI or COPII-coated. Clathrin coated
vesicles were the first to be identified and demonstrate the principles of vesicle formation
common to coat proteins (Reviewed in Traub and Wendland 2010; McMahon and Boucrot
2011).   Clathrin  is  responsible for  vesicles shuttling between the plasma membrane and
endosome,  and between the endosome and outer  (trans)  Golgi  network,  while  COPII  is
responsible for exporting vesicles from the endoplasmic reticulum (ER).  COPI  vesicles exist
in the early secretory pathway, transporting primarily between Golgi stacks (cisternae), but
otherwise from the Golgi to constitutive secreting vesicles or back to the ER (Pearse 1976;
Owen et al., 2004; Barlowe et al., 1994; Letourneur et al., 1994; Waters et al., 1991).
Clathrin is composed of  three light and three heavy protein chains that together make a
‘three-legged’ structure  (triskelion),  this  can  be  recruited  to  a  membrane  by  specialised
adaptor proteins.  The progressive recruitment of clathrin then forms a basket-like structure
on a membrane, the curvature of which is thought to promote budding of the new vesicle
(Lundmark and Carlsson 2010). Overcoming the energy barrier of vesicle fission requires the
action of proteins such as dynamin, physically distorting the bud and recruiting lipid modifying
enzymes. Upon fission, the coat proteins disassemble to leave a ‘naked’ transport vesicle.
Figure 7.) Clathrin coat assembly (from McMahon and Boucrot 2011).  Five steps of clathrin coat assembly:
nucleation, cargo selection, coat assembly, scission, and uncoating.
Clathrin  coated  vesicle  formation  can be broken down into  five  steps:  nucleation,  cargo
selection,  coat  assembly,  scission and uncoating  (Figure 7;  Reviewed in  McMahon and
Boucrot  2011).   Nucleation  is  the  conglomeration  of  initial  coat  protein  effectors,  with
PI(4,5)P2  rich areas of the membrane binding FCH domain only proteins (FCHO 1,2), which
in  turn  aids  the  recruitment  of  intersectin  and  epidermal  growth  factor  receptor  (EGFR)
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pathway substrate 15 (EPS15) and EPS15 related (EPS15R) (Henne  et al., 2010).   The
presence of PI(4,5)P2, FCHO proteins and  EPS15-EPS15R aids binding of adaptor protein 2
(AP2) and generates some initial membrane curvature, leading to the start of clathrin coating.
Cargo selection  is  made possible  by cargo-specific  adaptors binding AP2,  these include
Numb (for Notch recruitment), β-arrestin (recruiting G-protein coupled receptors), and ARH,
selecting  low density  lipoprotein  (LDL)  receptors  (Ferguson  et  al., 1996;  Santolini  et  al.,
2000; Keyel et al., 2006).  Coat assembly continues through the progressive recruitment and
polymerisation of clathrin triskelions, creating an increasingly spherical bud.  Amphiphysin
and sorting nexin 9 (SNX9) are BAR-domain containing proteins; they bind AP2 and recruit
dynamin to the 'neck' of the budding vesicle; dynamin triggering scission of the vesicle upon
GTP hydrolysis (Wigge et al., 1997; Boucrot et al., 2010).  Uncoating of the vesicle's clathrin
shell is performed by heat shock cognate 70 (HSC70) ATPase, in conjunction with cyclin G-
associated kinase (GAK) or auxillin (Schlossman  et al., 1984; van der Bliek  et al., 1993;
Sweitzer et al., 1998; Stowell et al., 1999). Phosphatases such as synaptojanin (a curvature
sensitive 5' phosphatase) are recruited through the maturation of the clathrin coat, and are
capable of dephosphorylating inositol headgroups, in this case the loss of PI(4,5)P2 changes
the identity (protein binding profile) of the vesicle (Cremona et al., 1999; Chang-Ileto et al.,
2011).
1.3.1.3 Vesicle Targeting, Docking and Fusion
For  a  vesicle  to recognise a specific  destination  and begin  fusion,  targeting  is  required.
Targeting depends on Rab proteins, (small GTPases in the Ras superfamily), complementary
Rab  effectors  and  vesicular/target  SNARE  proteins  (soluble  N-ethylmaleimide-sensitive
factor attachment protein receptors). Rab proteins recognise complimentary Rab effectors, in
a docking context these effectors ‘tether’ vesicles with the target membrane (Reviewed in
Bonifacino and Glick 2004).  Tethering allows SNARE proteins on the vesicle (v-SNARE) and
the  target  membrane  (t-SNARE)  to  interact,  docking  the  vesicles  and  catalysing  fusion
(McNew et al., 2000; Pfeffer 1999; Jahn and Scheller 2006).
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The process of vesicle docking and fusion begins with Rab proteins, a diverse group with
highly selective distribution (Pereira-Leal and Seabra 2001).  Rab proteins cycle between
their GTP bound, membrane associated state and GDP bound, cytosolic state.  The GDP
bound state keeps the Rab inactive and primarily in the cytosol through association with
another protein, the Rab-GDP dissociation inhibitor (GDI) (Garrett et al., 1994).  Rabs contain
a prenylated tail capable of membrane anchoring, but need GDI displacement factor (GDF)
and a Rab specific GDP/GTP exchange factor (Rab-GEF) to remove GDI binding and allow
interaction with its effector (Figure 8; Grosshans et al., 2006).  To reverse the behaviour of
Rabs,  a GTPase-activating protein (GAP) hydrolyses GTP allowing Rab sequestration by
GDIs (Ullrich et al., 1993; Ullrich et al., 1994; Soldati et al., 1995; Rak et al., 2003).
Figure  8.)  Rab  membrane  association  and  activation  (from Grosshans  et  al., 2006).   Prenylated  Rab
GTPase is soluble and inactive when bound to GDI. GDF allows the Rab GTPase to be released from GDI and
attached to the organelle membrane via its isoprenyl anchor.  The activation of Rab GTPases involves the GEF
mediated exchange of GDP for GTP on the organelle anchored Rab, facilitating the binding and action of specific
effectors.  Recycling  of  Rab  GTPases  occurs  through  Rab  specific  GAPs  which  increase  the  rate  of  GTP
hydrolysis, the inactive Rab GTPase can then be removed from the membane by GDI to rejoin the cytosolic pool.
Rab  effectors  can  vary  depending  on  the  required  function  including  motor  proteins  for
vesicle transport or tethering proteins for vesicle docking.  In the case of vesicle docking,
tethering proteins  interact  with Rabs to allow an initial  docking of  the vesicle and target
membrane (Grosshans et al., 2006).  To fuse a vesicle and a target membrane requires both
membranes to be effectively touching, exchanging lipids, and for water to be displaced from
the surface of each membrane, this energetically unfavourable event requires specialised
proteins, SNAREs.
Vesicle fusion occurs when two specific corresponding SNAREs bind to each other: a single
stretch v-SNARE and 2-3 member t-SNARE complexes, tightening in a zipper-like fashion
(Sutton  et al., 1998).  Full  fusion does not necessarily occur immediately,  in the case of
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neurotransmitter  exocytosis  Ca2+ triggers  the  final  rapid  fusion.   After  membrane  fusion
SNAREs must be recycled for reuse; the cell uses a protein called NSF and two accessory
proteins to pry the SNAREs apart in an ATP-dependent manner (Söllner et al., 1993).
1.3.2 Intracellular Vesicular Trafficking
The compartments that make up the intracellular trafficking system consist of the ER, the
Golgi apparatus, secretory vesicles, plasma membrane (cell exterior), early endosome, late
endosome, and lysosome.  
By internalising plasma membrane via the process of endocytosis, the cell imports materials
such  as  nutrients,  some of  which  require  capture  and  internalisation  by  the membrane.
Plasma  membrane  proteins  can  also  be  expected  to  receive  damage,  lose  function  or
otherwise require removal due to changing cellular needs.
Endocytosed material must be sorted to differentiate between material destined for recycling
or  degradation;  compartments  termed  early  endosomes  fulfill  this  function  in  retrograde
transport.  If not retrieved from early endosomes to be translocated or recycled, a transition
to late endosomes occurs via multivesicular bodies, so named for their highly invaginated,
vesiculated  morphology  (Reviewed  in  Katzmann et  al., 2002;  Gruenberg  and  Stenmark
2004).
Multivesicular  bodies  process  deeper  into  the  cell  via  microtubule  mediated  transport
(Nielsen  et  al., 1999)  where  protein  composition  and  the  internal  environment  of  the
compartment  changes:  inactive  degradative  proenzymes  build  up  and  the  progressive
acidification of the lumen takes place through the action of V-type ATPase proton pumps.
Fusion of existing lysosomes introduces active hydrolases, in turn activating the proenzymes
present (Reviewed in Huotari and Helenius 2011).
34
1.3.2.1 Endocytosis and the Early Endosome
The internalisation of plasma membrane during endocytosis results in vesicles consisting of
plasma membrane and the proteins associated with it, in addition, any materials associated
with this protein is also internalised.  The cell must make "decisions" about the fate of this
material,  it  does  this  in  the  early  endosome.   LDL,  transferrin  and  EGF  receptors  are
representitive of how the early endosome sorts endocytosed material.  The main method of
cholesterol transport in the body is in protein bound form (LDL).  LDL receptors on the cell
surface  sequester  LDL,  which  is  then  internalised  by  the  cell  via  clathrin  mediated
endocytosis.  The resulting vesicles join with the early endosome where the mildly acidic
environment dissociates the LDL cargo from its receptor (Anderson et al., 1977).  The early
endosome membrane tubulates around the free receptors, enriching them away from lumen
soluble material, these tubules then bud off, being recycled back to the plasma membrane.
Transferrin receptors bind the iron transport molecule transferrin, and upon binding follows
the same route as LDL into the early endosome.  The transferrin receptor differs in that it is
only the iron that dissociates from transferrin within the early endosome, while transferrin and
its receptor are recycled to the cell surface where the iron-free transferrin dissociates again
(Dautry-Varsat  et al., 1983).  The EGF receptor differs yet again, first activating a cellular
signalling response, then being irreversibly downregulated upon ligand binding, desensitising
the cell to further signals (Sigismund et al., 2008).  EGF and its receptor is sorted to the late
endosome, much like LDL and its bound cholesterol.
1.3.2.2 Exocytosis
The ER is  a network of  tubules surrounding the nucleus,  and an extension of  the outer
nuclear membrane, central to protein and lipid synthesis as well as Ca2+ homeostasis. Newly
synthesised proteins associated with the ER are passed on to the Golgi apparatus, a stack-
like arrangement of flattened compartments.  The Golgi acts as a site of oligo/polysaccharide
synthesis, protein modification, and ultimately as an import / export hub, sorting products for
their respective destinations.  
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1.3.3 Degradative Pathways
Lysosomes are the primary site of digestion within the cell, containing a myriad of digestive
enzymes: proteases, lipases, nucleases, glycosidases, phosphatases, phospholipases and
sulphatases,  acid  hydrolases  requiring  low  pH  for  proteolytic  activation  and  continued
function.  The lysosome maintains a low pH through the use of V-type ATPase, which pumps
H+ into the lumen, in a reversal of the method for cellular ATP synthesis, where H+ gradient is
used to form ATP (reviewed in Holliday 2014).  Lysosomes are formed from the convergence
of several pathways, and as such exhibit a somewhat heterogenous morphology (Warburton
and Wynn 1976; Kelly et al., 1989).  Lysosomal hydrolase precursors are sourced from the
secretory  pathway,  while  membranes  and  digestion  targets  come  from  endocytosis,
endosomal maturation or autophagy. New lysosomes are also 'seeded' by the hydrolases
and  undigested  products  of  existing  lysosomes.   The  progressive  nature  of  lysosome
formation and hetrogeneity  makes the  distinction  between  late  endosome and  lysosome
difficult, leading to the more general term "endolysosome".
Lysosomal  activity  attempts  to  digest  material  down  to  basic  molecular  building  blocks,
releasing them back into the cell for reuse (Sagné and Gasnier 2008).  Some materials are
resistant to lysosomal action and undergo successive cycles of degradation in endosomal
compartments termed residual bodies.  Residual, degradation resistant material must either
be exocytosed or allowed to exist in the cytoplasm as lipofuscin granules  (Schnitka 1965;
Kerr 1970; Schellens 1974; Munnell and Cork 1980).  Lysosomal disfunction and exocytosis
is an emerging area of interest, with an varied biological and clinical implications including
Alzheimer's disease and Parkinson's disease (Annunziata  et al., 2013;  Reviewed in  Samie
and Xu 2014; Zhang  et  al.,  2009).  Melanin secretion is  a specialised form of  lysosomal
exocytosis  (Mishima  1967),  and  plasma  membrane  repair  can  rapidly  take  place  upon
lysosome/plasma  membrane  fusion  (Reddy  et  al., 2001),  other  more  recent  discoveries
include a  role  in  microglial  signalling  (Dou  et  al., 2012),  neurite  outgrowth (Arantes and
Andrews 2006) and phagocytic control (Samie et al., 2013; Czibener et al., 2006).
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1.3.3.1 The Late Endosome
From the early endosome, materials not recycled or otherwise retreived are destined for the
lysosome for degradative processing.  The cell must ensure membrane-bound material is
collected  within  the  endosomal  space  and  does  this  by  clustering  membrane  proteins,
invaginating  the  membrane  that  contains  them  into  the  lumen  of  the  endosome.   The
resulting intravesicular budding creates vesicles within the endosomal membrane which is
now termed a 'multivesicular body' (Seglen and Bohley 1992).  Subsequent lysosomal fusion
allows  digestion  of  both  soluble  and  transmembrane  material.   The  internal  vesicles  of
multivesicular bodies are created using a specialised group of complexes: ESCRT-0,I,II,III
(Babst  et al., 2002; Katzmann et al., 2001).  The ESCRT complexes recognise membrane
proteins tagged for degradation by ubiquitin and progressively collects them, then sequesters
these enriched vesicles into the endosomal lumen (Wollert et al., 2009).
1.3.3.2 The Ubiquitin-Proteasome System
The ubiquitin-proteasome is responsible for the vast majority of protein degradation including
damaged,  abnormal,  and  heavily  regulated  proteins  (Rock  et  al., 1994).   The  ubiquitin-
proteasome system degrades proteins by attaching ubiquitin, a 76 amino acid polypeptide to
a target protein, this can lead to either deubiquitination, where the target protein is "rescued"
from destruction, or it can continue to be ubiquitinated until destruction by the proteasome
(Lilienbaum 2013; Figure 9).  Proteasome based degradation is primarily carried out by the
26S proteasome complex, a 20S barrel shaped catalytic subcomplex made of proteases and
a 19S regulatory subcomplex responsible for the capture, movement, and unfolding of the
ubiquitinated protein (Groll and Huber 2003).
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Figure 9.) The Ubiquitin-Proteasome System (from Lilienbaum 2013).  Ubiquitin (Ub) is loaded onto an E1-
activating enzyme (E1 enzyme) in an ATP-dependent manner, this "activated" ubiquitin is then translocated to E2-
conjugating enzyme (E2 enzyme).  E3 enzymes facilitate transfer to the substrate protein, this substrate protein
can be rescued from the proteasome by deubiquitinating enzymes (DUB) or  undergo subsequent  rounds of
ubiquitination.   Further  ubiquitination  by  E2/3  or  rapid  multiubiquitination  by  E4,  commits  the  substrate  to
degradation by the proteasome, releasing amino acids and ubiquitin.
1.3.3.3 Autophagy
Autophagy is the process of destroying damaged and aggregated proteins, oxidised lipids,
organelles and intracellular pathogens.  The cell performs autophagy by manipulating internal
membranes  and  the  proteins  that  associate  with  them to  form an  autophagosome.   An
autophagosome is a double membraned vesicle that engulfs cellular material and degrades it
upon fusion with acid hydrolase rich lysosomes.
38
Figure 10.) Autophagosome Initiation Dependent on mTORC1 Inactivity (adapted from Lilienbaum 2013).
Energy and stress signalling determines mTORC1 signalling – high energy, low stress means mTORC1 activity.
Lack of mTORC1 signalling leads to dissociation from the ULK complex, subsequent activation of the Beclin-
vps34 complex which intiates autophagosome development.
Autophagy initiation can be controlled by Unc-51 like autophagy activating  kinase (ULK)
complex, which is made up of an ULK protein (ULK1 or ULK2), Atg13, focal adhesion kinase-
family interacting protein of 200kDa (FIP200) and Atg101 (Jung et al., 2009; Mercer  et al.,
2009).  Under growth positive (high energy) conditions, autophagy is inhibited by mTORC1,
which  binds  the  ULK  complex,  phosphorylating  Atg13  and  deactivating  it.   Inactivity  of
mTORC1  leads  to  dissociation  of  mTORC1  from  the  ULK  complex  and  eventual
dephosphorylation of Atg13 (Chang et al., 2009; Ganley et al., 2009; Hosokawa et al., 2009;
Jung  et al.,  2009).   When active,  ULK1 phosphorylates "activating molecule of  Beclin 1-
regulated autophagy 1" (Ambra1) of the Beclin1 complex (Kang et al., 2011).  The Beclin1
complex in turn associates with the class III phosphatidylinositol 3-kinase Vps34 (with other
protiens including Atg14) to form the Beclin-Vps34 complex, capable of synthesising PI(3)P
from  phosphatidylinositol,  which  is  key  to  the  identity  /  development  of  the  initial
autophagosomal membrane, the phagophore (Figure 10; Kihara et al., 2001; Funderburk et
al., 2010; Devereaux et al., 2013; Lilienbaum 2013).
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The phagophore (also known as the isolation membrane) is the initial nucleation point for the
autophagosome which will  eventually become the autolysosome (Figure 11;  Longatti  and
Tooze 2009).  The source of phagophore lipid membrane has been the subject of much
debate, with contributions ranging from ER and Golgi to mitochondria (Hayashi-Nishino  et
al., 2009; Yla-Anttila  et al., 2009; Hailey et al., 2010; Mari  et al., 2011).  Regardless of the
source, the phagophore must elongate to form a mature autophagosome.  This process is
completed with the transmembrane protein Atg9, trafficked from the trans-Golgi network and
late endosome, thought to act in lipid and protein recruitment (Kim et al., 2002).  A host of
other  proteins  are  recruited  to  the  autophagosome  by  PI(3)P  to  aid  in  nucleation  and
elongation: WD-repeat domain phosphoinositide interacting proteins (WIPI1 and 2), double
FYVE-containing protein (DFCP1), and autophagy linked FYVE protein (ALFY).
Figure 11.) Development of the Autophagosome (from Longatti and Tooze 2009). With the initial creation of
the phagophore (IM/PAS) through ULK1 and the synthesis of PI(3)P, the membrane is expanded with the addition
of lipidated LC3 and the Atg12-Atg5 system.  Closure around the captured cell material creates an immature
autophagosome  (Avi)  which  eventually  develops  with  the  contribution  of  endosomal  compartments  and
lysosomes (E/LY) into a degradative autophagosome (Avd), maturation leads to the fully funtional autolysosome
capable of destroying the cellular material captured within.
Two ubiquitin-like conjugation systems exist in the elongating phagophore.  The Atg12-Atg5
system forms an E3-like (ubiquitin ligase-like) enzyme, while microtubule-associated protein
light  chain  3  (LC3)  is  reversably  sequestered  from the  cytoplasm.  Sequestration  occurs
through processing and subsequent conjugation with phosphatidylethanolamine (PE) to form
the lipidated "LC3-II" (the unlipidated form being termed "LC3-I") (Hanada et al., 2007; Fujita
et al., 2008). Both LC3-II and the Atg12-Atg5 system contribute to the phagophore either by
elongation  or  autophagosome closure  (Hanada  et  al., 2007;  Xie  et  al., 2008;  Geng and
Klionsky  2008).   In  addition  to  allowing  autophagosome elongation,  LC3  proteins  make
targeted autophagy possible by recruiting adaptor proteins such as p62 that in turn sequester
cargos (ubiquitinated proteins in the case of p62) (Pankiv et al., 2007; Shvets et al., 2008).
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After  closure  of  the  autophagosome,  maturation  occurs  through  fusion  with  early/late
endocytic compartments (Liou et al., 1997; Berg  et al., 1998). Lysosomal fusion completes
maturation  to  a  degradative  autolysosome,  allowing  vacuolar  V-ATPases  and  cathepsin
hydrolases to work in tandem to acidify and proteolytically digest the contents, respectively
(Lukacs et al., 1990; Mullins and Bonifacino 2001).  The products of completed autophagy
eventually  find  their  way  back  into  cytoplasm  to  be  recycled  through  the  actions  of
permeases (Yang  et al., 2006),  increasing the nutrient  pool of  the cell  and subsequently
restoring energy signalling.
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1.4 The Mechanistic Target of 
Rapamycin
The mechanistic  target  of  rapamycin  (mTOR)  is  a  large  serine  /  threonine  kinase,  with
orthologues existing down to the level of yeast (Kunz et al., 1993).  mTOR is named after the
macrolide antibiotic and immunosuppresant rapamycin that lead to its discovery.
mTOR acts  as  the  linchpin  of  energy  signalling  within  the  cell,  integrating  internal  and
external  energy cues such as  insulin,  amino acid  abundance,  AMP,  oxygen,  and growth
factors.  mTOR translates upstream energy signals into appropriate responses – blocking
autophagy,  encouraging  mRNA  translation,  changing  the  level  of  lipid  synthesis,
mitochondrial  proliferation  and  function  (Reviewed  in  Zoncu  et  al., 2011;  Laplante  and
Sabatini 2012).
1.4.1 mTOR Structure
The mTOR protein itself is a 289kDa kinase subunit that exists in two distinct complexes,
mTOR complex 1 and mTOR complex 2 (mTORC1 and mTORC2, respectively) (Figure 12;
Loewith  et  al., 2002).   These  complexes  have  structural  overlaps;  both  containing  the
proteins mTOR, DEP domain containing mTOR interacting protein (DEPTOR) (Peterson et
al., 2009)  and mammalian lethal  with SEC13 protein 8  (mLST8)  (Loewith  et  al., 2002).
Distinctions  between  the  complexes  include:  regulatory  associated  protein  of  mTOR
(RAPTOR) (Hara  et al., 2002) and 40kDa Pro-rich Akt substrate (PRAS40) (Sancak  et al.,
2007) in mTORC1 and rapamycin insensitive companion of mTOR (RICTOR); mammalian
stress activated MAP kinase interacting protein 1 (mSIN1) (Yang  et al., 2006); and protein
observed  with  RICTOR  (PROTOR)  restricted  to  mTORC2  (Sarbassov  et  al., 2004;
Wullshleger et al., 2005; Pearce et al., 2007).
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Many mTOR subunits beyond the kinase domain itself are primarily concerned with binding –
the DEP and PDZ domains in DEPTOR, WD40 repeats of mLST8, RNC, HEAT repeats and
WD40 repeats in RAPTOR, as well  as the PH domain and RBD of mSIN1.  The mTOR
subunit also contains many domains concerned with binding, including HEAT repeats, FAT,
FRB, and FATC domains.  Elements of mTORC2 without obvious domains (RICTOR and
PROTOR) stand out as likely structural scaffolds.
Figure 12.) The structure of mTORC1 and 2.   mTORC1 and 2 have overlapping subunit members, mTORC1
contains  the  subunits  mTOR,  DEPTOR,  mLST8,  RAPTOR  and  PRAS40,  while  mTORC2  contains  mTOR,
DEPTOR, mLST8, RICTOR, mSIN1 and PROTOR. The mTOR kinase is shown in black, other shared subunits
are shown in blue, with those unique to mTORC 1 and 2 are red and green respectively.
mTORC1 is perhaps the better understood complex, activated by growth factor receptors via
the  tuberous  sclerosis  complex  and  the  monomeric  GTPase  Rheb.  mTORC1  is  also
controlled by amino acid abundance via Rag-GTPases and the Ragulator complex (Figure
13; Garami et al., 2003; Tee et al., 2003; Sancak et al., 2008; Sancak et al., 2010)
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Figure  13.)  mTORC1  signalling  pathway.  Energy  signalling  controls  cell  behavior,  ensuring  the  correct
response to high or low energy availability and stresses. Appropriate energy management is acheived through the
interaction of induction or suppression signals (green and red arrows respectively). mTORC1 is a central point in
energy signalling, integrating positive energy signals such as external signalling proteins and hormones (Wnt,
insulin),  growth factors (IGF), and nutrients (amino acids), or  negative energy / stress signals such as AMP,
hypoxia or DNA damage.  mTORC1 turns the upstream signals into downstream effects through its action as a
kinase on proteins such as S6K1 and 4EBP1. Control of mTORC1 is tightly linked to the state of the GTPase
Rheb, which activates mTORC1 when GTP-bound, but not when converted to its GDP-bound state (black arrow).
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Figure  14.)  mTORC2  signalling  pathway.  mTORC2,  like  mTORC1  helps  acheive  appropriate  energy
management through the interaction of induction or suppression signals (green and red arrows respectively).
mTORC2 signalling  overlaps  with  mTORC1,  both  of  which  integrate  energy signals  into  cellular  responses,
however mTORC2 also has its own downstream effects.   mTORC2, like mTORC1 is susceptible to insulin /
growth factor signalling, and feeds into mTORC1 signalling via Akt phosphorylation of TSC1/2. mTORC2 controls
apoptosis  and stress  response genes  by targeting  FOXO1/3 via  SGK and Akt.  Another  established role  for
mTORC2 is the control of cytoskeletal reorganization via PKC and Rho GTPases.
mTORC2 is less well understood, but signals via growth factors to serum and glucocorticoid-
regulated  kinase  (SGK)  to  regulate  cell  survival  via  fork  head  box  protein  O1  and  3
(FOXO1/3), protein kinase C (PKC) and Rho GTPases to control cytoskeleton organization,
and Akt.  Akt phosphorylation at Ser473 signals both mTORC1 via TSC1,2 and a second
signal to FOXO1/3, promoting cell survival and cell cycle progression (Figure 14; Jacinto et
al., 2004; Guertin et al., 2006; Shiota et al., 2006; Garcia-martinez and Alessi 2008; Ikenoue
et al., 2008; Facchinetti et al., 2008).
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1.4.2 mTOR in Human Health
After first being pursued as an antibiotic (Vézina et al., 1975; Sehgal et al., 1975), rapamycin
was  found  to  be  capable  of  preventing  organ  allograft  rejection  through  suppression  of
mTOR mediated immune cell expansion (Calne  et al., 1989; Collier 1989; Thompson and
Woo 1989;  Tocci  et  al., 1989).   Further  investigation  into  the  mechanism  of  rapamycin
revealed just how significant its action was on how a cell functions: having a role in the cell
cycle (Heitman et al., 1991; Brown et al.,  1994) including mammalian cells (Sabatini  et al.,
1994;  Sabers  et  al.,  1995),  and  involvement  in  translation  initiation,  transcription  factor
localisation and dependence on nutrient state (von Manteuffel et al., 1997; Hara et al., 1998;
Wang et al., 1998; Schmidt et al., 1998; Beck et al., 1999; Gingras et al., 2001).
mTOR and insulin signalling are relevant to pathology in that insulin resistance can occur via
an  mTORC1  dependent  feedback  loop.  The  downstream  target  of  mTORC1,  S6K1
encourages mRNA translation but  also phosphorylates IRS1,  making the insulin  receptor
insensitive  to  further  insulin  signals  (Um  et  al., 2004).  The  reliance  on  an  mTORC1
dependent feedback signal is key here – chronically high amino acid levels would signal
insulin resistance,  just as an insulin signal would, shutting down glucose uptake, but still
signalling a ‘high energy state’ for the cell (Newgard et al., 2009).
The wider biological context of mTOR signalling is primarily one of metabolic and proliferative
control, but by extension, also one of ageing.  Research has shown mTOR inactivation to be
linked with longevity in yeast (Kaeberlein et al., 2005), worms (Jia et al., 2004), flies (Bjedov
et  al., 2010),  and  possibly  even  in  mammals  (Neff  et  al.,  2013;  Harrison  et  al., 2009;
Blagoskonny 2013; Ehninger and Neff 2014).
mTOR as a driver of ageing can be explained by several mechanisms.  One factor that may
play a role is stem cell exhaustion, where mTORC1 signalled proliferation pushes stem cells
towards  senescence,  so  that  old  cells  can  no  longer  be replaced  (Janzen  et  al., 2006;
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Molofsky et al., 2006). Damage to DNA and cellular components by reactive oxygen species
(Reviewed in  Cui  et  al., 2011),  may be  relevant  because  of  mTOR’s  proposed  positive
regulation of mitochondrial function and biogenesis (Cunningham et al., 2007). The turnover
of  misfolded  and  damaged  cellular  components  is  a  likely  contributing  factor  to  mTOR
suppression  dependent  longevity.   The  importance  of  autophagy  in  longevity  related  to
mTOR inhibition  has been consistently  reported (Hansen  et  al., 2008;  Toth  et  al., 2008;
Bjedov  et al., 2010) and changes in mRNA translation such as 60s ribosomal depletion or
eIF4E modulation also appears to be intimately linked (Hansen et al., 2007; Pan et al., 2007;
Syntichaki et al. 2007; Steffen et al., 2008).
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1.5 The Phosphoinositide Kinase 
PIKfyve
The PIKfyve complex acts as a phosphoinositide kinase, phosphorylating the 5' position of
PI3P to produce PI(3,5)P2 which is also thought to act as a source of PI5P after phosphatase
processing (Zolov  et al., 2012). The PIKfyve complex consists of the kinase PIKfyve itself,
the scaffold protein Vac14, and Fig4, a 5’ lipid phosphatase (regulating PI(3,5)P2 production).
1.5.1 Structure
Structurally,  the human PIKfyve kinase subunit  contains several  recognisable domains:  a
FYVE,  DEP,  HSP chaperonin-like  domain  (Cpn60_TCP1)  and  a  CHK homology  domain
(containing many cysteine,  histidine and lysine residues),  as well  as the catalytic  PIP5K
domain.  The FYVE domain is crucial for binding the protein to target membranes containing
PI3P, PIKfyve's substrate (Shisheva et al., 1999; Sbrissa et al., 2002a;  Sbrissa et al., 2002b;
Rutherford et al., 2006), while the role of the DEP, Cpn60_TCP1 and CHK domains are less
clear.   DEP domains are associated with binding stability and G-protein signalling in  the
context of other proteins (Wong  et al., 2000; Abramow-Newerly  et al.,  2006; Ballon  et al.,
2006),  the  CHK  domain  shows  spectrin-like  repeats  that  are  implicated  in  cytosketetal
binding  (Djinovic-Carugo  et  al., 2002)  and   chaperonin-like  domains  classically  relate  to
correct protein folding, but the one present in PIKfyve may to bind the Rab9 effector p40
(Ikonomov et al., 2003) and JLP (Ikonomov et al., 2009).  The PIP5K (catalytic) domain is
capable of phosphorylating PI(3)P at the 5' position to create PI(3,5)P2, and has also been
reported as a protein kinase in vitro (Sbrissa et al., 2000; Ikonomov et al., 2003).
Beyond the kinase subunit, Vac14 stands out as containing many HEAT repeats that allow
relevant protein-protein interactions (Dove et al.,  2002; Jin et al., 2008) while Fig4 contains
PIKfyve's regulatory 5' phosphatase.
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 Figure 15.) Model of PIKfyve arrangement and binding (adapted from Ikonomov  et al., 2009). PIKfyve is
arranged around the binding of PI3P via its N-terminal FYVE domain, the C-terminal kinase domain and the Fig4
phosphatase.  Structural support appears to be given by Vac14 binding Fig4 and PIKfyve.
In  terms  of  organisation,  the  PIKfyve  complex  appears  to  be  dependent  on  the
multimerisation of Vac14 as a form of scaffold for the rest of the complex, with the HSP
chaperonin-like  domain presumed to lay in  a way that  allows both the N-terminal  FYVE
domain and the C-terminal kinase domain to bind and modify PI(3)P, respectively (Figure 15;
Jin  et al., 2008; Sbrissa et al., 2008; Ikonomov et al., 2009; Alghamdi et al., 2013).
1.5.2 Function
PIKfyve is evolutionarily conserved and is found in yeast as Fab1. In yeast PI(3,5)P2 levels
spike rapidly upon exposure to hyperosmotic shock, but return close to basal levels within 30
minutes, suggesting a tightly regulated system and a role in stress response (Dove  et al.,
1997; Bonangelino et al., 2002; Cooke  et al., 1998).  PI(3,5)P2 depletion in yeast leads to
swollen vacuoles, which are defective in retrograde trafficking with poor acidification.  Study
of  mammalian PIKfyve has been aided by the creation of  mouse mutants with defective
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PIKfyve complex elements: perturbations in the effectiveness of PIKfyve lead to endosome
enlargement / vacuolation in cells and embryonic lethality / neurodegeneration in mice (Chow
et al., 2007; Zhang et al., 2007; Zolov et al., 2012).  Interestingly, while Fig4 antagonises the
action  of  PIKfyve,  it  is  also  required for  PIKfyve activation,  making study of  a  PI(3,5)P2
overabundant phenotype difficult.  
In  addition  to the functions of  PI(3,5)P2,  it  should be noted that  this  phosphoinositide is
capable of being modified by myotubularin related proteins (MTMRs) into PI(5)P, meaning
PI(3,5)P2 may contribute indirectly to the formation of PI(5)P within the cell (Berger  et al.,
2002; Zolov et al., 2012; Oppelt et al., 2013).
PIKfyve exists in a cytosolic pool when inactive and is recruited to the site of action through
association with  the endosomal  membrane (Shisheva  et  al., 2001).   The specific  site  of
PIKfyve action has been somewhat controversial, however it is generally agreed that PIKfyve
colocalises  with  primarily  late  endosomal  and  lysosomal  markers,  with  some  early
endosomal  involvement  (Rutherford  et  al., 2006).   Mechanisms underlying  the  action  of
PIKfyve in mammals is unclear, however it appears to be required for the maintenance of
endosomal  trafficking,  including  that  which  is  associated  with  the  recruitment  of  ESCRT
proteins  and  the  formation  of  vesicles  within  multivesicular  bodies,  endosome-to-TGN
transport and autophagy progression (Gary et al., 1998; Odorizzi et al., 1998; Whitley et al.,
2003; Rusten et al., 2006; Rutherford et al., 2006; Zhang et al., 2007).
In spite of its relevance in cellular homeostasis and organism health, the PIKfyve signalled
effectors remain  poorly  characterised.   Interestingly,  there  appears  to be a  link  between
PIKfyve activity and mTOR, with PI(3,5)P2 levels increased in cells upon addition of energy
positive signals such as amino acids and insulin (Bridges et al., 2012).  Bridges et al. found
that loss of a fully functional PIKfyve complex resulted in low phosphorylation of S6K1 (a
primary  downstream  target  of  mTOR),  and  that  the  mTORC1  subunit  RAPTOR  binds
PI(3,5)P2.  Subsequently, it was found that PIKfyve's effect on mTOR is reflected in yeast,
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with the S6K1 homolog Sch9 recruited by PI(3,5)P2 for TORC phosphorylation (Jin  et al.,
2014).   The  channel  mucolipin  TRPML  (Reviewed  in  Zeevi  et  al., 2007)  is  another
established effector of PI(3,5)P2. PI(3,5)P2 deficiency prevents TRPML activation, blocking
Ca+ release from the endosomal lumen. Ca+ is required for endosomal / lysosomal fusion
events, leading to lysosomal swelling (Dong et al., 2010).
1.5.3 PIKfyve in Human Disease
A functoning PIKfyve complex is crucial to endosomal homeostasis and as such, defects can
have a significant impact on the cell and organism as a whole.  Studies in mice have shown
similar themes in mutant or null copies of PIKfyve complex members, with vacuolation and
neurodegeneration being the overarching phenotype (Chow et al., 2007; Zhang et al., 2007;
Zolov et al., 2012).
Corneal Fleck Dystrophy (CFD) is a condition linked to heterozygous null PIKfyve.  CFD is
characterised by visible white bodies within the cornea, thought to be distended keratocyte
vacuoles (Li  et al.,  2005).  While Vac14 has not yet been conclusively linked to a specific
human disease, it does appear to be down-regulated in those with chronic fatigue syndrome
(Carmel et al., 2006), and perhaps more significantly, Vac14 null mice show severe neuronal
degeneration with perinatal  death (Zhang  et al.,  2007). Mutations in Fig4 cause Charcot-
Marie-Tooth  syndrome  type  4J,  a  disease  characterised  by  progressive  peripheral
neurodegeneration,  including  vacuolisation  of  sensory  neurons  and  lysosomal  storage
dysfunction in motor neurons, with eventual demylenation leading to loss of sensation and
muscle function (Zhang et al., 2008; Chow et al., 2009; Katona et al., 2011; McCartney et al.,
2014  Nicholson  et  al., 2011).   A more  severe  form  of  disease  occurs  as  Yunis-Varón
syndrome, when homozygous or compound heterozygosity for a Fig4 null mutation leads to
systemic defects, primarily presenting as central nervous system dysfunction and skeletal
abnormalities (Campeau et al., 2013).
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1.6  Investigating  Novel  Interaction
Partners of APP
Recent work aimed to establish APP interaction partners, specifically those that interact with
APP’s  intracellular  domain.  An  interactome  was  established  using  a  proteo-liposome
presenting  method  (Pocha  et  al., 2011),  followed  by  Label  Free  Quantification  mass
spectrometry (Hubner et al., 2010).  
Proteo-liposome presentation  was  performed by  creating  liposomes that  include reactive
maleimide-lipid anchors (Figure 16A).  An N-terminal cysteine on bacterially expressed AICD
couples the protein to the maleimide moiety of the lipid anchor producing AICD presented to
the external environment (Figure 16B).  AICD is presented in a similar manner to APP on an
endosomal surface in vivo, which exposes its intracellular domain to the cytosol.  The AICD-
liposomes were incubated in pig brain cytosol, which acted as a protein pool from which
AICD could pull interaction partners from (Figure 16C). After liposomes were washed and
the attached proteins digested, the resulting peptides were identified and quantified by mass
spectrometry to determine proteins interacting with AICD.
Figure 16.) AICD Proteo-liposome presentation method. A) Liposomes were created with reactive maleimide-
lipid anchors embedded (green). B) AICD (red) was coupled to the lipid anchor. C) AICD proteo-liposomes were
incubated in pig brain cytosol to provide a protein pool.
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The  proteo-liposome presentation  method  has  the  advantage  of  providing  a  'membrane
context', allowing interactions that require membrane interaction in addition to AICD.  Mass
spectrometry of bound proteins revealed 327 interaction partners significantly enriched over
those from control  proteo-liposomes in three replicate experiments.   Among the enriched
proteins were the established interaction partners Fe65, X11/Mint, SNX17 and Numb.
In addition to established AICD interactors, two candidate interactors of AICD that particularly
stood out amongst those identified were the mTORC1 and PIKfyve complexes.  Interestingly,
in  both  cases  multiple  individual  proteins  from  the  complexes  were  enriched:  mTOR,
RAPTOR and mLST8 from mTORC1, and PIKfyve, Fig4 and Vac14 (all members) from the
PIKfyve complex (unpublished dataset; Balklava et al., 2015).
1.6.1 Confirming and Elaborating the Physical 
Interaction Between APP and mTOR
The interaction data must  be interpreted with caution in light  of  the artificial,  non-cellular
conditions in which it  is obtained.  Building upon initial findings, Western blotting of AICD
proteo-liposomes  was  performed,  and  confirmed  the  presence  of  mTOR  and  Raptor.
Pulldown  assays  using  AICD  and  HEK-293t  lysates  independently  verified  the  mTOR
interaction  (unpublished  dataset).   Further  experiments  in  HeLa  cells  showed  strong
colocalisation between mTOR, the late endosomal marker LampI and either APP-GFP or
AICD-GFP (unpublished dataset).  
To  elaborate  the  interaction,  the  respective  requirements  for  binding  were  investigated.
mTOR truncation, expression in  E. coli, purification and AICD proteo-liposome recruitment
showed  AICD  only  binds  to  the  kinase  domain  (R1955-W2549)  (unpublished  dataset).
Subsequently,  truncation  of  AICD  showed  the  membrane  proximal  10  amino  acids
(Truncation 4) to be necessary and sufficient for mTOR binding (unpublished dataset).
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The experiments on APP-mTOR interaction described above appear to show that APP and
mTOR bind through a direct protein-protein interaction between the kinase domain of mTOR
and the 10 membrane proximal amino acids of AICD. The binding of AICD to the kinase
domain of mTOR raises interesting questions about the nature of the interaction, in particular,
if the kinase domain of mTOR is bound by AICD, what specific effect does that binding have?
Does AICD alter mTOR signalling?
1.6.1.1 Biological Significance of the APP/mTOR Interaction
The plausibility of the interactions between APP and mTOR being of functional significance
in  vivo is  supported  by  the  fact  that  mTOR  signalling  has  already  been  linked  with
Alzheimer’s  disease.   Indeed,  the  role  of  increased mTOR signalling  in  Alzheimer's  has
already  been  been  reviewed  in  some  detail,  with  discussions  including  research  into
dysfunctional protein synthesis, mTOR dependent tau phosphorylation and mTOR signaling
dependent neurodegeneration (Pei and Hugon 2008).
1.6.2 Confirming and Elaborating the Physical 
Interaction Between APP and the PIKfyve Complex
As with the mTOR interaction, initial interaction data must be confirmed for further research
to be justified.  Western blotting of AICD proteo-liposomes was performed, and confirmed the
presence of Vac14, a member of the PIKfyve complex, on proteoliposomes (Balklava et al.,
2015).   Further experiments in HeLa cells showed colocalisation between Vac14-mCit, APP-
CFP and either  the early endosomal marker EEA1 or the late endosomal marker LampI
(Balklava et al., 2015).  Results also appear to align with previous research showing PIKfyve
to be related to the endosomal sorting of receptors (Rutherford et al., 2006).
Currinn  et  al.  used  truncation  mutants  to  verify  and  elaborate  on  the  requirements  for
interaction, pulldown of Vac14 was performed from HEK293 lysates using AICD or truncation
mutants of AICD. Truncation of AICD showed that, in contrast to the requirements of mTOR
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binding, the C-terminal (cytosolic)  extremity of AICD is important to the binding of Vac14
(Currinn et al., 2016).
The experiments described above demonstrated that the PIKfyve complex and APP interact
via a direct protein-protein interaction between Vac14 and the C-terminus of AICD.  An APP
interaction with the PIKfyve complex is novel, and to our knowledge, no previous research
directly  indicates  a  link.   Whether  this  interaction  has  biological  significance  requires
experimental investigation.
1.6.3 Challenges in APP Family Research
When considering the practicalities of experiments involving APP manipulation, the potential
pitfalls in experimental approach and interpretation must be considered.  Perhaps the most
overt challenge in APP research is the redundancy with other proteins within the APP family:
APP,  APLP1  and  APLP2  have  differing  capacities  to  compensate  for  the  loss  of  other
members functions.  In the case of APP, single knockout mice are viable and fertile, though
they exhibit lower body and brain weight, impaired grip strength and altered behaviour as
compared to wild type mice (Muller et al., 1994; Zheng et al., 1995; Li et al., 1996; Magara et
al., 1999).   APP/APLP1 double  knockout  mice are  also  viable  (Heber  et  al., 2000).   In
contrast APP/APLP2 and APLP1/APLP2 double knockout mice both exhibit perinatal lethality
(von Koch et al., 1997; Heber et al., 2000). While APLP2 single knockout mice are viable, it
appears that APLP2 is an absolute requirement for viability, suggesting perhaps that APLP2
is the exemplar of the APP family, rather than the more widely studied APP (Table 3; Heber
et al., 2000).
Table 3.) APP family: mouse knockouts and coresponding phenotypes (adapted from Heber et al., 2000).
Knockout Phenotype Reference
APP Viable, low body weight, poor grip 
strength, altered behaviour
Zheng et al., 1995; Mϋller et al., 1994; Li 
et al., 1996; Tremml et al., 1998
APLP1 Postnatal growth deficit Heber et al., 2000
APLP2 Viable, Normal Von Koch et al., 1997
APP+APLP1 Viable Heber et al., 2000
APP+APLP2 Perinatally lethal Von Koch et al., 1997; Heber et al., 2000
APLP1+APLP2 Perinatally lethal Heber et al., 2000
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An answer to investigational difficulties caused by functional redundance may lie in simpler
model organisms containing one APP orthologue, such as  C. elegans.   In addition, such
simpler  organisms  can  be  a  superior  system  that  gives  a  high  level  of  control  over
experimental conditions and potential confounding factors.
Mammalian  cell  lines  can  bridge  the  gap  between  an  easily  manipulated  model  and
relevance in higher organisms, as an example,  RNA interference (RNAi)  can be used to
knock down gene expression.  One weakness of RNAi is the possibility of off-target effects,
where the RNAi used targets other mRNA for destruction, however, this can be mitigated by
using two different RNAi sequences for each target protein to identify target-specific effects.
With  regards  to  the  APP  family,  functional  redundance  is  problematic  but  is  not
insurmountable.   Studying knockdown of  APP family proteins  simply requires  a modified
approach to the canonical single knockdown.  The HeLa cell model may have advantages
with regards to APP: according to expression data, HeLa cells do not express APLP1 (NCBI
2007;  Scotto  et  al. 2008;  NCBI  2008),  although  some  companies  selling  polyclonal
antibodies against APLP1 claim to detect it in HeLa cells (GeneTex 2013; Elabscience 2015).
Lack of  APLP1 drastically reduces the number of  conditions required for  study.   Another
challenge to studying AICD in particular is the small, transient nature of the protein; due to
prompt destruction by the cell,  it  is particularly difficult to manipulate in a meaningful way
through classical overexpression (Cupers et al., 2001).  GFP fusion is unlikely to overcome
this  issue –  either  interfering  with  interactions  under  investigation  or  otherwise failing  to
stabilise  the protein  enough to  overcome this  issue (Chang 2010).   The challenge is  to
manipulate the level of AICD rapidly, in a reproducible manner.  
1.6.4 Challenges in mTOR Research
While mTOR research is an established area of study, there are issues associated with it.
mTOR signalling lies within a complicated network of cellular signalling, with a broad impact
on major cellular functions in higher organisms.  On a cellular level, mTOR controls many
aspects of metabolism, stress response and proliferation, while on an organism wide scale,
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mTOR impacts on aging and energy balance, in addition to its originally recognised role in
immune responses (Heitman et al., 1991; Brown et al., 1994; Calne et al., 1989; Collier 1989;
Thompson and Woo 1989; Tocci et al., 1989).
The systems used to study mTOR can be expected to have an effect on results, cultured
cells in particular. In cell lines, the genetic background is already highly abnormal at the gene
and chromosomal level, in order to enable continued culture.  Characteristics required for
prolonged and optimum culture include altered cell cycle controls, energy sensing and stress
response, which of course are all within  the domain of mTOR control.  Furthermore, cell
culture generally involves pushing cells into a growth state, be it through atmospheric oxygen
concentrations,  or  the  abundance  of  glucose  and  other  nutrients,  all  of  which  are  not
representative of in vivo conditons (Schmelzle and Hall 2000; Pópulo et al., 2012).  
Interpreting  results  from  cell  culture  becomes  extremely  difficult:  are  results  due  to
experimental  manipulation or  are they an artifact  of  altered mTOR behaviour?  With the
weaknesses of studying mTOR in cell culture it is important to avoid or mitigate limitations by
changing experimental conditions such as nutrient or growth factor availability.  Furthermore,
results  should  be  supported  using  a  system  other  than  cell  culture,  for  example  with
experiments performed in model organisms.
1.6.5 Challenges in PIKfyve Research
PIKfyve is a particularly challenging complex to study:  PIKfyve’s  product,  PI(3,5)P2 is  an
extremely low abundance phosphoinositide,  classically requiring specialist  equipment and
procedures to detect it.  For example, doping target cells with tritiated inositol, extraction of
lipids  without  degrading  the  target  phosphoinositides,  followed  by  HPLC/radionuclide
detection (Dove et al., 1997; Bonangelino et al., 2002) or  32P (Nocot  et al.,  2006; Zhang et
al., 2007; Jefferies et al., 2008). Biochemical quantification by classical methods is prohibitive
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in terms of time, effort and equipment required, and as such has been a major roadblock in
the field of PI(3,5)P2 research. The ability to visualise PI(3,5)P2 distribution would drastically
improve  PIKfyve  research,  allowing  deeper  dissection  of  the  processes  and  interactions
surrounding the complex.
1.6.5.1 Phosphoinositide Probes
Phosphoinositides  provide  a  substrate  capable  of  signalling  the identity  of  a  membrane,
binding  effectors  that  go  on  to  enact  the  dynamic  processes  specific  to  that
microenvironment.  A variety of phosphoinositide binding sites have been discovered within
proteins,  including Pleckstrin  Homology (PH),   Phox Homology (PX)  and FYVE domains
(Cullen et al., 2001; Itoh and Takenawa 2002; Lemmon 2003).  These binding sites can be
specific for certain phosphoinositides depending on sequence and have been used as the
basis  for  specific  probes.   Phosphoinositide  probes have been employed in  research to
elucidate the functions of inositides and characterise the processes of endosomal function
and trafficking.  Phosphoinositide specific probes are created by fusing the binding domain
specific to the phosphoinositide of interest  to a reporter  such as GFP, examples of  such
probes include the FYVE domain of Early Endosome Antigen 1 (EEA1) for PI(3)P or the PH
domain of phospholipase C for PI(4,5)P2 (Table 4; Halet 2005). A PI(3,5)P2 probe has the
potential  to  open  a  variety  of  investigations  which  may  otherwise  be  impossible  with
previously available techniques.
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Table 4.) Phosphoinositide probes by  in vitro specificity (from Halet 2005).  A variety of phosphoinositide
probes have been developed using binding domains shown to have specificity in vitro and used to study the
endosome.
In vitro specificity Protein Domain Reference
PI(4,5)P2 PHPLCδ Lemmon et al., 1995; Garcia et al., 1995; Kavran et al.,
1998
PI(3,4,5)P3 PHBtk
PHCRP1
PHcytohesin
PHARNO
Rameh et al., 1997; Kojima et al., 1997; Klarlund et al.,
1997; Klarlund et al., 1998; Venkateswarlu et al., 
1998a; Venkateswarlu et al., 1998b; Venkateswarlu et 
al., 1999
PI(3,4,5)P3/PI(3,4)P2 PHPDK1
PHPKB
French et al., 1997; Stokoe et al., 1997; Franke et al., 
1997; Kavran et al., 1998
PI(3,4)P2 Pxp4/phox
PHTAPP1/2
Kanai et al., 2001; Ellson et al., 2001; Stahelin et al., 
2003; Dowler et al., 2000; Thomas et al., 2001; Watt et
al., 2004; Ago et al., 2001; Zhan et al., 2002
PI(3)P FYVEEEA1
FYVEHrs
PXp40phox
Burd and Emr 1998; Gaullier et al., 1998; Patki et al., 
1998; Gillooly et al., 2000; Ellson et al., 2001; Kanai et 
al., 2001
PI(4)P PHOSBP
PHFAPP1
Levine and Munro 1998, 2002; Dowler et al., 2000
PI(5)P PHDING2 Gozani et al., 2003
1.6.5.2 TRPML1 and the PI(3,5)P2 Probe
The  Transient  Receptor  Potential  Mucolipin  1  (TRPML1)  is  a  Ca2+ release  channel
specifically  activated  by  PI(3,5)P2,  TRPML1 is  a  65kDa protein,  mutations  of  which  are
associated with type IV mucolipidosis, a lysosomal storage disorder (Bargal et al., 2000; Sun
et al., 2000; Dong  et al., 2010).  ML1N, the N-terminal polybasic domain of TRPML is the
binding domain of TRPML, specific for PI(3,5)P2,  because of its specificity,  ML1N was an
ideal candidate for development of a PI(3,5)P2 probe.  Li  et al. developed ML1Nx2-GFP to
facilitate identification of PI(3,5)P2 positive vesicles (Dong et al., 2010; Li et al., 2013).  This
probe, if  specific and as effective as reported, represents an advance in the investigative
tools for the study of PI(3,5)P2 , and will be useful in the study of an APP/PIKfyve interaction.
59
1.6.6 Project Aims
Previous research has found a physical interaction between APP/mTOR and APP/PIKfyve.
This project aims to answer the following questions:
A)  Does  the  physical  interaction  detected  between  APP  and  mTOR  represent  a
functional relationship?
B)  Does  the  physical  interaction  detected  between  APP  and  PIKfyve  represent  a
functional relationship?
C) What is the nature of any functional relationship, specifically, how does this fit into
the biology of the cell and relate to human disease?
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Chapter 2
Materials and
Methods
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2.1 Materials and Methods
2.1.1 Materials
Table 5. Protein Purification Solutions
Wash buffer 50mM Potassium chloride (Fisher Scientific)
25mM HEPES (Fisher Scientific)
1mM Magnesium chloride (Fisher Scientific)
pH7.0
Protein purification cell lysis buffer 150mM Sodium chloride (Fisher Scientific)
50mM Tris (Fisher Scientific)
10mM Imidazole (Sigma Aldrich)
pH7.2
Elution Buffer 250mM Imidazole (Sigma Aldrich)
150mM Sodium chloride (Fisher Scientific)
50mM Tris (Fisher Scientific)
pH7.2
Clearance buffer 500mM Sodium chloride (Fisher Scientific)
50mM TrisCl pH8.0 (Fisher Scientific)
10mM EDTA (Fisher Scientific)
Dialysis Buffer 125mM Potassium acetate (Fisher Scientific)
20mM HEPES (Fisher Scientific)
 1mM EDTA (Fisher Scientific)
pH7.2 (with KOH)  (Fisher Scientific)
Table 6. Bacterial Culture Solutions and Media
Lysogeny Broth (LB) 1L Distilled water
20g LB (Melford Bioscience)
(autoclaved)
LB agar 1L Distilled water
37.5g LB agar  (Fisher Scientific)
(autoclaved)
Selective bacteriological media LB agar or broth
kanamycin (50μg/μl) (Sigma Aldrich) or ampicillin (100μg/μl) (Sigma Aldrich)
Nematode Growth Medium 
(NGM)
132ml K2HPO4 (1M stock solution)  (Fisher Scientific)
868ml KH2PO4 (1M stock solution)  (Fisher Scientific)
3g NaCl  (Fisher Scientific)
2.5g Bacto peptone (Sigma Aldrich)
10g Agar (Sigma Aldrich)
10g Agarose (Fisher Scientific)
After autoclaving:
1ml MgSO4 (1M stock solution, filter sterilised) (Fisher Scientific)
1ml CaCl2 (1M stock solution, filter sterilised) (Fisher Scientific)
1ml Cholesterol stock solution (5mg/mL in ethanol, filter sterilised) (Sigma 
Aldrich)
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Table 7. Cloning
10 x PCR buffer 500mM Potassium chloride (Fisher Scientific)
100mM Tris Cl pH8.8 (Fisher Scientific)
25mM Magnesium chloride (Fisher Scientific)
1% (v/v) Triton X-100 (Fisher Scientific)
Cloning PCR 40μl Sterile, distilled water
5μl 10x PCR buffer
1μl Primer 1 (10μM)
1μl Primer 2 (10μM)
1μl Taq polymerase (New England BioLabs)
1-2μl DNA template (1-10ng/μl)
Analytical PCR 16μl Sterile, distilled water
2μl 10x PCR buffer
0.4μl Primer 1 (10μM)
0.4μl Primer 2 (10μM)
0.4μl Taq polymerase (New England BioLabs)
0.5-1μl DNA template (1-10ng/μl)
Plasmid preparation solution 1 50 mM TrisCl pH 8.0 (Fisher Scientific)
10 mM EDTA (Fisher Scientific)
100μg/ml RNaseA  (Fisher Scientific)
Plasmid preparation solution 2 200mM Sodium hydroxide (Fisher Scientific)
1% (w/v) SDS  (Fisher Scientific)
Plasmid preparation solution 3 3M Potassium acetate pH5.5 (Fisher Scientific) 
TAE buffer 40mM Tris  (Fisher Scientific)
20mM Acetic acid  (Fisher Scientific)
1mM EDTA  (Fisher Scientific)
pH8.0
TE buffer 10mM TrisCl pH8.0  (Fisher Scientific)
1mM EDTA  (Fisher Scientific)
Table 8. Tissue Culture Solutions and Media
Phosphate buffered saline (PBS) 137mM Sodium chloride (Fisher Scientific)
10mM Disodium phosphate (Fisher Scientific)
2.7mM Potassium chloride (Fisher Scientific)
1.8mM Potassium dihydrogen phosphate (Fisher Scientific)
pH7.4
Cell culture medium: DMEM Dulbecco’s Modified Eagle Medium (DMEM) (Gibco)
10% (v/v) foetal calf serum (FCS) (Gibco)
1% (v/v) penicillin/streptomycin (Gibco)
Cell culture medium: RPMI 1640 Roswell Park Memorial Institute 1640  (RPMI 1640) medium (Gibco)
10% (v/v) FCS (Gibco)
1% (v/v) penicillin/streptomycin (Gibco)
Freezing medium 70% (v/v) cell culture medium
30% (v/v) FCS (Gibco)
10% (v/v) DMSO (Fisher Scientific)
4% Formaldehyde 4% formaldehyde from paraformaldehyde (w/v) (Fisher Scientific) dissolved in 
PBS (Fisher Scientific)
Mowiol mounting media 12.0ml 0.2M Tris Cl, pH8.5 (Fisher Scientific)
6.0ml H2O
6.0g glycerol (Fisher Scientific)
2.4g Mowiol 4-88 (Sigma Aldrich)
2.5% (w/v) 1,4-diazobicyclo-[2.2.2]-octane (DABCO) (Sigma Aldrich)
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Table 9. SDS-PAGE and Western Blotting Solutions
Mammalian cell lysis buffer 150mM Sodium Chloride (Fisher Scientific)
50mM Tris pH 8.0  (Fisher Scientific)
1% (v/v) Triton-X100  (Fisher Scientific)
2.5mM β-glycerophosphate (Sigma Aldrich)
1mM EDTA  (Fisher Scientific)
1mM NH4F (Fisher Scientific)
1mM Vanadate (Sigma Aldrich)
1mM PMSF (Sigma Aldrich)
10mM Pyro-phosphate (Sigma Aldrich)
4μg/ml E-64 (Sigma Aldrich)
3.3μg/ml Aprotinin (Sigma Aldrich)
1μg/ml Pepstatin (Sigma Aldrich)
4x Laemmli buffer 200mM Tris pH 6.8 (Fisher Scientific)
40% (v/v) Glycerol (Fisher Scientific)
4% (w/v) SDS (Sodium dodecyl sulphate) (Fisher Scientific)
4% (v/v) β-mercaptoethanol (Fisher Scientific)
0.04% (w/v) Bromophenol blue (Fisher Scientific)
4x Separation gel buffer 1.5M Tris pH8.8 (Fisher Scientific)
4x Stacking gel buffer 0.5M Tris pH6.5 (Fisher Scientific)
SDS running buffer 190mM Glycine (Fisher Scientific)
25mM Tris (Fisher Scientific)
3.5mM SDS (Fisher Scientific)
10x Blotting buffer 1.9M Glycine (Fisher Scientific)
0.25M Tris base (Fisher Scientific)
pH8.3
Blotting buffer 400mM Tris base (Fisher Scientific)
50mM Glycine (Fisher Scientific)
20% (v/v) Methanol (Fisher Scientific)
pH8.3
10x TBS 1.5M Sodium chloride (Fisher Scientific)
0.2M Tris base (Fisher Scientific)
pH7.5
TBSt 10% (v/v) 10x TBS
1% (v/v) Tween 20 (Fisher Scientific)
Blocking solution TBSt
5% (w/v) Bovine serum albumin (BSA) (Fisher Scientific)
0.1% (v/v) Sodium azide (Fisher Scientific)
Enzyme substrate solution 100mM Tris pH 8.5 (Fisher Scientific)
1.25mM Luminol (Sigma Aldrich)
0.18mM Coumaric acid  (Fisher Scientific)
0.01% (v/v) Hydrogen peroxide (added  immediately before procedure)  (Fisher 
Scientific)
X-ray film developer solution Carestream® Kodak® autoradiography GBX developer/replenisher (Sigma 
Aldrich)
X-ray film fixer solution Carestream® Kodak® autoradiography RP X-Omat LO fixer/replenisher (Sigma 
Aldrich)
Coomassie destain 70% (v/v) Distilled water
20% (v/v) Methanol (Fisher Scientific)
10% (v/v) Acetic acid (Fisher Scientific)
Coomassie stain 50% (v/v) Ethanol (Fisher Scientific)
40% (v/v) Distilled water
10% (v/v) Acetic acid (Fisher Scientific)
0.25% (w/v) Coomassie Brilliant Blue-R250 (Fisher Scientific)
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Table 10. Antibodies
Target Company Catalogue 
Number
Dilutions Concentration
4EBP1 (rabbit IgG) Cell Signaling Technology 9644 1:2000 Lot specific
4EBP1 Thr37/46 phospho-specific (rabbit 
IgG)
Cell Signaling Technology 2855 1:2000 Lot specific
4EBP1 Ser65 phospho-specific (rabbit 
IgG)
Cell Signaling Technology 13443 1:2000 Lot specific
4EBP1 Ser70 phospho-specific (rabbit) Cell Signaling Technology 9455 1:2000 Lot specific
Akt (rabbit) Cell Signaling Technology 9272 1:2000 Lot specific
Akt phospho-Ser473 phospho-specific 
(rabbit)
Cell Signaling Technology 9271 1:2000 Lot specific
Anti-mouse HRP (Horse IgG Secondary) Cell Signaling Technology 7076 1:4000 Lot specific
Anti-rabbit HRP (Goat IgG Secondary) Cell Signaling Technology 7074 1:4000 Lot specific
Anti-mouse Alexa 488 (Goat IgG F(ab')2 
Secondary)
Cell Signaling Technology 4408 1:500 Lot specific
Anti-rabbit Alexa 488 (Goat IgG F(ab')2 
Secondary)
Cell Signaling Technology 4412 1:500 
(immunostain)
Lot specific
Anti-mouse Alexa 555 (Goat IgG F(ab')2 
Secondary)
Cell Signaling Technology 4409 1:500 Lot specific
Anti-rabbit Alexa 555(Goat IgG F(ab')2 
Secondary)
Cell Signaling Technology 4413 1:500 Lot specific
APLP2 (rabbit IgG) Abcam ab140624 1:1000 Lot specific
APP (mouse IgG2b) Santa Cruz Biotechnology sc-53822 1:1000 200µg/ml
EEA1 (mouse IgG1) BD Biosciences 610457 1:200 250µg/ml
eEF1A (mouse IgG1) Upstate 05-235 1:2000 Lot specific
GFP (mouse IgG2b) Santa Cruz Biotechnology sc-81045 1:2000 100µg/ml
LampI (mouseIgG1) Santa Cruz Biotechnology sc-20011 1:200 200µg/ml
MBP (mouse IgG1) Cell Signaling Technology 2396 1:2000 Lot specific
mTOR (rabbit IgG) Cell Signaling Technology 2983 1:2000 Lot specific
mTOR Ser2448 phospho-specific (rabbit) Cell Signaling Technology 2971 1:2000 Lot specific
mTOR Ser2481 phospho-specific (rabbit) Cell Signaling Technology 2974 1:2000 Lot specific
PIKfyve PIP5KIII (mouse IgG2a) Santa Cruz Biotechnology sc-100408 1:2000 100µg/ml
Raptor (mouse IgG1) Santa Cruz Biotechnology sc-81537 1:1000 100µg/ml
Rictor (rabbit IgG) Cell Signaling Technology 9476 1:1000 Lot specific
S6K1 (rabbit) Cell Signaling Technology 9202 1:2000 Lot specific
S6K1 phospho-Thr389 (phospho-specific)
(rabbit)
Cell Signaling Technology 9205 1:2000 Lot specific
Tau (mouse IgG1) Thermo Fisher MN1000 1:2000 200µg/ml
Tubulin (rabbit IgG) Abcam ab125267 1:2000 0.5mg/ml
Vac14 (mouse IgG2b ) Santa Cruz Biotechnology sc-271831 1:2000 200µg/ml
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2.1.2 General Methods
2.1.2.1 Creation of Electrocompetent E. coli
E. coli (TOP10 / BL21DE3) overnight cultures were inoculated from frozen stocks into 2L
conical flasks containing 500ml LB broth at a concentration of 1:100.  Cultures were grown at
37°C in a 200rpm shaking incubator to 0.6 OD600.   The culture was chilled on ice for 20
minutes, then pelleted by centrifugation: 4000x g for 15 minutes at 4°C.  Supernatant was
removed, then cells resuspended in half the original culture's volume of ice cold, 10% (v/v)
glycerol.  The new suspension was centrifuged again (4000x g for 15 minutes at 4°C), then
resuspended  in  1/10th  the previous  volume of  10% glycerol.   A final  centrifugation  was
carried  out,  as  above  and  the cells  resuspended  in  a  minimal  volume of  10% glycerol,
aliquoted into microcentrifuge tubes, then rapidly frozen in liquid nitrogen.  Samples were
stored at -80°C until used for transformation.
2.1.2.2 Bacterial Transformation of Electrocompetent E. coli
Bacterial transformation was performed by adding 100μl of electrocompetent bacteria and
5μl of the required plasmid into an electroporation cuvette.  A pulse of 1.8kV was passed
through the solution using a MicroPulser Electroporator (Bio Rad). and 1ml warm LB broth
was immediately added.  The transformed bacterial solution was incubated at 37°C for 1
hour, then inoculated onto an LB agar plate with added antibiotic (the antibiotic depending on
the resistance found in the plasmid).  Plates were incubated at 37°C for 24 hours prior to
selection  of  transformed,  antibiotic  resistant  clones.  Clones  were  subsequently  used  for
plasmid isolation, cloning or protein production.
2.1.2.3 Plasmid Isolation
Small  volume,  high  quality  plasmid  preparation  was  performed  using  PeqGold  plasmid
miniprep kit (PeqLab) using the manufacturer's instructions.  
Larger  volumes  of  DNA were  prepared  by  inoculating  bacteria  containing  the  required
plasmid into 200ml LB broth plus an appropriate antibiotic. Cultures were grown overnight in
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a 200rpm shaking incubator at 37°C, then centrifuged for 20 minutes at 2500x g and 4°C.
Supernatant was discarded, then the pellet was resuspended in 5ml of 'solution 1' (50mM
TrisCl, pH8.0, 10mM EDTA, 100μg/ml RNase A). 5ml 'solution 2' was added (200mM NaOH,
1% SDS), and the resulting mixture inverted then incubated for no more than 5 minutes at
room temperature.  5ml solution 3 was added (3M potassium acetate, pH5.5), the mixture
inverted repeatedly, then centrifuged for 20 minutes at 2500x g, 4°C.  The floating debris
layer was removed and discarded then the supernatant passed through a 0.45μm syringe
filter.  The filtered supernatant was combined with 15ml ice cold 100% isopropanol, mixed
vigorously then incubated on ice for 15 minutes.  The mixture was centrifuged as above once
more  and  the  supernatant  removed,  then  the  pellet  washed  with  70%  ethanol  and
centrifuged again for 10 minutes.  The supernatant was drained from the pellet, and the pellet
dried through evaporation.  The pellet was dissolved in an appropriate volume of TE buffer
dependent on pellet size for further use.
2.1.2.4 Restriction Digests
For cloning purposes 10μg plasmid was added to 40μl sterile, distilled water with the correct
buffer at the correct concentration, as per manufacturer instruction (New England BioLabs or
Roche).   4μl  of  each  relevant  restriction  enzyme was  added,  and  the  resulting  mixture
incubated at the required temperature suggested by the manufacturer.
2.1.2.5 Cloning
Agarose  gels  for  DNA electrophoresis  were  made  by  disolving  1%  agarose  (molecular
biology grade) in TAE buffer and adding ethidium bromide to a final concentration of 0.01%.
The solution was cooled at room temperature to roughly 60°C, poured into an appropriate gel
cast / well comb combination, then left to set at room temperature.  The first well was loaded
with 5μl 0.1-10kb DNA marker (PeqLab) subsequent lanes were loaded with relevant DNA
samples.  Gels were run at 100V.
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2.1.2.6 Polymerase Chain Reaction (PCR)
The DNA template to be used in the PCR reaction was diluted with distilled water to an 
appropriate concentration (plasmid DNA 1-10ng/µl, cDNA ~100ng/µl, genomic DNA 100-
500ng/µl).  Primers were diluted to a working concentration of 10µM, then the PCR reagents 
mixed on ice in PCR tubes with volumes dependent on whether PCR products are to be 
used for cloning or analytical purposes (Table 11).
Table 11. PCR Reagents cycle parameters were dependent on reaction requirements
Volume (μl) for cloning Volume (μl) for analytical purposes Reagent
40 16 Sterile, distilled water
5 2 10x PCR buffer
1 0.4 dNTPs (10mM) (New England BioLabs)
1 0.4 Primer 1 (10μM)
1 0.4 Primer 2 (10μM)
1 0.4 Taq polymerase (New England BioLabs)
1-2 (1-10ng/μl) 0.5-1 (1-10ng/μl) DNA template
PCR cycle programming was as follows:
1) 94°C, 1:30 minutes.
2) 94°C, 30 seconds.
3)  60°C,  30  seconds  (annealing  temperature,  variable  depending  on  primer  length  and
composition).
4) 72°C, 1 minute per kilobase of PCR product.
5) Step 2-4 x35.
6) 72°C 10 minutes.
7) 4°C, ∞minutes.
Mixed samples were sealed and inserted into the PCR machine with the tube surface in full
contact with the sample holder and the PCR cycling started. Finished products were run on
1-2% agarose gels for analysis / purification.
2.1.2.7 Thawing Cell Stocks for Mammalian Tissue Culture
Inside a laminar  flow cell  culture cabinet,10ml cell  culture media (DMEM for HeLa cells,
RPMI  for  SH-SY5Y)  was  dispensed  into  a  sterile  15ml  centrifuge  tube  and  5ml  into  a
seperate tube, both warmed in a 37°C waterbath.  A vial of cells was removed from storage
and thawed in the waterbath by gentle agitation, keeping the cap above the water to avoid
contamination.  The vial and 15ml tube of media were placed in a laminar flow cell culture
cabinet and sprayed with 70% ethanol before the vial contents was added to the tube of
media. The cell suspension was centrifuged at 300x g for 5 minutes to pellet cells, then the
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supernatant was removed from the pellet and replaced with the remaining 5ml pre-warmed
media. Cells were gently resuspended and added to a sterile T25 cell  culture flask, then
placed in a 5% CO2 incubator at 37°C overnight. The following day old media was replaced
with fresh, warmed media.  Cells were passaged between 80-90% confluency.
2.1.2.8 Mammalian Tissue Culture Passage
Fresh cell culture media, sterile calcium/magnesium free PBS, and trypsin-EDTA was pre-
warmed at 37°C in a waterbath, old media was removed and cells washed with PBS. PBS 
was removed and replaced with 1ml trypsin-EDTA, ensuring the cell covered surface of the 
flask was covered.  The flask was incubated at 37°C and checked every 2 minutes for loss of
cell adhesion.  Once cells detached, 5ml fresh media was added and gently aspirated to 
dissociate clumps of cells.  50µl of cell suspension was removed and mixed with 450µl 
Trypan blue for counting.  The volume required for the seeding density of the next passage 
was calculated using a haemocytometer (e.g. 2x104 cells/cm2 x25cm2 for HeLa cells 
undergoing 4 days growth before passage), enough media to cover the surface of the new 
cell culture flask was used.  The appropriate volume of cell suspension was mixed with warm
cell culture media and seeded into a new cell culture flask.  If growth is required for 
prolonged period, culture medium was replaced with fresh, warm media every 2 days.  
2.1.2.9 Mammalian Tissue Culture Transfections
DMEM  cultured  HeLa  cells  were  seeded  at  100,000  cells  per  0.5ml  in  24  well  plates
containing sterile glass coverslips. For each well, on the following day 1μg of plasmid DNA
was  diluted  in  50μl  OptiMEM  media  (Gibco)  and  added  to  2μl  Lipofectamine  2000
(Invitrogen) diluted in 50μl OptiMEM media.  After incubation (18 hours, 37°C, 5% CO2) cells
were washed twice with warm tissue culture medium and incubated overnight (37°C, 5%
CO2) prior to experimentation / fixation.
2.1.2.10 Preparation of Mammalian Tissue Culture Cells for Western Blotting
Cultures of HeLa or SH-SY5Y cells were seeded at 100,000 cells per 0.5ml in 24 well plates
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and incubated overnight   (37°C, 5% CO2).   Cell  culture medium was removed and cells
washed with ice cold PBS, 100μl mammalian cell lysis buffer was added per well, and the
cells scraped and aspirated from the well using a micropipette.  The lysate was centrifuged at
maximum speed on a benchtop microcentrifuge for  15 minutes at  4°C and the resulting
supernatant mixed with Laemmli buffer and heated to 95°C for 5 minutes.
2.1.2.11 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Polyacrylamide gels were created by mixing appropriate ingredients in different amounts to
create  one  section  for  adding  and  collecting  protein  above  another  section  designed  to
resolve the proteins depending on molecular weight / charge.  Higher percentage gels were
used to resolve lower molecular weight proteins (and vice versa) as appropriate.
Table 12. Acrylamide Gel Ingredients (Per Gel)
Gel Type Tris Glycerol Bis/Acrylamide (40%) SDS (10%) APS (10%) d.H2O
Stacking (5%) 0.5ml 
(0.5M 
pH6.5)
0.4ml 0.25ml 20μl 10μl 0.82ml
Separation 
(8%)
1.25ml 
(1.5M, 
pH8.8)
1ml 1ml 100μl 50μl 1.6ml
Separation 
(10%)
1.25ml 
(1.5M, 
pH8.8)
1ml 1.25ml 100μl 50μl 1.35ml
Separation 
(15%)
1.25ml 
(1.5M, 
pH8.8)
1ml 1.88ml 100μl 50μl 0.73ml
Separation gel polymerisation was initiated by the addition of 2.5μl Tetramethylenediamine
(TEMED), the solution was then briefly mixed, promptly added into gel-casting glass plates
(BioRad) which were already sealed on the bottom and sides. The gel was overlaid with
isopropanol and left to polymerise at room temperature for ~30 minutes. Isopropanol was
rinsed off with water then allowed to drip dry.  1μl TEMED was introduced to the stacking gel,
which was mixed and added on top of the separation gel, a well comb was placed in the
stacking gel and the completed gel allowed to set.
A molecular weight marker was added to the first well (ColorPlus prestained protein ladder,
broad range, New England BioLabs), and an appropriate volume of protein or lysate mixed
with Laemmli buffer was added to subsequent wells.  SDS-PAGE was run in SDS buffer,
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passing 150V through the gel for ~1 hour or until adequate band resolution was obtained.
When not used for western blotting, gels were stained with 400ml coomassie blue stain for 3-
4hrs  at  room  temperature,  then  proteins  resolved  with  repeated  coomassie  destain
application.
2.1.2.12 Western Blotting
Western blot cassettes were assembled, containing an outer layer of Whatman filter paper
(8x6cm) with an electrophoresed protein containing SDS-PAGE gel and a methanol activated
PVDF membrane (BioRad) cut to 8x5.7cm within. Cooling blocks were added to a western
blotting tank, which was then filled with blotting buffer and set to mix at 200rpm using a
magnetic bar.   Protein transfer  was performed at 200mA for 120 minutes.   The resulting
membrane was incubated in blocking solution for 1 hour at room temperature or overnight at
4°C.  Blocking solution was removed and replaced with primary antibody solution, diluted as
required in blocking solution and the membrane incubated in primary antibody for 1 hour at
room  temperature  or  overnight  at  4°C.   The  primary  antibody  was  removed,  and  the
membrane washed three times for 10 minutes each in TBSt.  The final wash of TBSt was
replaced with the relevant HRP-conjugated secondary antibody, diluted as required in TBSt,
the membrane was then incubated for 1-2 hours.  Secondary antibody was removed and the
membrane washed three times for 10 minutes each in TBSt.  Membranes were incubated in
2.5ml enzyme substrate then sealed in cling film and allowed to expose X-ray film (RX NIF
130mm x 180mm Fujifilm, Fisher Scientific) in a dark room for varied time-points.  The film
was incubated in developer solution (Kodak) for up to 5 minutes, rinsed in running tap water,
then incubated in  fixer  solution  (Kodak)  for  approximately  5  minutes.   Film was washed
thoroughly in running tap water, then left to drip dry at room temperature.
2.1.2.13 Immunostaining
HeLa cells grown on coverslips in 24 well plates were washed in warm PBS, then fixed for 20
minutes in  4% formaldehyde fixative  (4% formaldehyde  from paraformaldehyde in  PBS).
Following two subsequent washes with PBS, cells were permeablised using 0.1% Triton X-
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100 in PBS for 4 minutes, followed by two more washes with PBS.  Cells were incubated
under 2% bovine serum albumin (BSA) in PBS for 15 minutes.  Cells were exposed to the
relevant  primary antibody,  diluted (1:100-1:300) with 2% BSA in PBS for  1 hour at  room
temperature.  Coverslips were washed three times with PBS, then incubated with secondary,
fluorophore-conjugated antibody diluted (1:500) with 2% BSA in PBS.  Following a further
three PBS washes, cells were mounted on slides using Mowiol.
2.1.2.14 Microscopy
Immunostained,  BODIPY,  and  Lysotracker  stained  samples  were  imaged  with  confocal
microscopy using a Leica Microsystems SP5 TCS II MP DM16000B microscope.  Cells  in
situ were visualised and imaged under an inverted Nikon Eclipse TS100 microscope with 40x
objective.
2.1.3 Investigation Specific Methods
2.1.3.1 Construction of AICD, TAT and TAT-AICD
pET28-MBP-AICD was  created  using  AICD PCR amplified  from pEGFP-n1-APP,  in  turn
created from HeLa APP695 cDNA cloned into pEGFP-n1 (Clontech) (Currinn  et al., 2016).
AICD encoding DNA was amplified with a TAT domain containing 5'-primer, and cloned into
pET28-MBP-TEV (Pocha et al., 2011) using 5' BamHI and 3' XhoI sites to make pET28-MBP-
TAT-AICD.   A  HindIII  site  between  TAT  and  AICD  was  used  in  conjunction  with  Pfu
polymerase  plus  ligation  resulting  in  a  frame-shift  introducing  four  bases  after  TAT,  but
eliminating AICD, creating  pET28-MBP-TAT (Guscott et al., 2016).
2.1.3.2 Protein Expression and Purification
10ml  E. coli (BL21DE3) overnight cultures containing expression plasmids were inoculated
into  conical flasks containing 1L LB broth with 50μg/μl kanamycin.  Cultures were grown at
37°C in a 200rpm shaking incubator to 0.6 OD600. Protein expression was induced by adding
100μM IPTG and the culture incubated for a further 3 hours at 37°C in a 200rpm shaking
incubator.   Cultures  were  harvested  by  2500x  g  centrifugation  at  4°C  for  20  minutes,
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supernatant was drained and the resulting pellet stored overnight at -20°C.  
Pellets were resuspended in 10ml lysis buffer plus the protease inhibitors E-64 (4μg/ml),
aprotinin (3.2μg/ml),  pepstatin (1μg/ml) and PMSF (1mM).  Resuspension was aided with
three cycles of 1 minute sonication followed by 3 minutes incubation on ice.  Cell debris was
cleared from the lysate using 10,000rpm centrifugation for 30 minutes at 4°C, then passed
through a 0.45μm syringe filter.  
A Ni-NTA agarose column (Pierce, Thermo Scientific) was equilibrated in protein purification
lysis buffer, lysate passed through the column with flow through collected.  The column was
washed with 6x 10ml protein purification lysis buffer, then the bound protein was eluted using
5ml elution buffer, collected in five elution fractions of 1ml.  10μl samples of each elution
fraction were mixed with Laemmli buffer and run on 10% SDS-PAGE to determine the elution
fractions containing protein.  Columns were cleared of residual protein using 10ml clearance
buffer followed by a 10ml distilled water wash.  Cleared columns were stored in 20% ethanol
and reused by clearing the column of ethanol then washing with 5ml 100mM nickel sulphate.
14000 MWCO dialysis tubing was rinsed in distilled water,  then dialysis buffer.  Relevant
elution fractions were pooled and sealed within the tubing,  then incubated in  1L dialysis
buffer ovenight at 4°C with gentle stirring.  Dialysis buffer was changed and the samples
incubated again for a total of approximately 24 hours.  Purified proteins were aliquoted and,
after samples were taken for protein quantification, frozen for future use.
Protein quantification was performed by comparing test samples to bovine serum albumin
solutions of known concentration.  Triplicate samples were prepared, each with the following:
5μl of protein solution, 25μl BioRad DC protein assay reagent A, 200μl BioRad DC protein
assay reagent B (BioRad). Samples were prepared in a 96 well plate and absorbance at
595nm was read for each well.  Triplicates were averaged, and the resulting absorbances
plotted against  known protein concentration.   Purified protein concentrations ranged from
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2.5mg/ml to 3.5mg/ml.
2.1.3.3 TAT Uptake Assay
HeLa cells were grown on coverslips in 24 well plates, seeded at 50,000 cells/0.5ml two days
prior to the experiment and transfected the day before experimentation.  TAT uptake assay
cells  were  transfected  with  pEGFP-c3-2xML1N  using  Lipofectamine  2000.   Cells  were
treated with 350nM or 700nM MBP-TAT, MBP-AICD, or MBP-TAT-AICD.  After incubation of
up to 1 hour, cells were exposed to 4% formaldehyde, then immunostained for MBP (1:200
primary antibody dilution) as described in 2.1.2.13.
2.1.3.4 RNAi Suppression
RNAi against two APP and APLP2 targets were used alone or in combination and compared
to a luciferase targetting control:  APPI, APPII,  APLP2I,  APLP2II,  DoubleI  (APPI+APLP2I),
DoubleII (APPII+APLP2II) and Luci. (Luciferase).  HeLa cells seeded at a density of  50,000
cells/0.5ml in a 24 well plate and incubated overnight.  A transfection mix of 100μl OptiMEM,
12pmol RNAi and 3μl Interferin (PolyPlus) was mixed and incubated at room temperature for
20 minutes.  Fresh media was added to cells, then the RNAi transfection mix was added to
cells, for a 20nM final concentration.  Cells were allowed to grow for 48-72 hours prior to
fixation / lysis.
2.1.3.5 Vacuole Quantification
48-72 hours  after  RNAi  transfection  cells  were  imaged under  an  inverted  Nikon Eclipse
TS100 microscope with a 40x objective.  A minimum of 25 cells per image were scored for
the presence of vacuoles, counting the structures per cell for each condition.  
2.1.3.6 Vacuole Quantification in PIKfyve Inhibitor Sensitised Cells
Cells were either RNAi suppressed against APP family members and luciferase (2.1.3.4), or
treated with 350nM MBP-TAT, MBP-AICD or MBP-TAT-AICD, for 1 hour.  PIKfyve inhibitor
sensitisation was performed by adding 1μM YM201636 to cells for 45 minutes.  After two
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washes of warm PBS and fixation for 20 minutes with 4% formaldehyde, cells were imaged
under an inverted Nikon Eclipse TS100 microscope with a 40x objective.  The vacuoles in the
first 5 cells per image, top left to right, were counted and used to quantify structures per cell
for each condition.  One-way ANOVAs (α=0.05) were performed in GraphPad Prism 6 to
compare vacuoles per cells.
2.1.3.7 APP Overexpression and mTOR Manipulation in HeLa and SH-SY5Y Cells
Plasmids  for  lentiviral  transfection  were  PCR  amplified  and  cloned  into  pEGFP-n1  and
pmCherry-n1,  then subcloned  into  pXLG3-GFP for  lentiviral  expression (Wassmer  et  al.,
2009),  APP  with  or  without  Swedish  mutation  were  obtained  from  Dr.  Eric  Hill  (Aston
University).  Cell cultures expressing APP species or GFP controls (HeLa and SH-SY5Y)
were cultured in RPMI plus 10% foetal bovine serum (FBS), seeded into 24 well plates at
50,000 cells/0.5ml and incubated overnight.  
mTOR manipulation was carried out by washing a subset of cells with warm PBS and their
media replaced with RPMI devoid of amino acids (US Biological) for 2 hours, with some then
receiving essential and non-essential amino acids (PAA) for 30 minutes prior to lysis and
western blotting for  pmTOR-Ser2448, mTOR, APP, pS6K1-Thr389,  S6K1, p4EBP1-Thr70,
p4EBP1-Ser65,  4EBP1 and eEF1A (HeLa cells)  and pmTOR-Ser2448,  pmTOR-Ser2481,
mTOR, APP, pS6K1-Thr389, p4EBP1-Ser65, pAkt-Ser473, Akt, Tau and eEF1A (SH-SY5Y
cells.
2.1.3.8 C. elegans culture
C. elegans was maintained on NGM agar aseptically poured into petri  dishes, allowed to
cool, with 50µl E.coli OP50 liquid culture then added and grown overnight at 37°C.  A scalpel
was soaked in 70% ethanol, then the ethanol burned off through exposure to a bunsen flame,
the now sterile  scalpel  was used to transfer  a square of  worm containing agar  from an
existing culture of worms to the new plate.  Other worm manipulation such as the transfer of
individual worms was performed with a 32 gauge platinum wire, sterilised in a bunsen flame,
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visualised under a dissecting microscope.
2.1.3.9 Lipid Quantification in C. elegans by Oil Red O and BODIPY Staining
RNAi knockdown can be acheived in C. elegans by feeding with bacteria expressing dsRNA
against the target genes (Kamath 2003).  dsRNA for each of the gene was expressed in E.
coli (HD115)  by  inserting  a  segment  of  coding  region  into  a  plasmid  vector  L4440
(pPD129.36),  a  cloning  vector  containing  two  T7  polymerase  promoters  in  opposite
orientation. (Timmons et al., 2001; Timmons and Fire 1998).  To perform RNAi, 3ml LB plus
100µg/ml ampicillin was inoculated with a single RNAi clone colony from a culture grown on
LB agar plus 100µg/ml ampicillin and 12.5µg/ml tetracycline.  Clones were grown in a shaker
incubator at 37°C overnight and 100µl seeded onto 3cm NGM Lite agar plus 0.5mM IPTG.
After overnight induction at room temperature, worms were transferred to induced plates and
incubated until analysis.
C.  elegans  strains  lon-2(e678) and  apl-1(yn5) were  obtained from the  C.  elegans stock
collection (University of Minnesota) and Dr. Li  (City College of New York),  and grown on
nematode growth medium (NGM) inoculated with a bacterial lawn of E. coli (OP50) (Brenner
1974).  RNAi  knockdown  in  controls  (lon-2(e678))  or apl-1(yn5) (a  mutant  devoid  of  the
intracellular domain of apl-1),  was obtained by feeding E. coli (HD115) expressing dsRNA
against either daf-15, let-363 or a control vector (L4440) grown on NGM supplemented with
IPTG (Timmons and Fire 1998).
Staining protocols were adapted from other publications (O'Rourke et al.,  2009; Klapper  et
al., 2011). Animals for Oil Red O staining were washed in M9 buffer, fixed for 30 minutes in
4% formaldehyde, washed three times in PBS, then twice in 70% isopropanol, then stained
for 30 minutes with 60% Oil Red O solution. Animals for BODIPY staining were washed in M9
buffer, fixed for 30 minutes in 4% formaldehyde, washed three times in PBS, then treated
with a solution of 1μg/ml BODIPY 493/503 in PBS for 1 hour.  Animals were mounted using
Mowiol and visualised using compound light and confocal microscopy for Oil  Red O and
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BODIPY, respectively.
2.1.3.10 Lysotracker Staining
HeLa cells seeded in 24 well plates at 50,000 cells/0.5ml were incubated overnight.  Cells
were treated for 4 hours with either apilimod (0nM, 25nM, or 250nM), YM201636 (100nM or
1μM) or ammonium sulphate (10mM).  1μM Lysotracker Red DND-99 was added, and the
plate incubated for 5 minutes before cells were washed with warm PBS and fixed using 4%
formaldehyde.  Cells were washed a further two times before being mounted on slides using
Mowiol.  Cells  were imaged by confocal  microscopy for  the quantification of  Lysotracker
positive structures per cell and intensity per unit area.
2.1.3.11 Automated Vesicle Quantification
Using  Fiji  ImageJ,  maximum  projections  of  Z-plane  stacks  were  created  from  confocal
microscope  images,  whole  cells  in  an  image  were  cut  and  pasted  into  a  new,  black
background image and exported for analysis with an individual identity.  Each cell underwent
automated Squassh analysis using the MOSAIC suite in ImageJ (Rizk  et al., 2014).  Data
was  exported to  LibreOffice  Calc  where a  threshold  was applied  to  remove background
noise,  excluding structures less than 1 pixel  in size or  0.15 average intensity.   One way
ANOVA (α=0.05) with Tukey's post-hoc test was performed in GraphPad Prism 6.  Automated
vesicle  quantification  was carried  out  to  quantify  GFP-ML1Nx2 structures per  cell,  GFP-
ML1Nx2 area per  µm2,  lysotracker positive vesicles per cell,  lysotracker intensity per unit
area, LampI vesicles per cell and area of LampI per µm2.
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Chapter 3
Results
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3.1 TAT-AICD as a Biochemical Tool
3.1.1 Introduction
3.1.1.1 Manipulating APP
To investigate protein interactions it is important to A) have a method for manipulating the
systems in question and B) have a way of detecting changes that have arisen from that
manipulation.
Considering APP specifically, there are viable, classic tools to be used for manipulation such
as overexpression via transfection or knockdown via RNA interference (RNAi), these can be
used to test hypotheses about APP’s behaviour.  The hypothesis underlying this work is that
APP’s interaction with PIKfyve, as described (Balklava et al., 2015) has a functional element,
or,  put simply: APP affects PIKfyve function.  A second hypothesis stems from the same
proteo-liposome data that discovered the APP/PIKfyve interaction, that of APP and mTOR or:
APP alters mTOR function.  While some aspects related to the manipulation of APP may be
simple  to  perform,  there  are  also  many  complications  and  potential  pitfalls,  requiring
specialised approaches.
3.1.1.2 Challenges in Overexpressing AICD
AICD was found to interact with PIKfyve and mTOR, and as such it  is worth studying in
isolation from the rest of APP.  AICD is a relatively small protein fragment of 47 amino acids
and is prone to degradation (Cupers et al., 2001).  This rapid degradation presents difficulties
for the study of APP biology: overexpression of AICD proves to be difficult; GFP on the N-
terminal end is unlikely to be enough to prevent rapid degradation and C-terminal GFP would
likely  interfere  with  the  action  of  the  protein  considering  its  proximity  to  binding  and
phosphorylation sites critical  to trafficking and protein interaction (Chang and Suh 2010).
Producing high levels of AICD rapidly within each and every cell in a population, on demand,
would provide a powerful tool for revealing the intracellular outputs of APP.
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3.1.1.3 TAT
The Trans-Activator of Transcription (TAT), a promoter of gene expression for the Human
Immunodeficiency Virus was the first protein shown to spontaneously and efficiently cross
the cell membrane in 1988 (Frankel and Pabo 1988; Green and Loewenstein 1988).  Since
then research into TAT’s unusual behaviour and the promising possibility of a TAT based drug
delivery  platform  led  to  further  refinement,  creating  the  shortest  sequence  preserving
penetrative behaviour: TAT(48-60) peptide, a Cell Penetrating Peptide (CPP) (Ezhevsky  et
al., 1997; Vivés et al., 1997).
3.1.1.4 Mechanisms of TAT Entry
CPP mechanisms have been the subject of much discussion over the last 20 or so years
(Reviewed  by  Bechara  and  Sagan  2013),  with  research  focusing  on  whether  uptake  is
temperature and energy independent (Derossi et al., 1994) or clathrin mediated (Lundberg et
al., 2003). Positive charge is key in cellular uptake (Ryser and Hancock 1965), but more
specifically to CPPs; the guanidinium headgroup of arginine is important: polyarginine was
found  to  increase  uptake  beyond  that  of  other  polycationic  moieties  such  as  polylysine
(Mitchell et al., 2000), while alanine scanning of basic residues reduced uptake (Wender et
al., 2000).
With focus so heavily on positive charge, the first models developed for CPP internalisation
involved the binding of  positively  charged residues  on  the CPP with  negatively  charged
species on the cell surface such as the phosphates of phospholipids, leading to disrupted
membrane integrity and translocation (Figure 17).
Complicating matters, later research noted flaws in previous work, where fixation artifacts
could arise when studying CPPs using fluorophore tags (Lundberg et al., 2003), leading to
doubts about receptor independent internalisation.
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Figure 17.) Examples of proposed CPP translocation mechanisms (from Bechara and Sagan 2013).  A)
Inverted micelle formation. B) Pore-formation. C) Adaptive translocation.
Evidence now exists for CPP internalisation via many pinocytic methods: CPP uptake can be
lowered  by inhibiting  clathrin  mediated  endocytosis  with  chlorpromazine,  lipid  raft  import
using MβCD and macropinocytosis using 5-(N-ethyl-N-isopropyl)amiloride (EIPA), (Duchart
et al., 2007) suggesting a promiscuous approach to cell entry. Interestingly, Duchart  et al.
also found that preference for uptake method was dependent on peptide concentration, with
macropinocytosis prevailing under 10μM.
The original model for CPP uptake has been reinvigorated by several more recent studies:
membrane translocation can occur at 4°C (Jiao  et al., 2009) and in a cell free membrane
model devoid of endocytic machinery (Saalik  et al., 2011), while another group determined
both passive and active internalisation occurs (Guterstam et al., 2009).
Regardless of initial mechanism for translocation, it is accepted that CPPs find their way into
the cytosolic  space through  direct  translocation  or  endosomal  escape  (Guterstam  et  al.,
2009; Bechara and Sagan 2013).  Importantly, as we know CPPs can gain access to the
cytosolic milieu their potential as a tool in molecular biology starts to emerge.
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3.1.1.5 Using TAT as a Tool in Molecular Biology
CPPs, simply put are peptides able to efficiently enter cells, with this in mind it presents an
opportunity to study cell biology: a TAT-fusion can be used to produce an acute spike in the
protein of interest within all cells exposed, with only minor modification to that protein and
with easy control over magnitude.  The use of CPPs overcomes the weaknesses of classic
overexpression, which can result in variable expression.
By  fusing  TAT  to  AICD  it  should  be  possible  to  determine  effects  of  acute  AICD
overexpression  on  the  cell,  giving  us  a  unique  opportunity  to  examine  the  validity  and
relevance of a PIKfyve/AICD and mTOR/AICD interaction.  Previous results point towards
AICD as having a positive influence on PIKfyve function (Balklava  et al. 2015), assuming
TAT-AICD mimics this effect, it opens possibilities for the use of TAT-AICD beyond the field of
Alzheimer’s research into endosomal /  PIKfyve research.  While PIKfyve function can be
induced  in  yeast  using  osmotic  stress  (Dove  et  al., 1997),  with  no  reliable  method  of
increasing PIKfyve activity, PIKfyve research has been limited to loss of function studies in
higher  organisms.   TAT-AICD may be  a  novel  method  for  increasing  PIKfyve  activity  in
mammalian cells.  In short,  the aim of  creating TAT-AICD was to determine whether  it  is
useful as a tool in PIKfyve research, capable of entering the cell and acting on prospective
interactors of AICD.  
3.1.2 Results
Before  using  TAT-AICD as a  tool  for  studying  the interactions  and  outputs  of  APP,  it  is
important to characterise the behaviour of TAT-AICD and confirm its action as compared to
relevant controls.
3.1.2.1 Confirmation and Characterisation of TAT Uptake
Confirming the viability and usefulness of TAT as a tool is crucial before investigating any
specific  interactions.   Studying  TAT-AICD  requires  proper  controls  that  show any  effect
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observed is not due to the presence of A) protein added exogenously, and B) is not just the
effect of the TAT sequence itself.  Describing the cellular distribution of TAT-AICD over time is
particularly important to determining possible AICD functions in the cell: where does AICD
localise and over what timeframe upon addition to the cell?
Three proteins were created and produced bacterially: His-MBP-AICD and His-MBP-TAT as
controls and His-MBP-TAT-AICD (“AICD”, “TAT” and “TAT-AICD”, respectively) for future use
in studying AICD interactions (Figure 18A). Purified protein was found to run at 40-50kDa,
with little degradation (Figure 18B).
Figure 18.)  Design Expression and Purification of  TAT,  TAT-AICD,  AICD.  A) Diagram showing  layout  of
bacterially produced proteins for investigation of TAT-AICD.  N-terminal to C-terminal layout left to right: Grey = 6x
Histidine tag, Black = Maltose Binding Protein (MBP), Red = TAT peptide sequence, Blue = AICD.  B) Purified
proteins used in the investigation of  TAT-AICD as seen on SDS-PAGE using Coomassie Brilliant  Blue (~40-
50kDa). Left to right: AICD, TAT, TAT-AICD.  Note the minor degradation in TAT-AICD: full length TAT-AICD is
indicated by higher molecular weight compared to controls.
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One of the novel APP interaction partners under investigation is the PIKfyve complex, which
creates PI(3,5)P2 from PI(3)P.  The PI(3,5)P2 probe GFP-ML1Nx2 provides the ideal tool to
investigate the sub-cellular  sites of  PIKfyve activity,  by combining its expression with the
immunostaining of MBP, the distribution of PIKfyve activity and TAT-AICD can be compared.
To confirm and characterise  TAT /  TAT-AICD uptake in  comparison to the distribution  of
PIKfyve activity, HeLa cells transfected with ML1Nx2-GFP were treated with 700nM of MBP-
AICD, MBP-TAT or MBP-TAT-AICD protein for 5, 15, 30 or 60 minutes.  
(Figure 19) shows MBP staining where exogenously produced protein has penetrated the
cell  and diffused throughout the cytoplasm.  700nM TAT or TAT-AICD penetrates the cell
rapidly (with as little as 5 minutes incubation), while AICD alone does not penetrate to any
appreciable degree.  The distribution of MBP staining in TAT and TAT-AICD treated cells is
similar  at 5 minutes exposure, seen to highlight the cell  surface but otherwise be diffuse
throughout the cell.  Interestingly, timepoints after 5 minutes begin to show a divergence in
staining morphology:  while  TAT alone stays homogenously distributed,  TAT-AICD staining
becomes progressively clustered and punctate.
The distribution of  GFP-ML1Nx2 is notable when compared to that  of  MBP in TAT-AICD
treated cells.  (Figure 20) shows GFP-ML1Nx2 and MBP in TAT, TAT-AICD or AICD treated
cells: Colocalisation is evident between MBP immunostain (red) and GFP-ML1Nx2 (green) in
TAT-AICD treated cells, but not controls, showing TAT-AICD and the PI(3,5)P2 probe can both
be found associated with the same intracellular compartments at the same time.
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Figure  19.)  Penetration  and  cellular  distribution  of  MBP-TAT  and  MBP-TAT-AICD  in  GFP-ML1Nx2
transfected HeLa cells. MBP immunostaining in cells treated with 700nM TAT, TAT-AICD or AICD (left to right)
for 5, 15, 30 or 60 minutes (top to bottom) TAT and TAT-AICD proteins were taken up and retained by cells, while
AICD alone was not, showing TAT to be required for rapid cell penetration.  TAT alone exhibits a diffuse staining
pattern, while TAT-AICD appears to be primarily vesicular. Images representative of cells in n=3. Scale bar, 20μm.
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Figure 20.) Penetration and cellular distribution of MBP-TAT, MBP-TAT-AICD and GFP-ML1Nx2 in GFP-
ML1Nx2 transfected HeLa cells.  Distribution of the endogenously expressed PI(3,5)P2 probe GFP-ML1Nx2,
MBP immunostaining and merged GFP-ML1Nx2/MBP channel (left to right) in cells treated with 700nM TAT, TAT-
AICD or AICD (top to bottom) for 30 minutes. GFP-ML1Nx2 colocalises with TAT-AICD but not TAT or AICD.
Images representative of cells in n=3. Scale bar, 20μm.
3.1.2.2 TAT-AICD Appears to Increase PIKfyve Function
Combining the ability to tightly manipulate AICD levels in large numbers of cells, with the
ability  to  detect  changes  in  PI(3,5)P2 metabolism  is  potentially  useful.   It  would  allow
elucidation of a relationship between APP and the PIKfyve complex.  The ability of AICD to
influence PIKfyve function was investigated by treating cells with TAT-AICD and observing
the abundance and size of GFP-ML1Nx2 positive vesicles or the abundance of vacuoles
associated with PIKfyve inhibition.
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Upon transfection  with  the  PI(3,5)P2 probe GFP-ML1Nx2,  the GFP signal  appears more
pronounced and numerous in TAT-AICD treated cells (Figure 21A). TAT-AICD significantly
increases  the  number  (Figure  21B)  and  size  (Figure  21C)  of  ML1Nx2-GFP  positive
structures  within  the  cell  compared  to  controls,  as  measured  by  automated  Squassh
segmentation (Mosaic plugin for ImageJ).
Figure 21.) The effect of TAT-AICD on ML1Nx2-GFP in HeLa cells. A)  Distribution of GFP-ML1Nx2 in GFP-
ML1Nx2 transfected cells treated with TAT, TAT-AICD or AICD (left to right) TAT-AICD treated cells appear to have
altered  ML1Nx2-GFP distribution.  B,C) Number  (per  cell)  and  average area  (μm2)  of  GFP-ML1Nx2  positive
vesicles were significantly increased upon TAT-AICD treatment. Data was pooled from n=3.  Cells analysed: TAT
= 83, TAT-AICD = 68, AICD = 81.  Statistical tests in B and C were performed using one-way ANOVA with Tukey's
post-hoc test, α=0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  Error bars = SE. Scale bar, 20μm.
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To determine if  gross pathology of PIKfyve dysfunction could be influenced by TAT-AICD
exposure, cells were treated with TAT-AICD then briefly challenged with a specific PIKfyve
inhibitor (1μM YM201636, 45 minutes) and imaged by light microscopy (Figure 22A).  TAT-
AICD treatment was found to significantly mitigate cellular vacuolation caused by PIKfyve
dysfunction as compared to controls (Figure 22B).
Figure 22.)  The effect of TAT-AICD on PIKfyve inhibited HeLa cells. A)  Vacuoles visible in cells (arrows)
treated with 1μM YM201636 for 45 minutes after exposure to TAT, TAT-AICD or AICD (left to right). Scale bar
100μm. B) Number of vacuoles per cell in cells treated with 1μM YM201636 for 45 minutes after exposure to TAT,
TAT-AICD or AICD (left to right). Cells treated with TAT-AICD exhibit lower vacuolation. Cells analysed: 150 per
condition. Error bars = SE.  Statistical tests in B, C and E were performed using one-way ANOVA with Tukey's
post-hoc test, α=0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3.1.2.3 TAT-AICD and mTOR Substrates
Proteo-liposome recruitment lead to selection of two potential complexes as interacting with
AICD:  mTOR  and  PIKfyve.   Previous  results  in  mammalian  tissue  culture  suggest  a
functional role for mTOR, therefore HeLa cells were treated with either AICD, TAT or TAT-
AICD for 1 hour then lysed, western blotted and probed for the mTOR targets phospho-S6K1
Thr389 and phospho-4EBP1 Ser65.  TAT-AICD as seen in (Figure 23) does not appear to
modify the signalling of phospho-S6K1 Thr389 and phospho-4EBP1 Ser65.
Figure 23.)  mTOR signalling  in HeLa cells  upon treatment with TAT-AICD.  Western blots  showing  APP,
phospho-S6K1 Thr389, Tubulin, phospho-4EBP1 Ser65 levels (top to bottom) in cells treated with TAT, AICD or
TAT-AICD (left to right in triplicate, A to C).  No internally consistent change can be seen in the downstream
mTOR targets S6K1 (Thr389) and 4EBP1 (Ser65).
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3.1.3 Discussion
Studying  the  Intracellular  domain  of  APP has  previously  been  limited  due  to  unreliable
overexpression of fluorophore fused AICD and high turnover (Cupers  et al., 2001),  while
PIKfyve research is limited to loss of function due to a lack of reliable methods for increasing
PI(3,5)P2 levels. In this chapter the use of exogenous TAT-AICD is introduced as a tool for
investigating interaction partners of the intracellular domain of APP and PIKfyve function.
3.1.3.1 Confirming and Describing TAT and TAT-AICD Cellular Uptake
Cellular  uptake  of  TAT and  TAT-AICD  was  confirmed  by  immunostaining  for  MBP after
treating cells with increasing concentrations of protein for varying periods.  Uptake of TAT
constructs seem to occur rapidly with high cellular levels of MBP detected at 700nM after as
little as 5 minutes.
Importantly  TAT  and  TAT-AICD  show  very  different  cellular  localisation  profiles  -  TAT
localisation  was  found  to  be  homogenous  in  nature,  while  TAT-AICD  was  clearly
concentrated in distinct punctae within the cell. TAT and TAT-AICD’s only distinction is the
presence of AICD, so any differential behaviour can be attributed to AICD; AICD is localising
to these specific vesicles.  The divergence in MBP stain distribution after 5 minute exposure
between TAT versus TAT-AICD is significant.  The staining at 5 minutes is consistent with TAT
plasma  membrane  association  and  cytosol  diffusion,  while  distinct  TAT-AICD   punctae
development suggests some kind of interaction and sequestration.
3.1.3.2 TAT-AICD Colocalises with ML1Nx2-GFP
Interestingly,  GFP-ML1Nx2,  a  probe  for  the  PIKfyve  product  PI(3,5)P2 colocalises
substantially with TAT-AICD.  When considering a PIKfyve/AICD interaction it is important to
note overlap between one partner and the product of the other. Overlap of the  PI(3,5)P2
probe with TAT-AICD backs up initial data showing Vac14 colocalisation with APP (Balklava
et al., 2015), further suggesting an interaction between APP and the PIKfyve complex.
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3.1.3.3 TAT-AICD Decreases Sensitivity to PIKfyve Inhibition in HeLa Cells
To  investigate  whether  TAT-AICD  impacts  PIKfyve  function,  apilimod  (a  potent,  specific
PIKfyve  inhibitor)  was  added  briefly  to  TAT-AICD  treated  cells.   By  counting  vacuolar
structures in TAT-AICD treated versus control cells, TAT-AICD treatment imparted a partial
resistance  to  vacuolation.   The  results  suggest  a  functional  link  between  PIKfyve  and
AICD/APP,  but  are  indirect  measures  of  PIKfyve  dysfunction  rather  than  a  measure  of
PI(3,5)P2, the lower vacuole count alone is far from conclusive. In combination with the wider
body of evidence this experiment is more substantial, and together they strongly suggests
AICD as being related to PI(3,5)P2’s creation or turnover.  This is not the only explanation of
inhibited vacuole creation, but is perhaps the most obvious.
3.1.3.4 TAT-AICD Increases ML1Nx2-GFP Number and Size
Combining the acute treatment of exogenous TAT-AICD with the  PI(3,5)P2 probe provides
unique  and  compelling  evidence  of  an  APP/PIKfyve  interaction:  application  of  TAT-AICD
Significantly increases both the number and size of ML1Nx2-GFP positive vesicles.  While
ML1Nx2-GFP is not a direct biochemical measurement of  PI(3,5)P2,  changes in both the
number  and size  of  these vesicles  upon TAT-AICD application  are  consistent  with  AICD
increasing the amount of PI(3,5)P2 within the cell.
3.1.3.5 TAT-AICD is a Novel Tool for the Manipulation of PIKfyve Function
Previous work has shown the intracellular domain of APP (AICD) interacts with PIKfyve. A
bacterially  produced fusion protein  was  created consisting  of  a  Cell  Penetrating  Peptide
(CPP) linked with AICD (TAT-AICD).  TAT-AICD is capable of rapidly penetrating the cell, and
importantly,  colocalises  with  the  PI(3,5)P2 probe  GFP-ML1Nx2,  consistent  with  a
AICD/PIKfyve interaction.  Testing signs of PIKfyve function after TAT-AICD treatment shows
that TAT-AICD appears to be capable of consistently increasing PIKfyve activity (Figure 21-
22).
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Beyond the initial significance to the understanding of an APP/PIKfyve relationship, PIKfyve
research has previously been limited to studying purely loss of function in cells higher than
yeast due to the lack of reliable methods of increasing PI(3,5)P2 levels in mammalian cells.
 The ability  of  TAT-AICD to reliably increase PIKfyve activity may be useful  as a tool  in
PIKfyve research, a field previously plagued by technical challenges.
In spite of the positive results,  these findings have limitations.   While it  is clear that TAT
enters the cell  (Figure 19-20) the mechanism for that entrance is still  debated; until  that
debate  is  settled  some  ambiguity  will  remain  surrounding  the  interpretation  of  results,
particularly considering many models include the involvement of endosomal processes, the
very system this work tries to investigate.
3.1.3.6 TAT-AICD has no Discernable Effect on Several mTOR Substrates
Previous data suggests a link between mTOR/APP in C. elegans and mammalian cell culture
(unpublished dataset).   By treating cells  with TAT-AICD it  was expected that  any mTOR
interaction would become evident by western blotting treated cells then probing for changes
in mTOR substrates.  Interestingly, TAT-AICD appeared to have no effect on mTOR signalling
to the substrates tested:  phospho-4EBP1 Ser65 and phospho-S6K1 Thr389 (Figure 23).
This negative result does raise questions about the nature of an mTOR/APP interaction: it is
clear  that  any  APP/mTOR  relationship  is  more  complicated  than  a  simple  up  or
downregulation, and some effort should be made to explore this complexity.
An  important  point  is  that  some  inherent  property  of  the  exogenous  protein  prevents  it
influencing mTOR in the way that endogenously produced protein does, while this may be
the post-translational modification / phosphorylation state of AICD, the N-terminal placement
of TAT-AICD's His and MBP tags may be a more compelling possibility, interfering with an
mTOR interaction.  Indeed, initial investigation of the AICD/mTOR interaction narrows down
the  interaction  to  the  N-terminal  extremity  of  AICD  (unpublished  dataset), where  steric
interference from MBP may be expected.
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Using  different  experimental  systems  such  as  classical  overexpression  and  the  use  of
different cell models may shed light on an APP/mTOR interaction.  mTOR is not an easy
system to experiment with,  particularly in  immortalised mammalian cell  culture:  a system
defined by genetic eccentricities related to cell proliferation and metabolic control (Hanahan
and Weinberg 2011). Relating to this point, cell starvation prior to treatment may give a lower
background and using a different  cell  system or  testing  other  mTOR substrates  may be
useful.
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3.2 Investigating a Functional 
Interaction Between APP and mTOR
3.2.1 Introduction
mTOR is central to energy signalling within the cells, integrating inputs such as glucose and
amino  acid  abundance,  stress  signals  such  as  AMP /  hypoxia  and  DNA damage,  then
signalling appropriate downstream effects: either driving or inhibiting actions such as protein
production, cell division, lipid biosynthesis, autophagy and apoptosis.
mTOR signalling alteration has been reported in an APP / Alzheimer’s disease context. The
nature of  the  alteration  has been reviewed (Garelick  and Kennedy 2011),  with  points  in
favour  of  each  model  reviewed  by  Sweitch  and  colleagues  (Sweich  et  al., 2008).   The
interactions discussed and researched have often been framed as an indirect  one.   The
specific  nature  of  an  APP/mTOR  interaction  has  been  debated  as  to  whether  mTOR
signalling is upregulated or downregulated.
3.2.1.1 Evidence for mTOR Signalling Lowered in Alzheimer's Disease
Evidence for the lowering of mTOR signalling related to APP / Alzheimer’s disease can be
found from several laboratories.  A decrease in the level of protein synthesis in diseased
tissue has been detected in Alzheimer’s disease affected brains (Langstrom  et al., 1989)
which would imply inhibition of mTOR signalling.  Aβ42 exposure in neuronal cells, PS-1 /
APP mutant, transgenic mice are reported as exhibiting reduced mTOR dependent (Thr389)
phosphorylated  p70S6K1.  Interesting  to  note  is  that  the  mouse  model,  lowered  mTOR
signalling was only found in the cortex, not the cerebellum, a distribution that correlates with
Alzheimer’s disease pathology. Additionally, in the same paper, mTOR signalling was also
lowered in the lymphocytes of Alzheimer’s patients, an effect that correlated with the patient’s
mini mental status examination (MMSE) score (Lafay-Chebassier et al., 2005).
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Another approach that favours a decreased mTOR signalling model is that investigating long
term potentiation (LTP),  with evidence showing mTOR signalling inhibition correlates with
impairment of synaptic plasticity in hippocampal slices of a mouse model for Alzheimer’s
disease. The same study found LTP inhibition upon application of Aβ1-42 recovered when
cells were exposed to the GSK3β inhibitors lithium or kenpaullone (Ma et al., 2010).
A paper describing the positive effect of presenilin-1 on PI3K signalling, with subsequent
inactivation of GSK3 and reduced tau phosphorylation also supports a model of decreased
mTOR signalling in Alzheimer’s, as PS1 knockout mice show increased tau phosphorylation
(Baki et al., 2004).
At first the evidence for lowered mTOR signalling seems compelling, however it should be
noted that the above publications rely upon data derived from patients, patient tissues or
mouse models, where secondary pathology may be responsible for the prevailing signalling
environment, for example amyloid induced toxicity, general cell health and the energy state of
the patient or mouse cells at time of sampling / death and may not be representative of the
disease's underlying molecular mechanisms.
3.2.1.2 Evidence for Upregulated mTOR Signalling in Alzheimer's Disease
Many groups  conclude  an increase  in  mTOR signalling  in  Alzheimer's  disease  (Pei  and
Hugon  2008),  evidence  supporting  upregulated  mTOR  signalling  includes  mTOR
phosphorylated at Ser 2481 correlating with total tau and phospho-4EBP1 at Ser 65 and Thr
70 being increased significantly in Alzheimer’s brains (Li et al., 2005). The phosphorylation of
S6K1  at  Thr  421  /  Ser  424  has  also  been  reported  in  relation  to  increased  total  and
phosphor-tau (An  et al., 2003). A group studying a drosophila tauopathy model concluded
that TOR mediated cell cycle progression caused neurodegeneration (Khurana et al., 2006).
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In  addition to the above experimental  evidence,  rapamycin was described as  preventing
cognitive deficits (measured using the Morris water maze), decreasing the amount of Aβ42
and increasing autophagy in PDAPP mice, an animal model of Alzheimer’s (Spilman et al.,
2010).   Similar  results  were obtained by another  group (Caccamo  et  al., 2010)  in  triple
transgenic mice (APPswe, PS1M146V, Tau P301L) (Oddo et al., 2003). Caccamo et al. also
claimed in the same 2010 paper that Aβ42 increased mTOR signalling.  mTOR signalling
was enhanced in Alzheimer’s patients (Pei and Hugon 2008) and APP overexpression shows
similar changes (Caccamo  et al., 2011) in almost direct contradiction to Lafay-Chebassier
and colleagues.
When considering the likelihood of an APP/mTOR interaction it is important to note existing
research into the other APP family of proteins; APLP1 and APLP2 having been shown as
important modulators in glucose / insulin homeostasis (Needham et al., 2008), taken with the
functional redundance observed between the APP family of proteins, a role for APP in mTOR
function is rational.
It is important to note the differences in research concluding either an "up" or "down" model –
"down" evidence is reliant on late stage / established disease samples, which may hint at the
findings being artifacts  of  widespread cell  stress /  death.   Those concluding upregulated
mTOR  signalling  in  Alzheimer's  disease  have  a  lot  more  experimental  control  over
conditions, manipulating simple systems and observing specific outcomes.  To summarise, a
model for increased mTOR signalling in Alzheimer’s disease appears to be favoured by high
quality, well controlled research, consistent with a possible direct interaction.
3.2.1.3 Investigating an APP/mTOR Interaction
The investigation of an interaction between APP and mTOR requires tackling the specific
challenges associated with both proteins. Functional redundance between the APP family
proteins  (APP,  APLP1,  APLP2)  needs  to  be  taken  into  account.   Redundance  can  be
accounted for by either studying in a more primitive system prior to divergence of orthologs
96
(C. elegans or  D. melanogaster)  or  eliminating each protein alone or in combination,  for
example using RNAi in higher systems such as mammalian cells.
Studying mTOR specifically also has challenges associated with it. Tissue culture is a staple
experimental system, but often involves cells derived from sources such as tumours where
cellular controls of metabolism and cell division have been circumvented, the problem being
that these are the very systems controlled by mTOR (Schmelzle and Hall 2000; Pópulo et al.,
2012).  Beyond the genetic eccentricity found in tissue cultured cells, tissue culture media
also adds to experimental ambiguity with glucose levels often far exceeding physiological
levels; blood sugar levels are between 4-6.5mM in those with a high-starch diet (Daly et al.,
1998), while DMEM media may contain as much as 25mM glucose (Dulbecco and Freeman
1959; Morton 1970). The issues with tissue culture can be avoided by either experimenting in
a  model  organism where  physiological  nutrient  levels  are  present  or  accounting  for  the
glucose experimentally (comparing “normal” cell culture conditions with depleted nutrients for
example).
3.2.2 Results
3.2.2.1 APP Overexpression in HeLa and SH-SY5Y Cells Increases Downstream 
Phosphorylation in Targets of mTORC1 and mTORC2
If  APP does  indeed  interact  functionally  with  mTOR,  mTOR signalling  changes  may be
expected upon alteration of APP. To test APP’s effect on mTOR signalling APP-GFP was
overexpressed in HeLa and SH-SY5Y cells and compared to GFP overexpression. To further
investigate whether the presence and processing of full length APP is important in mTOR
signalling, overexpression of AICD-GFP and APP-GFP with Swedish mutation (APP(Swe))
was  performed,  with  subsequent  western  blotting  of  lysates  for  proteins  and  signalling
outputs  of  interest.   mTOR  function  is  altered  when  nutrient  abundance  changes,  to
determine if  APP affects this,  mTOR substrates were tested for phosphorylation in basal,
starved and recovering conditions.
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HeLa  cells  overexpressing  APP,  APP(Swe)  or  AICD  showed  an  apparent  increase  in
mTORC1 substrate phosphorylation under basal conditions as compared to controls (GFP),
this includes 4EBP1 phosphorylation at Ser65 and Thr70, and S6K1 at Thr389 (Figure 24A).
Akt  dependent  phosphorylation  of  mTOR (Ser2448)  also  increases,  pointing  to  elevated
mTORC2 signalling. Interestingly,  APP with Swedish mutation did not  appear to enhance
mTOR signalling any more than APP or AICD overexpression.  
Densitometry  was  performed  on  HeLa  lysate  western  blots,  densitometry  on  APP blots
demonstrates  an  increase  in  APP  signal  between  GFP  expressing  controls  and  those
expressing GFP-APP (Figure 24B). Densitometry also highlights that AICD-GFP expression
is sufficient to increase  mTORC target phosphorylation, both mTORC1 targets, as shown by
pS6K1 Thr389 (Figure 24C) and mTORC2 targets, as shown by pmTOR Ser2448 (Figure
24D).
With a likely effect of APP on mTOR phosphorylation targets in HeLa cells, the relevance of
this result in a neuronal system is worthwhile investigating when considering the implications
in Alzheimer’s disease, experiments were repeated in SH-SY5Y neuroblastoma cells.
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Figure 24.) APP drives mTOR signalling in HeLa cells. A) Lentiviral overexpression of APP (APP-GFP), APP
containing  the  Swedish  mutations  (APP(Swe)-GFP)  or  AICD  (AICD-GFP)  leads  to  increased  apparent
phosphorylation of  all  measured downstream targets of  mTOR compared to controls (GFP) in HeLa cells as
shown by western blot. Blots demonstrate APP is capable of driving mTORC1 and 2 activity via its intracellular
domain. To compare different cell energy states, cells were either given fresh media as a basal condition (Basal),
starved of nutrients for 2 hours with amino acid deficient media (Starved) or starved then allowed to recover in
fresh, complete media (Recovering).  Samples were blotted for pmTOR-Ser2448, mTOR, APP, pS6K1-Thr389,
S6K1, p4EBP1-Thr70, p4EBP1-Ser65, 4EBP1 and eEF1A (top to bottom). B) Densitometry on selected samples
blotted for APP from  A shows the apparent  increase in detectable APP upon APP-GFP expression, and the
possible loss of APP upon starvation. C-D)  Densitometry on selected samples blotted for pS6K1 Thr389 (C) and
pmTOR Ser2448 (D) from A shows AICD-GFP expression is sufficient to increase apparent basal, downstream
phosphorylation  of mTORC1 and mTORC2 targets  respectively.  B-D) Densitometry was performed in ImageJ
from n=3, error bars= SE.
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 Figure 25.) APP drives mTOR signalling in SH-SY5Y cells. Lentiviral overexpression of APP (APP-GFP) or
AICD (AICD-GFP) leads to increased phosphorylation of measured downstream targets of mTOR compared to
controls (GFP) in SH-SY5Y neuroblastoma cells, as shown by western blot. Blots demonstrate APP is capable of
driving mTORC1 and 2 activity via its intracellular domain. To compare different cell energy states, cells were
either given fresh media as a basal condition (Basal), starved of nutrients for 2 hours with amino acid deficient
media (Starved) or starved then allowed to recover in fresh, complete media (Recovering). Samples were blotted
for pmTOR-Ser2448, pmTOR-Ser2481, mTOR, APP, pS6K1-Thr389, p4EBP1-Ser65, pAkt-Ser473, Akt, Tau and
eEF1A (top to bottom). B) Densitometry on selected samples blotted for APP from A shows the apparent increase
in detectable APP upon APP-GFP expression, and the possible loss of APP upon starvation. C-D)  Densitometry
on selected samples blotted for pS6K1 Thr389 (C) and pmTOR Ser2448 (D) from A shows AICD-GFP expression
is  sufficient  to  increase  apparent  basal,  downstream  phosphorylation   of  mTORC1  and  mTORC2  targets
respectively. B-D) Densitometry was performed in ImageJ from n=3, error bars= SE.
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Data acquired in SH-SY5Y neuroblastoma supports that found in HeLa cells, showing APP
and AICD increasing mTORC1 and mTORC2 signalling (Figure 25A).  Basal, starved and
resupplemented cells in APP and AICD overexpression appear to be increased over and
above  corresponding  controls  in  phospho-mTOR  Ser2448,  phospho-S6K1  Thr389  and
phospho-Akt Ser473.
Densitometry  was  performed  on  SH-SY5Y  lysate  western  blots,  as  in  HeLa  cellsz
densitometry on APP blots demonstrates an increase in APP signal between GFP expressing
controls  and those expressing GFP-APP  (Figure 25B).  Densitometry also highlights  that
AICD-GFP  expression  is  sufficient  to  increase   mTORC  target  phosphorylation,  both
mTORC1 targets, as shown by pS6K1 Thr389 (Figure 25C) and mTORC2 targets, as shown
by pmTOR Ser2448 (Figure 25D).
3.2.2.2 APL-1 Mutation yn5 Creates an Additive Effect with daf-15 and let-363 
Knockdown, Showing Fat Droplet Accumulation as Seen by Oil Red O and BODIPY 
Staining
The insulin receptor in C. elegans (DAF-2) controls fat metabolism, inhibition of this system,
upstream of  mTOR, has been reported to increase lipid droplet  accumulation (Jia  et al.,
2004; Palgunow et al., 2012). To further establish whether a functional link exists between
mTOR and  APP,  and  whether  such  a  link  is  conserved,  lipid  droplet  accumulation  was
observed via Oil Red O staining (Figure 26A).   Manipulation was performed using RNAi
suppression of the mTOR ortholog gene let-363 and the RAPTOR ortholog daf-15, alone or
in combination with C. elegans carrying the APP ortholog C-terminal truncation,  apl-1(yn5).
Suppression of DAF-15 / LET-363, or the apl-1(yn5) mutation produces mild accumulation of
lipids, as seen by deeper Oil Red O staining.  Combining suppression of DAF-15 or LET-363
with the apl-1(yn5) mutation produces profound lipid accumulation over and above any single
condition, hinting at a conserved linked function for APP and mTOR.
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Figure 26.) Truncation of the intracellular domain from the C. elegans ortholog of APP, APL-1 (apl-1(yn5))
creates an increase in lipid deposition when combined with suppression of  C. elegans mTOR function.
Suppression of mTOR (LET-363) or RAPTOR (DAF-15) in  C. elegans by feeding respective dsRNA expressig
bacteria led to moderately increased lipid accumulation compared to empty L4440 plasmid expression.  Lipid
accumulation  increased  upon  mTOR knockdown  in  apl-1(yn5)  truncation  mutants  over  lon-2(e678)  controls.
Changes in tail lipid accumulation were visualised by Oil Red O (A) and BODIPY staining (B). Using confocal z-
stacks of  BODIPY stained worm images, quantification of  lipid accumulation was possible  (C).  Quantification
showed a moderate but significant increase in lipid droplet staining upon LET-363 or DAF-15 suppression, but a
large significant rise in lipid droplet staining when apl-1(yn5) is combined with LET-363 or DAF-15 suppression.
Data was pooled from n=3, total worms analysed: lon-2= 53, yn5= 56, lon-2 daf-15= 67, lon-2 let-363= 45, yn5
daf-15= 52, yn5 let-363= 53. Analysis was performed using one-way ANOVA with Tukey's post-hoc test, α=0.05,
** p≤0.01, *** p≤0.001, **** p≤0.0001. Error bars = SE. Scale bar, ~70μm.
Quantification was performed as an elaboration of the work of Palgunow et al. (Palgunow et
al., 2012). The effect of RNAi suppression of DAF-15, LET-363 levels and that of the alp-1
truncation mutant  apl-1(yn5) was evaluated, BODIPY 493/503 fluorescent dye was used to
stain and quantify lipid  droplets  in  the tail  of  each animal  (Figure 26B/C).  Intensity was
significantly increased in the tails of worms upon knockdown of TOR signalling elements, but
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even  moreso  when combining  TOR suppression  with  apl-1(yn5)  mutation  (Figure  26C),
showing a combination effect that would be expected from both proteins contributing to the
same pathway.
3.2.2.3 Knockdown of APP Family Proteins, Alone or in Combination Fails to Alter 
mTOR Signalling
To investigate loss of APP function on mTOR in mammalian cells RNAi suppression was
used in HeLa cells against relevant APP family members (note that APLP1 is not expressed
in HeLa cells); APP and APLP2 were knocked down alone, or in combination as a double
knockdown  to  allow for  possible  effects  of  functional  redundance  present  in  APP family
proteins (Heber et al., 2000).
APP,  APLP2 and double  knockdowns  were  confirmed by western  blotting  (Figure 27A),
corresponding protein levels were successfully inhibited: APPI and APPII lowered levels of
APP, APLP2I and APLP2II diminished APLP2, while DoubleI and DoubleII suppressed both
APP and APLP2 levels.
Figure 27.) Successful knockdown of APP family proteins in HeLa cells, alone or in combination, fails to
alter mTOR signalling.  RNAi suppression of the APP family proteins APP or APLP2 alone or in combination in
HeLa cells, shows a substantial loss in the corresponding protein as shown in western blots. (A)  APPI, APPII
knockdown  lowers  APP,  APLP2I,  APLP2II,  lowers  APLP2  while  DoubleI  (APPI+APLP2I)  and  DoubleII
(APPII+APLP2II) lower both APP and APLP2 levels showing successful knockdown. (B) Western blotting mTOR
substrates (S6K1-Thr389, 4EBP1-Thr70, 4EBP1-Ser65) and mTOR complex 2 (Akt-Ser473) shows no discernible
patterns as compared to each other and Luciferase (Luci.) controls.
APP family knockdowns were probed for  mTOR dependent  substrate  phosphorylation to
determine  whether  loss  of  APP  is  linked  to  mTOR  in  mammalian  cells  (Figure  27B).
Surprisingly, no alteration in mTOR signalling was evident in any conditions.
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3.2.3 Discussion
3.2.3.1 APP Overexpression in HeLa and SH-SY5Y Cells Increases Downstream 
Phosphorylation in Targets of mTORC1 and mTORC2
By overexpressing APP-GFP, APP(Swe)-GFP and AICD-GFP in HeLa cells then probing for
a wide range of mTOR substrates, increased mTOR signalling was detected, primarily in
basal  conditions.   The increase was not  only restricted to mTORC1, with Akt  dependent
phosphorylation  of  Ser2448  consistent  with  increased  mTORC2  activity.  In  addition,  no
difference was detected between APP and APP containing the Swedish double mutation, a
result that may not be expected if increased APP processing was directly linked with mTOR
signalling.  In all, these results show a clear role for APP in mTOR signaling in HeLa cells,
providing a high energy / proliferative signal.
To test the significance of an APP/mTOR interaction across multiple tissue types SH-SY5Y
neuroblastoma cells overexpressing APP/AICD were probed for changes in mTOR signalling.
Results showed similar behaviour to HeLa cells overexpressing APP/AICD: mTOR signalling
was  increased  across  multiple  substrates,  including  those  of  mTORC1  and  mTORC2.
Increased  mTOR signalling  in  HeLas,  in  and  of  itself  points  to  relevance  in  mammalian
tissue, but with similar results in neuronal cell culture, a role in two very different tissue types
is suggested, pointing to a significant role within the entire organism.  The changes in mTOR
signalling in  SH-SY5Y cells  in  particular  are significant,  showing relevance specifically in
neuronal context, which is potentially important when considering a role in the pathology of
Alzheimer’s disease as a neurodegenerative disorder.
3.2.3.2 APL-1 Mutation yn5 is Additive with daf-15 and let-363 Mutation, Showing Fat 
Droplet Accumulation as Seen by Oil Red O and BODIPY Staining
Evidence for APP’s interaction with mTOR signalling in HeLa and SH-SY5Y cells does not
necessarily translate  in vivo or represent a conserved function of the APP protein and its
orthologs. To investigate an in vivo, conserved role for APP, C. elegans was used as a model
organism,  genetic  interaction  was  determined  through  knockdown  of  mTOR  complex
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orthologs and an intracellular domain free truncation mutation in the C. elegans ortholog of
APP.  Using previously established methodology (Jia  et al.,  2004) Oil Red O was used to
visualise lipid droplet accumulation, showing the accumulation of lipid droplets upon loss of
mTOR function, which was potentiated by apl-1 mutation. The relevance of this finding was
that APL-1, the conserved ortholog of APP in C. elegans appears to regulate mTOR function,
demonstrating a conserved interaction.
Oil Red O appeared to show regulation of mTOR by APL-1, however this method was difficult
to quantify by conventional means, use of BODIPY shows more than twice the staining was
apparent when APL-1 mutation was combined with mTOR knockdown. These data confirm
and quantify the effects seen with Oil Red O, solidifying a role for APP in mTOR signalling
throughout the metazoan phylum.
3.2.3.3 Successful Knockdown of APP Family Proteins, Alone or in Combination Fails 
to Alter mTOR Signalling
Overexpression data in mammalian cells appeared to clearly show APP increasing mTOR
function.  APP knockdowns were performed to determine effects related to loss of function.
Surprisingly, while APP and APLP2 knockdown alone or in combination was successful, no
consistent, discernible changes to mTOR signalling were detected.
Explaining  these  results  are  difficult,  considering  just  how  clear  the  C.  elegans
knockdown/mutation and mammalian overexpression data is.  One possible justification of
this result is that APP only contributes to mammalian mTOR signalling in a positive manner
within this cell line, or that mammalian cancer cells are robust enough to normalise mTOR
signalling even with a positive component dramatically reduced.  HeLa cells are known to be
defective in  the tumour suppressor  LKB1, which is  upstream of  AMPK within the mTOR
signalling pathway (Shackleford and Shaw 2009;  Wingo  et  al.,  2009),  other  genetic  and
epigenetic changes may be expected.  While by no means fatal to the hypothesis of APP
being linked to mTOR signalling, it does raise doubts or suggest a more complex interaction.
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Future investigation is needed to elucidate the factors that influence APP/mTOR interaction
in a way that explains the results.  Performing knockdown in another cell line and measuring
a wider range of mTOR outputs in varying nutrient states or after being sensitised by an
mTORC inhibitor may help confirm APP involvement. If mammalian cells do indeed have a
further  mTOR  compensatory  mechanism  beyond  the  APP  family,  it  may  be  difficult  to
determine.   The specific  mechanism of  compensation may be better  understood via site
directed mutagenesis of  AICD or mTOR interaction sites,  which would go a long way to
characterise the interaction, with potential for relevant residues to be identified.
106
3.3 Investigating a Functional 
Interaction Between APP and the 
PIKfyve Complex
3.3.1 Introduction
The endosome is  a dynamic system of  compartments within the cell  responsible for  the
import, sorting transport, destruction or export of cargoes.  Each of the cargo fates require
distinct behaviours from the cell, an endosomal compartment must be transported to the right
location within the cell, the correct proteins must be recruited to the compartment's surface
and fusion / fission events need to be undertaken.  The identity and behaviour of endosomal
compartments is underpinned by phosphoinositides – membrane integrated lipids with an
inositol  head  capable  of  being  phosphorylated  into  a  vast  array  of  molecules  able  to
differentiate that surface from others.
PIKfyve is a phosphoinositide kinase, converting PI(3)P to PI(3,5)P2.  PI(3,5)P2 is of much
lower abundance than its precursor and is less well studied, but is clearly of significance to
the endosome and the cell generally.  Dysfunction of members within the PIKfyve complex
leads  to  cellular  vacuolation  and  neurodegeneration,  for  example  Fig4  mutation  causes
pigmentation and neurodegenerative defects in mice and PIKfyve dysfunction is associated
with human disease in the form of Charcot Marie Tooth 4J, Amyotrophic Lateral Sclerosis and
Yunis-Varón Syndrome (Chow et al., 2007; Zhang 2008; Chow et al., 2009; Campeau et al.,
2013).
To date PI(3,5)P2 has been shown as being responsible for the progression of the endosomal
system to a late endosomal/lysosomal phenotype (Ikonomov et al., 2002; Rutherford et al.,
2006;  de  Lartigue  et  al., 2009)  and  linked  to  lysosomal  action  through  interaction  with
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TRPML-1,  a  calcium  channel  which,  when  defective  leads  to  mucolipidosis  type  IV,  a
lysosomal storage disease (Bach et al., 2010).
Alzheimer’s  disease  can  be  easily  framed  as  being  related  to  endosomal  dysfunction;
enlarged endosomal compartments in the form of Granulovacuolar Degeneration (GVD) are
a primary hallmark of Alzheimer’s disease (Okamoto  et al., 1991), albeit one that is often
overlooked in favour of plaques and tangles.  In addition to being a feature of Alzheimer’s
pathology, the endosome is also an important system for the trafficking and processing of
APP, being a location of high beta and gamma secretase action (Bhalla et al., 2012).
Proteo-liposome analysis of  AICD recently discovered that  the PIKfyve complex interacts
physically with the AICD via Vac14, that APP and Vac14 migrate together under live-cell
imaging  (Balklava  et  al., 2015).  Balklava  et  al. also  began  investigating  the  functional
relationship between APP and PIKfyve using  C. elegans as a model.  The APP / PIKfyve
ortholog interaction was elaborated, showing shared and additive pathology in the form of
swollen hypodermal vacuoles upon loss of function in APL-1 or PPK-3 (APP and PIKfyve
orthologs), where the protein functions are reduced alone or in combination.  The vacuolation
present  in  APL-1  or  PPK-3  mutants  was  also  identified  as  primarily  RAB-7  and  LMP-1
positive (late endosomal and lysosomal, respectively), indicating late endosomal / lysosomal
disruption.    
Further  investigation  should  provide  insight  into  whether  this  interaction  has  functional
elements, whether the APP family has an effect on the function of PIKfyve, and if so, in what
way, particularly as it relates to higher organisms.
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3.3.2 Results
3.3.2.1 APP/APLP2 Double Knockdown Increases the Percentage of Cells with 
Vacuolar Structures in HeLa Cells Visible by Light Microscopy
To answer the question of whether the APP family has an effect on PIKfyve function, loss of
APP function was performed using RNAi suppression in HeLa cells against relevant APP
family members: APP and APLP2 were knocked down alone, or in combination as a double
knockdown to cover possible effects of functional redundance present in APP family proteins
(Heber et al., 2000).
Figure 28.) APP family siRNA for the investigation of an APP/PIKfyve interaction.  A)  Confirmation of APP
and  APLP2  knockdown  alone  or  in  combination,  by  Western  blotting. B)  siRNA sequences  for  APP family
members and analysis of vacuolation in HeLa cells. The total number of cells are shown (Total cells analysed),
with the number of images the results were pooled from in brackets. The percentage HeLa cells in which vacuoles
were observed (% Vacuolated cells) and the mean number of vacuoles per vacuolated cell (Mean vacuoles per
vacuolated cell) were quantified manually, standard error is shown in brackets. The number of vacuoles appeared
to increase upon suppression of both APP and APLP2, but analysis by ANOVA shows mixed results. Astrisks
denote significantly different results to Luciferase control, with APLP2I and Double II showing significantly higher
mean number of vacuoles per vacuolated cell. Data was pooled from n=4, analysis was performed using ANOVA
with Tukey's post-hoc test, α=0.05, **p≤0.01, ****p≤0.0001.
PIKfyve inhibition creates gross cellular pathology in the form of vacuoles visible via light
microscopy (Rutherford  et al., 2006; de Lartigue  et al., 2009). To investigate a relationship
between APP family loss and PIKfyve function, cells were RNAi suppressed for APP, APLP2
or both APP and APLP2, then the cells with vacuolar structures were counted.  APP, APLP2
and double knockdowns were confirmed by western blotting (Figure 28A),  corresponding
protein levels were successfully inhibited: APPI and APPII lowered levels of APP, APLP2I and
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APLP2II diminished APLP2, while DoubleI and DoubleII suppressed both APP and APLP2
levels.  The percentage of cells exhibiting vacuoles were counted for each condition, showing
an  apparent  increase  in  the  percentage  of  cells  exhibiting  vacuolar  structures  and  the
number of vacuoles per vacuolated cell (Figure 28B). Analysis gave mixed results, with only
APLP2I and Double II achieving a significant difference from Luciferase controls. 
3.3.2.2 APP/APLP2 Double Knockdown Increases Sensitivity to PIKfyve Inhibition in 
HeLa Cells
The RNAi suppression of APP or APLP2 appears to moderately increase vacuolation, but to
a  much lesser  extent  than PIKfyve  RNAi,  where cells  appear  to  be filled  with  vacuoles
(Rutherford  et  al., 2006),  suggesting  a  complementary,  secondary role  rather  than being
essential.  To further test this phenomenon the same experiment was undertaken, but with
cells exposed to chemical PIKfyve inhibition for only 45 minutes, the reasoning being that if
APP family  proteins  contribute  to  PIKfyve  function,  loss  may  sensitise  cells  to  PIKfyve
inhibition, creating vacuolation earlier than fully competent cells.
Visually, double knockdowns appear more vacuolated (Figure 29A), quantification of these
results show significantly higher vacuolation in double knockdowns as well as APLP2 duplex
I (Figure 29B). These data show double RNAi suppression of APP and APLP2 sensitises
cells to the depletion of PIKfyve activity, leading to increased vacuolation.
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Figure 29.) RNAi suppression of APP and APLP2 increases the number of vacuoles per cell in PIKfyve
inhibited HeLa cells. A) RNAi suppression of APP and APLP2 via two duplexes each (I and II) combined with
limited  PIKfyve  inhibition  (1μM  YM201636,  45min)  gave  an  apparent  increase  in  vacuoles  (arrows)  over
Luciferase RNAi control.  B) Increase in vacuolation was confirmed by quantification.  Data pooled from n=3.
Statistical test using ANOVA with Tukey’s post hoc analysis, α=0.05, only significant differences are indicated,
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. Total number of cells analysed per condition are indicated in each
bar in the diagram. Error bars = SE.
3.3.2.3 APP/APLP2 Double Knockdown Decreases the Number of ML1Nx2-GFP 
Positive Vesicles in HeLa Cells
The ML1Nx2-GFP probe, a tandem repeat of TRPML-1 PI(3,5)P2 binding domain fused to
GFP, is a powerful new tool to measure a prospective link between APP family proteins and
PIKfyve; able to detect the distribution of PI(3,5)P2 within the cell. By transfecting ML1Nx2-
GFP into HeLa cells then suppressing with RNAi against APP, APLP2 or both, the behaviour
of  PI(3,5)P2 under  APP family  depletion  was  elucidated  (Figure  30A).   The  number  of
PI(3,5)P2 positive structures was quantified using the mosaic suite for ImageJ (Rizk  et al.,
2014),  providing  automatic,  unbiased  segmentation  and  quantification  of  subcellular
structures using Squassh analysis.
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Squassh analysis showed a pronounced and significant drop in the number of ML1Nx2-GFP
positive structures per cell between Luciferase controls and knockdowns, with the exception
of APP duplex I (Figure 30B).  Results show that suppression of APP family proteins does
indeed impact the presence of PI(3,5)P2.
Figure 30.)  APP and APLP2 suppression leads to the reduction of ML1Nx2-GFP positive vesicles.   A)
Single or double suppression of APP and APLP2 resulted in an apparent loss of ML1Nx2-GFP positive structures
as compared to the Luciferase (Luci.)  negative control.   B) Loss of  ML1N-GFP was confirmed by automatic
segmentation and  quantification using the mosaic plugin for ImageJ.  Data pooled from n=3. Statistical testing
was undertaken using ANOVA with Tukey’s post hoc analysis, α=0.05, only significant differences are indicated,
*p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001. Number of cells analysed per condition are indicated in each bar in
the diagram. Error bars = SE. Scale bar, ~20µm.
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3.3.3 Discussion
3.3.3.1 APP/APLP2 Double Knockdown Increases the Percentage of Cells with 
Intracellular Structures in HeLa Cells Visible by Light Microscopy
To determine whether the physical link between APP and PIKfyve is truly functional in nature
requires that the presence or action of one protein be linked with that of the other.  PIKfyve’s
function as a PIP kinase lead to the hypothesis that APP is the likely upstream effector, and
as such APP family manipulation was the obvious choice for initial investigation.  The output
measurement  of  PIKfyve function  is  perhaps the most  challenging part  of  determining a
functional link; PIKfyve’s product is extremely low abundance and labile, as such it requires
specialised methods for measurement.
The morphology of cells deficient in PIKfyve function has been well documented (Rutherford
et  al., 2006;  Chow  et  al., 2007;  de  Lartigue  et  al., 2009),  with  widespread  vacuolation
obvious.  (Figure 29A) appears to show the percentage of cells with vacuolar structures do
indeed increase when APP family knockdown occurs, even if the effect is week alone, the
significance being that it suggests a functional link between APP and PIKfyve.  In spite of the
informative results, it is important to note that these do not conclusively show a functional link
between APP and PIKfyve.   The next  step is  to  find  whether  APP dysfunction  is  linked
directly to PIKfyve function or not.
3.3.3.2 APP/APLP2 Double Knockdown Increases Sensitivity to PIKfyve Inhibition in 
HeLa Cells
To link the loss of APP family proteins to PIKfyve function, cells were first sensitised with an
inhibitor  specific  for  PIKfyve;  a  decrease  or  non-significant  change  in  vacuolation  would
suggest the APP dependent vacuolation was unrelated to PIKfyve function, while an increase
vacuolation adds evidence that the two phenotypes are related or identical.  (Figure 30A)
shows  substantial  increase  in  the  vacuolation  phenotype  and  quantification  of  vacuole
numbers.  (Figure  30B)  confirms  significantly  increased  vacuolation  in APP  family
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knockdowns, particularly double APP/APLP2 knockdowns.  While far from conclusive when
taken alone, this is indicative of APP family proteins having an effect on PIKfyve function.
3.3.3.3 APP/APLP2 Double Knockdown Decreases the Number of ML1Nx2-GFP 
Positive Vesicles in HeLa Cells
The investigations of Li  et al. (Li  et al., 2013) suggest the ML1Nx2 probe is specific to the
presence of  PI(3,5)P2,  our  own independent  investigations  corroborate  the  idea  that  the
ML1Nx2 probe is a reporter of PIKfyve function (Currinn et al.,  2016; Guscott  et al., 2016).
Experiments  detailed  in  Currinn  et  al. show  that  PIKfyve  inhibition  almost  completely
eliminates vesicular ML1Nx2-GFP.  By knocking down APP family proteins and measuring
the change in vesicular ML1Nx2-GFP we found more evidence for a functional link between
APP and  PIKfyve:  loss  of  APP family  proteins  is  associated  with  the  significant  loss  of
ML1Nx2-GFP positive vesicles, and by extension PIKfyve function.
In  spite  of  the  inherent  difficulty  of  studying  both  APP and PIKfyve,  the  evidence  taken
together provides a growing case for an APP/PIKfyve relationship, which is not only physical,
but functional in nature.
Further to the results above, investigations undertaken and published recently support and
add to the findings, specifically that overexpression of APP or AICD was shown to stimulate
the formation of ML1Nx2 positive structures (Currinn et al., 2016).
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3.4 APP and Lysosomal Acidification
3.4.1 Introduction
Previous chapters have dealt with the evidence of an AICD interaction with mTOR and the
evidence  for  an  interaction  with  PIKfyve.   Both  of  these  prospective  interactors  are
particularly interesting in that they are thought to contribute to the same system: that of the
autophagosome/lysosome (de Lartigue 2009; Jung et al., 2010; Martin et al., 2013).
mTOR is central to energy signalling within the cell and as such controls the processes of
autophagy very carefully (Tokunaga et al., 2004).  Any disruption to mTOR signalling can in
turn be expected to alter  the capability for  autophagy,  this  is  seen with mTOR inhibition
leading  to  energy  conserving  “housekeeping”  responses  such  as  lowered  metabolism,
lowered mRNA translation and increased autophagy (Glick  et al., 2010).  This situation is
reversed upon mTOR overactivation, with autophagy inhibited.  Overactivation of mTOR is
proposed to be a contributing factor to ageing related disorders, including Alzheimer’s (Zoncu
et al., 2011), making this system particularly interesting when investigating a functional APP
interaction.
PIKfyve is known to drive progression of endosomes towards a late endosomal/lysosomal
phenotype  through  the  production  of  PI(3,5)P2,  additionally,  recent  debate  has  centred
around  possible  V-ATPase  regulation  by  PI(3,5)P2 (Li  et  al., 2014;  Ho  et  al., 2015).
Experiments detailed in the previous chapter show APP to interact physically and functionally
with PIKfyve,  this  leads naturally to  the hypothesis  that  APP,  through its  interaction  with
PIKfyve  supports  lysosomal  activity.   Data  from  both  an  APP/mTOR  and  APP/PIKfyve
interaction can be related to autophagy, making an opportunity to investigate this system
particularly intriguing.
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3.4.2 Results
3.4.2.1 Rapid Turnover of APP in SH-SY5Y Cells is Induced by Inhibition of mTOR Via 
Torin 1
When investigating the interaction of APP with mTOR in SH-SY5Y cells, a decrease in APP
levels were noted upon serum or amino acid starvation (Figure 24-25), two manipulations
which  lower  mTOR signalling.   The  loss  of  APP under  starvation  conditions  raises  the
possibility that the amount of APP within the cell is tightly controlled by mTOR.  The control of
APP by mTOR was tested via the manipulation of mTOR signalling (Figure 31), manipulation
was performed with amino acid starvation, or one of two mTORC inhibitors: rapamycin, an
allosteric mTOR inhibitor known to suppress some mTORC1 functions (Loewith et al., 2002;
Sarbassov et al., 2006) or Torin 1, an ATP competitive inhibitor capable of eliminating both
mTORC1 and mTORC2 signals (Thoreen et al., 2009).  The results show that while amino
acid starvation and Torin 1 treatment is able to diminish APP to a similar degree, rapamycin
does not.  Cellular APP levels are controlled by mTOR activity in a rapamycin insensitive
manner.
Figure 31.) APP abundance is dependent on mTOR catalytic activity in both SH-SY5Y cell controls and
those lentivirally overexpressing APP.  mTOR suppression with 2hr amino acid starvation (Starved) or 2hr Torin
1 application (Torin 1, 250nM or 1μm) lowers APP compared to basal nutrition (Basal) or 2hr rapamycin treatment
(Rapamycin, 250nM or 1μm) in SH-SY5Y cells lentivirally overexpressing GFP (GFP) or APP (APP-GFP), as
shown by western blot. Phosphorylation of S6K1 was used to indicate suppression of mTORC1, which occurred
in all but basal conditions. Samples were blotted for APP, pS6K1-Thr389, S6K1 and eEF1A (top to bottom).
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3.4.2.2 APP Turnover by Amino Acid Starvation is Halted by Lysosomal Inhibition
Enhanced  endosomal  sorting  for  lysosomal  degradation  is  the  classical  route  for
transmembrane receptor downregulation (Katzmann et al., 2001), making this the likely route
for APP turnover.  Degradative sorting can be prevented via pH quenching of endosomes
(Oda et al., 1991; Yoshimuri et al., 1991) or the inhibition of PI(3)P dependent sorting (Futter
et al., 2001). To test the dependence of rapid APP removal by endosomal sorting/lysosomal
degradation,  cells  were  amino  acid  starved  alone  or  in  combination  with  inhibitors:
chloroquine,  ammonium chloride or wortmannin, then probed for  APP levels (Figure 32).
APP was found to be rapidly removed upon amino acid starvation, but preserved by inhibition
of lysosomal acidification or PI(3)P dependent endosomal sorting.
Figure 32.)  mTOR inhibition-induced downregulation of APP is mediated by lysosomal degradation in
HeLa cells.  Loss of APP is induced upon removal of amino acids for 2 hrs (amino acids -), as compared to basal
control (amino acid +). Suppression of endosomal acidification with using the pH quenchers chloroquine (100μM,
250μM  Chloroquine)  or  ammonium  cloride  (10mM,  25mM NH4Cl)  prevents  starvation  dependent  APP loss.
Suppression  of  membrane  sorting  into  intraluminal  vesicles  using  the  PI3K  inhibitor  Wortmannin  (100nM
Wortmannin), a PI3K inhibitor is also capable of preventing amino acid starvation induced APP loss. Samples
were blotted for APP and eEF1A (top to bottom).
117
3.4.2.3 PIKfyve Inhibition Lowers the Number of Lysotracker Positive Structures 
Mimicking Inhibited Lysosomal Acidification
To determine PIKfyve’s relationship to acidic organelles, Lysotracker was used to measure
vesicular pH changes upon PIKfyve inhibition as compared to compounds known to alter
vesicular pH.  PIKfyve was inhibited with YM201636 and compared to control cells: untreated
HeLa  cells  or  those  treated  with  ammonium  sulphate,  an  inhibitor  of  lysosomal  acidity
(Figure 33).  Staining cells  with  Lysotracker  revealed the number  of  Lysotracker  positive
structures were significantly reduced upon PIKfyve inhibition compared to untreated HeLa
cells.  Positive  control  cells  (ammonium sulphate  treated)  show a similar  effect,  reducing
Lysotracker staining substantially.
PIKfyve inhibition using YM201636 reduced the average number of acidified vesicles in cells.
Inhibition  of  acidification  also  reduced  the  number  of  Lysotracker  positive  vesicles,
suggesting that the Lysotracker probe utilised indeed reflected acidification.
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Figure 33.)  PIKfyve inhibtion using YM201636 lowers the number of  acidic  vesicles.  Loss of  vesicular
acidification  lowers  lysotracker  staining,  as  such  the  number  of  acidified  vesicles  can  be  determined.  A)
Comparing Lysotracker staining of control cells against those pH quenched with ammonium sulphate (NH4SO4)
demonstrated that a loss of acidification translates into a loss of Lysotracker staining positive vesicles.  Inhibition
of PIKfyve activity  (100nM, 1µM YM201636) showed an apparent loss of lysotracker staining, demonstrating that
PIKfyve plays a role in acidifying cellular compartments.  B) Quantification confirms NH4SO4 treatment or PIKfyve
inhibition significantly suppresses acidification of cellular compartments as measured by the average number of
lysotracker  positive  vesicles  per  cell.  Data  was  pooled  from  n=3.  Cells  analysed:  ≥104  per  condition.
Quantification  was  performed  using  automatic  segmentation  with  the  mosaic  plugin  for  ImageJ.   Statistical
analysis was performed using one way ANOVA with Tukey's post-hoc test, α=0.05, *** p≤0.001, **** p≤0.0001.
Error bars = SE. Scale bar, 20µm.
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3.4.2.4 PIKfyve Inhibition Using Apilimod Reduces Lysotracker and LampI Positive 
Vesicles
PIKfyve inhibition is known to create cellular vacuolation (Rutherford et al., 2006; de Lartigue
et al.,  2009),  and has also been linked to suppressed endosomal acidification (Li  et  al.,
2014).  Lysotracker Red, a pH sensitive fluorescent dye useful for examining abnormalities in
lysosomal acidification is able to detect the number and distribution of lysosomal structures
(Colvin et al., 2010; Fonseca et al., 2012). Lysotracker has also been used quantitatively (Xu
et al., 2014), detecting lysosomal storage diseases through measurement of “Total Organelle
Intensity” by multiplying average vesicle intensity with the structure size.
To determine the suitability of Lysotracker in detecting PIKfyve dysfunction and to clarify the
relationship between PIKfyve dysfunction and late endosomal behaviour, HeLa cells were
treated with the specific PIKfyve inhibitor  Apilimod and either stained with Lysotracker or
immunostained for  Lamp1.   (Figure 34A)  shows an apparent  lowering in  the number  of
Lysotracker positive vesicles and intensity,  with segmentation confirming this loss (Figure
34B/C). (Figure 35A) shows a change in Lamp1 staining; Lamp1 positive vesicles appear to
be  larger  but  less  numerous.  Segmentation  verifies  the  visual  findings  with  PIKfyve
significantly lowering the number of Lamp1 positive vesicles, but significantly increasing their
size in a concentration dependent manner (Figure 35B/C).
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Figure 34.)  Inhibition of PIKfyve using apilimod affects acidified organelles. A) Inhibition of PIKfyve using
25nM or 250nM apilimod led to a decrease of  the number and intensity of  acidified organelles labelled with
Lysotracker. B) Quantification of the average number of Lysotracker positive vesicles per cell, measured using the
mosaic plugin for ImageJ. Both apilimod concentrations significantly reduced the number of Lysotracker positive
vesicles. C) Quantification of average vesicular Lysotracker intensity showed a significant, apilimod concentration
dependent reduction of vesicular Lysotracker staining.  A-C) Data were pooled from n=3.  Cells analysed: ≥309
cells per condition. B-C) was performed using one-way ANOVA with Tukey's post-hoc test, α=0.05, **** p≤0.0001.
Error bars = SE. Scale bar, 20µm.
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Figure  35.)  Inhibition of  PIKfyve  using apilimod affects  late  endosomes/lysosomes. A) LampI  positive
compartment immunostaining upon PIKfyve inhibition.  Apilimod apeared to alter the morphology and distribution
of  LampI  positive vesicles  within  the cell,  producing fewer,  larger  late  endosomal  /  lysosomal  structures.  B)
Quantification of LampI positive vesicles showed that PIKfyve inhibition reduced the number of LampI positive late
endosomes  and  lysosomes  in  a  way  that  was  dependent  on  apilimod  concentration.  C) Analysis  of  late
endosome/lysosomal structures showed that while the number of LampI vesicles per cell was reduced, their size
increased, suggesting swelling or aggregation of the compartment. Data was pooled from n=3. Cells analysed:
240 per condition.  B-C) was performed using one-way ANOVA with Tukey's post-hoc test, α=0.05, *** p≤0.001,
**** p≤0.0001. Error bars are SE. Scale bar, 20µm.
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3.4.3 Discussion
In this chapter APP was shown to be rapidly removed and that turnover is dependent on
mTOR,  but  in  a  rapamycin  resistant  manner.   The  turnover  of  APP  is  dependent  on
lysosomal  function,  being  halted  by  lysosomal  inhibitors,  including  chloroquine  and
wortmannin.  
Staining of cells with Lysotracker, a pH sensitive probe, was determined to be quantifiable in
relation to lysosomal function; changes in PIKfyve function can be detected as Lysotracker
positive structures are lost  upon PIKfyve inhibition,  albeit  to a lesser  degree than full  V-
ATPase inhibition, while mTOR suppression appears to increase the number of Lysotracker
positive structures.
To test a link between PIKfyve function and lysosomal function, cells treated with PIKfyve
inhibitor were stained with Lysotracker and others immunostained for LampI (Figure 33-35),
each compared to controls,  showing an increase in structure intensity consistent with an
increase in PIKfyve activity.
mTOR and PIKfyve have roles in lysosomal function.  Evidence for an AICD interaction with
mTOR and PIKfyve raises the intriguing possibility that APP may be linked to lysosomal /
autophagy function. The investigation of APP in lysosomal function drew from observations
that APP turnover was tightly controlled by mTOR signalling - starvation seemed to rapidly
degrade APP levels, most noticeably in SH-SY5Y neuroblastoma cells. Rapid turnover would
be expected from a protein requiring tight control, so is significant in and of itself, but is more
interesting considering the implication of APP in human pathology: amyloid deposition is a
result of inappropriate protein processing, be it high abundance, altered secretase action or
low lysosomal destruction (Hardy and Higgins 1992), if APP removal is rapid and alters the
very system that controls its turnover, the nature of APP involvement in lysosomal function
has significant consequences for our understanding of Alzheimer’s disease.
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3.4.3.1 Rapid Turnover of APP in SH-SY5Y Cells is Induced by Inhibition of mTOR Via 
Torin 1
Demonstration of rapid APP turnover upon starvation /  mTOR inhibition was a significant
finding,  highlighting APP as requiring tight  control  within the cell.   Highly controlled APP
levels are in keeping with an important cellular role, or one where the rapid increase of that
protein is itself important, e.g. p53 (Lane and Lavine 2010).  It is energetically expensive to
have a protein constantly made and destroyed and would be evolutionarily disadvantageous
if its removal were not absolutely necessary for the correct, healthy function of the cell.
Combining what we now know about APP turnover with the nature of APP as a protein liable
to produce an aggregation  prone peptide  product  (Aβ),  leads to  the lysosome being an
important  area of  APP study:  Alzheimer’s  disease can be easily framed as a disease of
dysfunctional protein processing, a mechanism intricately linked with endosomal sorting and
lysosomal function.
3.4.3.2 Amino Acid Starvation Dependant APP Turnover is Halted by Lysosomal 
Inhibition
As shown previously, APP removal is rapid upon starvation, showing autophagy as a primary
controller of APP abundance.  To confirm the dependence on the lysosome for the primary
control  of  APP,  lysosomal  inhibition  was used:  the rapid  turnover  of  APP was  halted by
disruption of lysosomal progression and maturation. By knowing how APP is controlled within
the cell, further research can be geared towards how the lysosome may play a role in APP
homeostasis and by extension, Alzheimer's disease.  Now that APP destruction is found to
be reliant on the correct function of mTOR and the lysosome, the ability for APP to influence
those very systems becomes hugely relevant.
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3.4.3.3 PIKfyve Inhibition Lowers the Number of Lysotracker Positive Structures 
Mimicking Inhibited Lysosomal Acidification
An  ongoing  discussion  in  PIKfyve  research  has  been  whether  PIKfyve  is  involved  in
lysosomal  acidification  (Li  et  al., 2014;  Ho  et  al., 2015).   The relationship  of  PIKfyve to
vesicular acidification was determined by comparing Lysotracker staining in untreated cells,
to those exposed to YM201636 or ammonium sulphate.  PIKfyve inhibition was found to
mimic  the  inhibition  of  lysosomal  acidification,  with  greatly  reduced  lysotracker  positive
structures. The results suggest a role for PIKfyve in endosomal acidification.
3.4.3.4 PIKfyve Inhibition Using Apilimod Reduces Lysotracker and LampI Positive 
Vesicles
As  an  extension  of  showing  PIKfyve  inhibition  mimicking  the  inhibition  of  lysosomal
acidification, the effect of PIKfyve inhibition on the late endosomal structures was used to
determine the extent of PIKfyve’s influence.
Lysotracker staining clearly shows a loss of acidification as measured by both the intensity of
Lysotracker positive vesicles and the number of those vesicles per cell when cells are treated
with the specific PIKfyve inhibitor, apilimod.  PIKfyve inhibition also lead to the number of
Lamp1 positive structures decreasing, but their size increasing, suggesting aggregation or
swelling of these compartments. Much like the loss of acidic structures, changes in Lamp1
are  indicative  of  an  alteration  in  endo/lysosomal  function,  indeed  PIKfyve  has  been
suggested to control early to late endosome maturation and their fission / fusion (Zou et al.,
2015; Miller  et al., 2015; Dong  et al.,  2010). Unlike the work of other groups, the findings
above are not meant to differentiate which mechanism may be responsible, be it directly on
V-ATPase  or  indirectly  via  TRPML.   The  aim  here  is  to  confirm  PIKfyve  has  a  role  in
endosomal acidification.
PIKfyve  being  shown  as  a  substantial  player  in  endo/lysosomal  function  is  potentially
significant  for  our  understanding  of  APP,  particularly  as  it  relates  to  pathology.   If  APP
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activates PIKfyve and PIKfyve is needed for lysosomal function, a model can be formulated
wherein a change to the processing of APP can lead to vacuolation / neurodegeneration
through depletion of PI(3,5)P2.
3.4.3.5 Further Evidence for APP/PIKfyve Interdependence
The results from this project complement those published in Currinn et al. (2016), where the
interdependence of APP and PIKfyve was investigated in some depth.  PIKfyve was found to
be required for the correct trafficking of APP.  By inhibiting PIKfyve with either YM201636 or
apilimod in cells containing fluorescent tagged APP, then immunostaining for the markers
EEA1 (early endosome), LampI (late endosome / lysosomal) and GM130 (Golgi), a marked
APP redistribution was found.  APP accumulated in EEA1 positive structures, while LampI
and GM130 positive pools diminished as compared to non-inhibited controls, where APP is
found abundantly in each.  
The experiment showed APP becoming trapped in early endosome derived vesicles upon
PIKfyve inhibition, suggesting that some function of PIKfyve is required for APP trafficking, be
it the control over endosomal acidification or sorting more generally. APP was also found to
increase PIKfyve activity in the Currinn et al. 2016 publication.  The effect of APP on PIKfyve
activity was determined by transfecting cells with an ML1Nx2 probe alongside different forms
of APP/AICD, and quantifying the number of ML1Nx2 positive vesicles in each case with or
without PIKfyve inhibition.  The number of ML1Nx2 positive vesicles was significantly higher
in  cells  transfected  with  APP,  AICD  or  AICD  with  an  N-terminal  (membrane  adjacent)
truncation, but not in APP lacking AICD (APPΔAICD) or APP with C-terminal truncations.
PIKfyve inhibition with YM201636 lowered the number  of  ML1Nx2 postive vesicles in  all
cases to a similar level.
Taken together there appears to be evidence for the presence of APP influencing PIKfyve
activity and PIKfyve activity in turn being required for the correct determination of APP's fate
in the cell.
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4.1 Discussion
This  project  aimed  to  determine  whether  interactions  detected  between  APP and  either
PIKfyve  or  mTOR  are  functional  as  well  as  physical  and  if  so,  the  nature  of  these
relationships.  
4.1.1 Summary of Findings
4.1.1.1 Creation and use of TAT-AICD as a Biochemical Tool
Challenges in the investigation of AICD interaction led to the creation of TAT-AICD, a cell
permeable biochemical tool intended for the acute, controlled exposure of cells to AICD.  This
was used to test for changes in PIKfyve and mTOR outputs: the ML1Nx2-GFP PI(3,5)P2
probe  or  PIKfyve  inhibitor  sensitised  cell  vacuolation  for  PIKfyve  and  mTOR  substrate
phosphorylation  state  for  mTOR.   Results  showed  TAT-AICD  was  capable  of  rapidly
penetrating cells unlike AICD alone, and with a clustered cellular distribution differing from
TAT alone.  
TAT-AICD was found to co-localise with the PI(3,5)P2 probe, which may be expected if AICD
interacts  with  PIKfyve,  as  indicated  by  previous  in  vitro findings  (Balklava  et  al.,  2015).
Treating GFP-ML1Nx2 expressing cells with TAT-AICD increased the number and area of
PI(3,5)P2 positive structures over TAT or AICD treatment alone which could be a sign of
increased PI(3,5)P2 production.  TAT-AICD treatment was also found to moderate vacuolation
in cells subject to brief PIKfyve inhibition, which would be expected if PI(3,5)P2  was more
abundant in TAT-AICD treated cells.
Treating  cells  with  TAT-AICD did  not  appear  to  create  any consistant  change  in  mTOR
signalling  as  shown  by  western  blot  detection  of  S6K1  Thr389  and  4EBP1  Ser65
phosphorylation,  downstream targets  of  mTOR.  Unpublished  data  suggests  AICD/mTOR
interaction occurs on the N-terminal extremity of AICD, in the case of TAT-AICD, this area
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may  be  sterically  hindered  by  MBP,  which  would  explain  the  lack  of  affect  on  mTOR
signalling. 
4.1.1.2 Testing Prospective APP Interaction Partners
The APP/mTOR interaction was primarily investigated using mammalian tissue culture and
C. elegans.  In mammalian tissue culture APP overexpression or APP family knockdown was
used, paired with detection of mTOR substrate phosphorylation.  In C. elegans, mutants with
truncated  APP  ortholog  were  compared  and  combined  with  mTOR  ortholog  subunit
knockdown, measured using lipid accumulation as an output.  The APP/PIKfyve interaction
was investigated using APP family  knockdown,  with outputs measured using vacuolation
upon PIKfyve inhibition or a PI(3,5)P2 detecting probe.
APP  overexpression  showed  that  mTOR  substrates  appeared  to  be  more  strongly
phosphorylated in APP expressing cells, be they HeLa or SH-SY5Y.  However, knockdown of
APP  family  proteins  failed  to  noticeably  or  consistently  alter  mTOR  substrate
phosphorylation.  Truncation of the  C. elegans APP ortholog led to visible, albeit subtle fat
droplet  accumulation,  a  sign  of  mTOR  dysfunction  (as  shown  by  mTOR  ortholog
knockdown).  This effect was compounded by combining mTOR ortholog knockdowns with
APP ortholog truncation to create a measurable, significant level of lipid accumulation.
Investigation of an APP/PIKfyve interaction using APP family knockdown resulted in a higher
percentage of double knockdown cells with vacuolation and sensitising cells with a PIKfyve
inhibitor lead to a significantly increased number of vacuoles per cell in double knockdowns.
Using the PI(3,5)P2 probe ML1Nx2-GFP, double knockdown of APP family proteins led to a
decrease  in  ML1Nx2-GFP  positive  vesicles,  indicating  an  impact  on  the  presence  of
PI(3,5)P2.
An  APP/mTOR  interaction  produced  compelling,  but  sometimes  unclear  results,  while
APP/PIKfyve results were overwhelmingly positive.  The results led to the conclusion that
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while the PIKfyve function is positively influenced by APP, an APP/mTOR interaction may be
more complex, requiring further study to understand.  
4.1.1.3 The Relevance of APP in the Endosome: A Result Driven Investigation
A profound  change  in  APP  levels  was  noticed  upon  mTOR  inhibition  during  previous
experiments on mTOR substrates.  This was investigated in SH-SY5Y cells using starvation,
rapamycin or Torin 1 and observing changes in APP levels.  The investigation found that APP
was less abundant in cells that have undergone either starvation or full chemical inhibition of
mTOR's catalytic function: APP's presence and turnover appeared to be intimately linked to
the function of mTOR.
To elaborate on the cellular impact of APP's interaction with mTOR or PIKfyve, autophagy
was a prime candidate for study, particularly considering its correlation with mTOR activity.
To confirm whether or not APP turnover is dependent on lysosomal activity, APP levels were
detected under amino acid starvation with or without lysosomal inhibition.  Results showed
starvation dependent APP turnover clearly requiring lysosomal acidification.
In light of APP being under tight lysosomal control, and appearing to have a clear positive
impact on PIKfyve, determining PIKfyve's role in this system becomes particularly interesting.
The nature of PIKfyve's involvement in the acidification of endo/lysosomes is beginning to be
explored, but is still somewhat unclear, particularly concerning mammalian systems (Li et al.,
2013; Ho et al., 2015).  
To better understand PIKfyve's role in acidification, cells were treated with PIKfyve specific
inhibitors or a pH quencher and compared to controls using the pH sensitive dye Lysotracker.
PIKfyve inhibition led to a significantly lower number of Lysotracker positive structures, while
not completely eliminating them.  This might be explained by a reduction in the acidification
of endo/lysosomes or a reduction in the number of these structures.  Further testing cells for
pH or the late endosomal /  lysosomal marker LampI showed that  PIKfyve inhibition was
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decreasing both the number and intensity of Lysotracker positive structures, while decreasing
the number and increasing the area of LampI positive structures – indicating a less acidic,
swelling/aggregating  phenotype.   The  results  point  to  PIKfyve  as  having  a  role  in  the
formation / maintenance of acidic compartments.
4.1.1.4 Summary
In  summary,  while  attempts  to  determine  the  nature  of  an  APP-mTOR interaction  gave
results  indicating  a  complex  relationship;  a  consistent  functional  interaction  between the
intracellular domain of APP and PIKfyve was found, where AICD was capable of promoting
PIKfyve  activity.   Investigating  the  relevance  of  the  endo/lysosomal  system,  APP
downregulation  was  found  to  be  dependent  on  both  lysosomal  acidification  and  loss  of
mTOR signalling.  Further study found that PIKfyve function was important in maintaining the
morphology and pH of late endosomal processes, suggesting an interplay between APP and
the lysosome which could be relevant to our understanding of cell biology and disease.
4.1.2 Significance
4.1.2.1 A Tool for Mammalian PIKfyve and AICD Research
The increase of PI(3,5)P2 in mammalian cells has been a manipulation absent in the toolbox
of PIKfyve researchers. It is significant in and of itself, with studies of mammalian PIKfyve
limited to loss of function up until now.  The creation of a tool for the rapid manipulation of
PIKfyve function has the potential for wide application in the field of PIKfyve research, but
also highlights the capability of cell penetrating peptides in biochemical research.
More generally, TAT-AICD benefits from being a simple to use tool that lends itself to large
replicate statistical analysis.  TAT-AICD is able to acutely raise the internal pool of a specific
protein (in this case AICD).  The benefit for AICD specifically is that the chronic effects of
exposure  are  avoided,  including  long-term  transcriptional  alteration  and  AICD
downregulation.  
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The  experiments  undertaken  with  TAT-AICD  in  this  project  were  quite  broad  in  scope,
primarily  looking at  vacuolation  and PI(3,5)P2 distribution.   However,  future study should
investigate biochemical changes in the cell with more detail.  Modification of the TAT-AICD
construct may also be useful for investigating site specific changes to AICD and their effect
on the cell.  
In summary, TAT-AICD avoids the downsides of other techniques, allowing greater control
over AICD experiments than has previously been possible and has a high potential for future
use.
4.1.2.2 Clues for APP's Role in Cellular Physiology
APP's capability of pushing PIKfyve or mTOR activity is intriguing when framed in what we
know about APP.  Research focusing on the extracellular domains of APP family proteins
have  pointed  towards  likely  roles  in  cell-cell  adhesion  and  growth  factor  like  behaviour
(Rossjohn et al., 1999; Hoefgen et al., 2014).  An endosomal APP function has given clues to
possible  downstream  behaviour  beyond  secretase  driven,  Fe65  partnered  nuclear
translocation.  
Degradative pathways in the cell are dependent on the proper control of PIKfyve and mTOR.
This project determined that these very pathways are affected by the intracellular domain of
APP.   Unusually,  the presence of  APP appears to be capable of  promoting both a high
energy, anti-degradative state through mTOR and the progression of degradative pathways
via PIKfyve.  The cellular context under which these signalling events occur is yet  to be
elucidated.  One possibility is that extracellular cleavage of dimerised APP may act as a
signal for either cell activity and division or activation of degradative pathways within the cell.
In light  of  results implicating APP in mTOR and PIKfyve activity,  development of a more
complete model for APP's role in the cell may be possible with further study.
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4.1.2.3 Ageing and Human Disease
Results showing APP as relevant in mTOR and PIKfyve activity are particularly interesting for
APP's role in ageing and human disease.  Control of energy and stress signals; destruction
of damaged, surplus or aggregating protein is key to longterm health of a cell, and the remit
of mTOR and PIKfyve.  Having APP as such a pronounced effector raises the possibility that
changes  in  the  processing  of  APP  may  affect  the  ability  of  the  cell  to  maintain  good
housekeeping generally and even the turnover of APP itself.  Impact on cell health and APP
turnover is of direct relevance to ageing and Alzheimer's disease.
Increased mTOR signalling in Alzheimer's has been described (Pei and Hugon 2008).  In a
Drosophilia model of tauopathy for instance, mTOR mediated cell cycle activation was found
to potentiate tau toxicity (Khurana  et al., 2006), whilst in tissue from brains of Alzheimer's
patients mTOR activity appears to correlate with total tau levels (Li  et al., 2005).  The fact
that APP was found in the interaction studies to bind to a catalytically active site in mTOR
(the  kinase  domain),  suggested  it  might  influence  mTOR  activity.  This  is  supported  by
existing evidence that APP overexpression in mammalian cells and murine models results in
mTOR  signalling.   More  generally,  mTOR  signalling  pushes  protein  synthesis  and
suppresses  degradative  pathways  which  are  important  to  cellular  health (Figure  31-33;
Hansen et al., 2008; Toth et al., 2008; Bjedov et al., 2010; Wu et al., 2013).
A significant  aspect  of  PIKfyve dysfunction is  cellular  vacuolation,  where late endosomal
compartments swell due to a breakdown in endosomal sorting.  Granulovacular degeneration
(GVD) is a vacuolar phenotype present in the hippocampus and other areas of Alzheimer's
disease affected brains (Ball 1978); the swelling of Rab5 and Rab7 positive endosomes and
lysosomal  accumulation has also  been implicated in  Alzheimer's  disease (Cataldo  et  al.,
2008).  
GVD bodies are basophilic and, like PIKfyve deficient cell vacuoles, are derived from late-
stage endosomal membranes (Funk et al., 2011).  The processes underlying GVD are poorly
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understood,  but  defects  in  endosomal  sorting  and  lysosomal  integrity  play  a  role  in
Alzheimer's disease (Lee et  al., 2011; Muhammad  et al., 2008; Nixon 2007; Wolfe  et al.,
2013).
 Interestingly, GVD bodies have been found to contain phosphorylated ribosomal protein S6
(pS6), the substrate of S6K, which is in turn a primary target of mTOR (Castellani  et al.,
2011).  pS6 is thought to have a role in RNA storage, degradation and translation, but is a
hallmark  of  stress  granules.  Stress  granules  are  transient,  intracellular  aggregations  of
protein and RNA that respond to oxidative stress and inappropriate transcription (Anderson
and  Kedersha  2008).   Similarities  between  PIKfyve  dysfunction  and  the  GVD bodies  of
Alzheimer's disease in conjunction with possible overactivation of mTOR may be explained
by APP signalling inappropriately.
4.1.3 Challenges and Limitations
Significance of the project's findings should not be understated, however the weaknesses
inherent in the investigations should be discussed.
4.1.3.1 Consoling mTOR and PIKfyve Activation
Activation of PIKfyve by APP appears to be well  supported using the evidence from this
project.   Although evidence for  mTOR functional  involvement  was  less  consistent,  some
results still support activation by APP.
PIKfyve and mTOR activities are linked: PI(3,5)P2 can act to recruit mTORC1 to membranes
by  directly  binding  RAPTOR and  is  also  required  in  yeast,  binding  of  Sch9,  the  yeast
homolog of  S6K (Bridges  et  al., 2012;  Jin  et  al., 2014).   On the surface,  these findings
appear to point to an mTOR activating role for PIKfyve, which would inhibit autophagy, while
results of this project as well as other publications clearly show PIKfyve's importance for a
functional lysosome.  To console this apparent contradiction it is perhaps better to think of
PI(3,5)P2 as being contributing, but not sufficient for mTORC1 activity.  Many more signals go
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into the activation of mTOR than membrane recruitment by PI(3,5)P2.
In the context of a functional APP interaction, it is difficult to delineate mTOR from PIKfyve.
An interaction of  APP with PIKfyve may potentiate a membrane to enable higher mTOR
activity or facilitate autophagy.
4.1.3.2 New Tools: The ML1Nx2-GFP Probe
Li  et  al. published the development  of  the  probe ML1Nx2-GFP,  claiming it  to  have high
specificity for PI(3,5)P2 (Li  et al., 2013).  This tool is potentially useful and indeed vesicular
staining correlates with expected PI(3,5)P2 levels and distribution.  Just how closely ML1Nx2-
GFP signal  reflects  the  abundance and distribution  of  PI(3,5)P2 specifically  is  difficult  to
validate  in  a  cellular  environment.   The  lack  of  comparable  PI(3,5)P2 measuring  tools
contributes,  but  also  the  difficulty  of  measuring  cross-reactivity  in  the  cell.   In  spite  of
questions revolving around specificity and result interpretation, the probe remains a unique
tool, albeit one that would be served by further investigation.  Results obtained with ML1Nx2-
GFP should be considered as a relatively new addition to the PIKfyve researcher's toolbox,
experiments utilising ML1Nx2-GFP should be considered as adding to a body of evidence
and not as a magic bullet for PI(3,5)P2 detection.
4.1.3.3 New Tools: TAT-AICD
While cell penetrating peptides have been known for many years (Frankel and Pabo 1988;
Green  and  Loewenstein  1988),  their  mechanism  of  action  has  been  widely  debated
(Reviewed by Bechara and Sagan 2013).  As such, cell penetrating peptides have not seen
extensive use in biochemical investigation, researchers preferring the more "tried and true"
method  of  transfection.   Results  obtained  should  be  viewed  in  the  light  of  the  unclear
mechanism of  action.  In spite of  this,  TAT fusion does hold potential  benefits over other
methods in its ease of use, repeatability, small molecular weight and the sheer number of
cells that can be analysed with it.
135
4.1.4 The Future of Alzheimer's Therapy and 
Research
Research into  Alzheimer's  disease therapy has been plagued by late phase clinical  trial
failure, with major issues in efficacy and / or safety.  Examples include γ-secretase inhibitor
semagacestat  (Doody  et  al., 2013),  where  interference  of  Notch  signalling  was  heavily
impacting  participants  (Henley  et  al., 2014),  and  the  beta  amyloid  clearing  monoclonal
antibody bapineuzumab (Miles  et al., 2013) that failed to improve clinical outcome in two
phase III trials (Salloway et al., 2014).  Both of these therapies focused on the prevention of
amyloid beta production or its clearing.  
In spite of the continued failure to address pathology by focusing on amyloid beta, efforts are
still being made to push development of similar drugs such as solanezumab that has already
been shown to fail at improving cognition and functional ability (Doody et al.,  2014).  One
drug  that  does  appear  promising  is  masitinib  (Piette  et  al., 2011;  Folch  et  al., 2015).
Masitinib  inhibits  c-Kit  (CD117)  and  Fyn  kinases,  masitinib's  mechanism  of  action  is  to
dampen  the  body's  immune  reaction  to  amyloid  through  suppression  of  mast  cells  and
inhibiting  pathways  to  tau  pathology.   Interestingly,  the  Fyn  kinase  also  contributes  a
significant  signal  to  mTOR,  indeed,  when  overactivated it  can induce cell  death  through
endoplasmic reticulum stress (Wang et al., 2015). In addition to contributing to tauopathy, c-
Kit also feeds a positive signal to mTOR through PI3K, and is key in cancer cell survival.  The
drug  has  been  associated  with  slowing  of  cognitive  decline  in  adjunct  therapy and  has
successfully completed futility testing in phase III trials, showing it to be capable of reaching
its efficacy objective (Airiau et al., 2013).
In summary, targeting the body's reaction to amyloid beta, preventing tau phosphorylation
and excitotoxicity may help slow Alzheimer's disease in comparison to targetting amyloid
beta alone (Nygaard et al., 2014).
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4.1.4.1 Approaches to APP Research
APP research has received a huge amount of attention due to its involvement in Alzheimer's
disease, attention that is only growing with an ageing population and the healthcare / social
impacts entailed.  The drive for effective Alzheimer's therapies has in turn impacted how
research is conducted.  APP research has overwhelmingly focused on its place in human
disease,  revolving  around  amyloid  beta  to  the  point  where  other  research  is  perhaps
overshadowed or underfunded.  It can be argued that a "race for the cure" has been a major
stumbling block in its own success, with laboratories focused on late pathological processes
before properly understanding the underlying biology of the molecules in question.  Escaping
the disease fixation in APP research allows focus on incremental elucidation of APP functions
which can then inform intelligent  drug /  therapy design where all  previous  amyloid  beta
targeting approaches have failed.
4.1.4.2 Next Steps in APP Research
Prioritising the cellular roles and context of APP family proteins may lead to a clearer picture
for  future Alzheimer's  therapy.   Previous research sees the APP extracellular  domain as
acting  in  cell-cell  adhesion  or  with  growth  factor  like  behaviour  (Rossjohn  et  al., 1999;
Hoefgen  et al., 2014) and the intracellular domain performing a role in nuclear signalling
upon secretase processing (Cao and Sudhof 2001).  This project has found a role for the
intracellular domain of APP in the endo / lysosome.  
Future  research  questions  should  address  how  the  functions  attributed  to  APP may  fit
together.  Although this seems a simple question, it becomes complex considering the myriad
variables.  Variables  include:  cell  type,  the  intracellular  location  of  APP at  any  one time,
phosphorylation of sites on AICD, preferential secretase activity.  Beyond this, extracellular
dimerisation and behaviour  upon secretase release,  isoform type,  and the importance of
anchored versus free AICD must all be considered.
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Knowing the specific circumstances required for the positive effect of APP on mTOR would
greatly benefit from further investigation.
Considering the APP-PIKfyve interaction specifically, further work surrounding the structural
biology of the physical interaction may be helpful: discovering which specific residues are
important on both molecules would go a long way to solidifying the interaction of AICD with
Vac14 as the basis for increased PIKfyve activity.
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